-

Ref. No.: F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: edprmsc@rajasthan.gov.in

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF FIRMS FOR DRUGS AND MEDICINES

(Rate Contract for the period ending on 31.03.2027)

!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	**24.02.2025 & 06.00 PM**
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	**25.02.2025 & 11.00 AM**

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

मुख्यमंत्री नि:शुल्क दवा योजना

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India

Phone No: 0141-2228066, 2228064 Website: www.rmsc.health.rajasthan.gov.in

CIN:U24232RJ2011SGC035067 E-mail : edprmsc@rajasthan.gov.in

Ref. No.: F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:-

NOTICE INVITING E-Bids

e- Bids are invited by RMSCL, Jaipur from bonafide MANUFACTURERS / LOAN LICENSEE / IMPORTERS / CO-MARKETERS with sole marketing rights for imported proprietary items for rate contract cum supply and empanelment of bidders for Drugs & Medicines. The last date of submission of duly filled up form along with documents on e-proc i.e http://eproc.rajasthan.gov.in and submission of fees is upto 6.00 PM of 24.02.2025 Details of NIB may be seen at the website of State Public Procurement Portal https://sppp.rajasthan.gov.in/, http://eproc.rajasthan.gov.in., http://rmsc.health.rajasthan.gov.in and may be downloaded from there.

Estimated Value (Rs) :- **2204.81 Crore**

UBN No. –

Executive Director(Proc),
RMSCL

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF FIRMS FOR SUPPLY OF DRUGS AND MEDICINES

(Rate Contract for the period ending on 31.03.2027)

Bid Reference	F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:-
Date and time for downloading bid document	29.01.2025 from 06.00 PM
Pre- bid conference	05.02.2025 at 11.30 AM (Board room)
Last date and time of submission of online bids	24.02.2025 up to 06:00 PM
Date and time of opening of Online technical bids	25.02.2025 at 11:00 AM
Estimated bid Cost	**Rs. 2204.81 Crore**
Cost of Bid Document	**Rs. 2,360/- (including GST @ 18%)**
Cost of Bid Document For MSME Unit of Rajasthan	**Rs. 1,180/- (including GST @ 18%)**
RISL Processing Fees	**Rs. 2950/- (including GST @ 18%)**
Bid Security Fees	**@2% (for MSME unit of Rajasthan @ 0.5%) of Estimated Bid value for each quoted item as per Annexure VIII)**
Empanelment Fees (Optional)	**Rs. 5,900/- (including GST @ 18%)**

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

INDEX

-

GENERAL INSTRUCTIONS FOR BIDDERS

The bidders are instructed to read the complete bid document carefully. The following points may be noted so that mistakes/lapses/shortcomings during Bid submission can be avoided.

1. It is expected from all bidders that they will ensure that documents to be used in bid set will be given to a reliable person only, and that only a fully reliable person shall be authorized for DSC. So that the confidentiality of your bid/ rates can be maintained upto bid opening & that your documents are not put to any misuse.

2. In case you are given any assurance of any advantage in RMSC, by anybody or if you are directly or indirectly threatened or intimidated of harming your bidding & subsequent work in RMSC, please inform immediately about the same to MD, RMSC or ED (Proc.) RMSC. It would be better if evidence of such unfair activity of such person is produced so that action can be taken against such person / institution and their details can be put on the website.

3. It is advisable for bidder to authorize only those persons for RMSCL tender who are employed in your company on salary basis.

4. The turnover should be as per bid conditions. Do not submit Bid if the turnover of the firm is less.

5. Quote only for the products for which Product Permission meets the Bid specifications. Do not quote if it differs with regard to any parameter.

6. Quote rate in BOQ for the packing unit exactly given in annexure VIII.

7. Highlight the quoted items in the documents like Product Permission and Market Standing Certificate, and also mark the item code no. at appropriate place in the documents.

8. The uploaded product permission and other documents should be clearly legible. Date of issue of the documents should be clearly legible.

9. Upload the Bids on the e-portal well in advance so that failure in uploading can be avoided and no desired document remains un-uploaded.

10. In case there is any suggestion regarding Bid conditions/specifications/shelf life, strength, packing/turn over etc. The suggestions should be submitted/sent/E – Mailed one/two days earlier from the date of pre bid meeting so that the representation of the bidders may be well processed and decision could be taken well in time. **Bidders may submit their representations within one working day after pre-bid meeting. Representations received after that would not be entertained.**

11. **One person can only be authorized by one bidder for a particular item. In case, it is found that one person is authorized representative of more than one bidder for a particular item then all such bidders shall be disqualified on the ground of conflict of interest.**

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

12. If there is any query regarding terms and conditions in Bid document, you may contact :-

Sh. Krishna Pratap Singh, **Senior Accounts Officer (Proc)**

Ph.0141-2228064, Mob. No. 9953092656

Smt. Swati Sethi, **Senior Manager (Drug)**

Ph.0141-2228064, Mob. No. 7340662491

If any condition or term which is contrary to RTPP Act 2012 or RTPP Rules 2013, then provisions of RTPP Act 2012 or RTPP Rules 2013 shall prevail and be binding on bidders

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

Rajasthan Medical Services Corporation Ltd., (hereinafter referred to as Bids Inviting Authority unless the context otherwise requires) invites **E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES**.

1. LAST DATE FOR RECEIPT OF BIDS AND BID FEES, BID SECURITY, RISL PROCESSING FEES AND EMPANELMENT FEES

(a) E-Bids in two separate bid (Technical bid & Price Bid) can be submitted till up to 06.00 P.M. 24.02.2025 on e-proc portal i.e. https://eproc.rajasthan.gov.in/, for the rate contract cum supply and empanelment for supply of drugs and medicines. **(Rate Contract for the period ending 31.03.2027)**

(b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity period for an additional specified period of time. The Bidder may refuse extension of bid validity, and in such a case its Bid security deposit shall not be forfeited.

(c) The Bids will be received on e-procurement web-portal of Govt. of Rajasthan. Every Bidder will be required to pay the following fees:

S. No.	Fee / Security	In favour of	Mode	Amount (In Rs.)
1	2	3	4	5
1	Bid Processing fee	M.D. RISL	Only DD/ BC	2950/-
2	Bid form fee	M.D. RMSCL	D.D. / BC/ NEFT/ RTGS /IMPS/ Bank challan*	2,360/- (for MSME unit of Rajasthan @ 50% of Bid form fee)
3	Bid Security	M.D. RMSCL	D.D. / BC/ NEFT/ RTGS /IMPS/BG/ e-BG/ Bank challan / **Insurance Surety Bonds**	@2% (for MSME unit of Rajasthan @ 0.5%) of Estimated Bid value for each quoted item as per Annexure VIII)
4	Empanelment fee (Optional)	M.D. RMSCL	D.D. / BC/ NEFT/ RTGS /IMPS/ Bank challan	5,900/-

Note:-

1. Bank challan* (format enclosed in Annexure-I) in any branch of the BANK OF MAHARASHTRA Account no.-60460019022 & IFSC Code no. MAHB0000389 throughout country.
2. S. No. 1, 2 & 4 fee amounts including GST @ 18% (as applicable).

All D.D. / Banker cheque/copy of all the receipts of NEFT/RTGS/WIRE/BANK CHALLAN/ **BG/ e-BG / of a scheduled bank or Insurance Surety Bonds issued by**

-

Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds should be submitted physically in the office of RMSCL on 24.02.2025 up to 6:00 PM. The bidders shall submit/upload scanned copy of all the receipts, D.D./BC/NEFT/RTGS/IMPS/BANK CHALLAN/ **BG/ e-BG/ of a scheduled bank or Insurance Surety Bonds issued by Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds** in Technical Bid. Bids will be opened only after ensuring receipt of Bid document fees along with processing fees and Bid Security Deposit. In the absence of Bid document fees and processing fees and Bid Security Deposit the Bids will be rejected and will not be opened. **The validity of Bank Guarantee/e-BG should be for 6 months from the date of issuance of BG/e-BG.**

(d) Click on offline mode (either DD or BC) on e procurement portal for the purpose of bid uploading only. For Empanelment as supplier for drugs and medicines, bidders are required to deposit separately an Empanelment Fee (Optional) of Rs 5900 (inclusive of GST @18%) (Five Thousand Nine Hundred rupees only) as mentioned above in condition no. 1(c). Please see clause 20 and Annexure-XI in this regard.

(e) **DD/ BC/ NEFT/RTGS/IMPS/BANK CHALLAN/BG/e-BG submitted by bidder should have been purchased/transferred/deposited from the account of the bidder only. If it is found that such fee have been paid from any bank account / person other than the bidder, than such fee would not be considered and such bids would be rejected.**

2. ELIGIBILITY CRITERIA

(a) Bidder should be a manufacturer having valid manufacturing license/loan license or direct importer holding valid import license. Distributors/ Suppliers / Agents are not eligible to participate in the Bids.

For patented / proprietary imported items manufactured outside India, Co-marketers having sole marketing rights in India are also eligible to participate.

(b) In Case of Manufacturer The bidder must have a valid manufacturing license issued by the State Licensing Authority / Central Licensing Authority.

(c) In Case of Importer Bidder should have a valid import license for the quoted item (s) issued by the Central Licensing Authority. Importer should also have a valid sale license (On form no. 20B, 21B also as applicable.)

(d) **Bidder should have valid Product Permission to manufacture the item /drug quoted as per specification given in the Bid from the State Licensing Authority / Central Licensing Authority product permission of brands shall be accepted in the Bid submitted.**

-

(e) **Bidder must have WHO-GMP (WHO - Good manufacturing practices Certificate) Certificate issued by the State Licensing Authority / Central Licensing Authority.**

(f) Bidder must have Non-conviction Certificate issued by the State Licensing Authority/Central Licensing Authority. It should be recent and not more than one year old.

(g) Bidder must have Market Standing as per required in technical bid.

Note: (i) The Market Standing Certificate issued by State Licensing Authority/Central Licensing Authority should not be more than 2 years old from the last date of bid submission.
(ii) The period of Market Standing will be reckoned from the date of issue of Product Permission.

(h) Annexure-VII as per bid document. (Declaration & Undertaking on Non-Judicial Stamp Paper of Rs. 500/-).

(i) Bidder should have Average Annual Turnover (for Drugs & Medicines including Surgical and sutures or medical devices business) as per technical bid. (Clause 5(m))

(j) Bidder must have submitted GST registration Certificate and its GST returns for the last three months form the last date of bid submission.

(k) Bidder must have committed monthly supply of 5% of the tendered quantity for each item.

(l) <u>Debarring/Banned/Blacklisting/ Not of Standard Quality etc.:-</u>

I. Bid should not be submitted for the product/products for which the concern/company stands blacklisted /banned/debarred on the date of bid submission either by Bid inviting Authority or Govt. of Rajasthan or its departments on any ground. The Bid should not be submitted for those products also for which the concern/company stands blacklisted/banned/debarred on the date of bid submission by any other State/Central Govt. or it's any agencies (central Drugs procurement agencies) on the ground of conviction by court of law or the products being found Not of Standard Quality. (NoSQ)

II. The concern/company/firm which stands blacklisted/banned/debarred on any ground either by Bid Inviting Authority (RMSCL) or Govt. of Rajasthan or its departments on the date of bid submission, shall not be eligible to participate in the Bid. The concern/company/firm which stands blacklisted/banned/debarred on the ground of conviction by court of law or the products being found Not of Standard Quality (NoS[illegible] by any other

State /Central Government or it's any agencies (central Drugs procurement agencies) shall also not be eligible to participate in the Bid. For Specific cases regarding other quality issues the purchase committee of RMSCL may decide the case on merit basis.

III. If any product/products of a company/firm have been declared as not of standard quality, as per Drugs & Cosmetics Act 1940 and Rules 1945 during last 2 years anywhere, such concern/company/firm shall not be eligible to participate in Bid for such product/products. If any company/firm is found to have any such product quoted in the Bid, the product shall be blacklisted for 2 years and Bid security of that item shall be forfeited

IV. The concern/firm/company whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court shall not be eligible to participate for that particular product, in the Bid. Similarly convicted firm/company shall also not be eligible to participate in the Bid.

3. PURCHASE PREFERENCE

i. Price preference is not applicable as GST has been made effective from 01.07.2017 in place of VAT.

ii. Purchase preference shall be given to MSME's unit of Rajasthan as per notification of Finance (GF&AR Division) Department, Government of Rajasthan notification S.O.165 dated 19.11.2015).

4. GENERAL CONDITIONS

(a) At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by way of amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority can at his discretion, extend the date and time for submission of Bids.

(b) Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority, i.e RMSCL.

(c) In case any document submitted by the bidder or his authorized representative is found to be forged, false or fabricated, the bid will be rejected and Bid Security/Performance Security will be forfeited. Bidders or their representative may also be blacklisted/banned/debarred. Report with police station can also be filed.

5. TECHNICAL BID

The Bidder should furnish the following in technical bid along with relevant documents:-

(a) Bidders are allowed the option to quote for anyone item o[illegible]em(s) as

mentioned in bid (list of drugs and medicines proposed to be purchased at Annexure-VIII). The amount of Bid Security Deposit shall be @ 2% of Estimated Bid value for each quoted item as per Annexure – VIII

(b) The bidders shall submit/upload scanned copy of all the copy of receipts, NEFT/RTGS/IMPS/BANK CHALLANS, D.D. / BC/BG/e-BG annexed with Technical Bid as proof of deposition/ submission of Bid document fees, RISL processing fee and Bid security. The required Bid Security Deposit / Bid document fees may be in form of physical D.D./ BC and should be in favour of M.D. RMSCL. The Bid Security may be given in the form of bank guarantee or electronic bank guarantee (e-BG) also in specified format of a scheduled bank in case the amount exceeds Rs 5 lac. For amount of up to Rs 5 lac, it should be deposited through D.D. / BC/ NEFT/RTGS/IMPS. The validity of bank guarantee / e-BG should be for 6 months from the date of issuance of BG / e-BG. RISL fee should be paid in form of DD/BC only in favour of M.D. RISL. D.D./ BC submitted by the bidder should have been purchased from the account of the bidder only **If it is found that such fee have been paid from any bank account / person other than the bidder, than such fee would not be considered and such bids would be rejected.**

(c) Those who Bidders which are found responsive on technical grounds would be empanelled also on submission of Annexure-XI and payment of empanelment fee of Rs. 5000 +GST@18% for supply of drugs and medicines item (s) mentioned in Annexure-VIII for one year. The empanelment would entitle a firm to participate in limited bids invited by the RMSCL. Such situations may normally arise when the open bid for drugs and medicines item (s) fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reasons. The Bidder has to submit an undertaking in the format given at Annexure –XI, The Bidder who have already paid empanelment fee earlier (within a year), need not to submit the empanelment fees for the item (s) being quoted in this bid. However the required Annexure-XI must be submitted.

(d) Documentary evidence for the constitution of the company / firm such as Memorandum and Articles of Association with certificate of incorporation issued by registrar of companies, Partnership Deed, Self declaration on letter head in case of proprietor ship firm etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.

(e) **The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed. (Annexure XVII).**

One person can only be authorized by one bidder for a particular item. In case, it is found that one person is authorized representative of more than one bidder for a particular item then all such bidders shall be disqualified on the ground of conflict of interest.

-

(f) Bidder have to submit following valid licenses:-

i) For Manufacturer:- The bidder must submit a valid manufacturing license / loan license issued by the State Licensing Authority/Central Licensing Authority under Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable for each quoted item (s).

In case bidder has submitted expired manufacturing license, then a copy of acknowledgment of renewal application issued by the State Licensing Authority/Central Licensing Authority or copy of original treasury challan regarding manufacturing license retention fees shall also be enclosed.

ii) **For Importer:-** In case of importers, Bidder should have a valid import license for the quoted item (s)issued by the Central Licensing Authority.

In case bidder has submitted expired Import license, then a copy of acknowledgment of renewal application issued by the Central Licensing Authority or copy of original treasury challan regarding Import license retention fees shall also be enclosed.

Importer should have to submit valid sale license (On form no. 20B, 21B also as applicable.)

iii) For Co –marketer :- Bidder should have to be submitted following documents -

1. Import license of principle manufacturer of patented/proprietary imported items.
2. WHO- GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US- FDA approval, etc.
3. Sale license of co-marketer firm.
4. Non conviction certificate of both firms i.e. importer and co-marketer firm. (Condition no. 5 (k) shall be applicable)
5. Market standing certificate for quoted item as per tender conditions. (condition no. 5 (j) (2) shall be applicable)
6. Market standing certificate of co-marketer firm as per tender conditions. (condition no. 5 (j) (2) shall be applicable)
7. Undertaking that the Co-marketing firm shall be accountable towards all responsibilities/ liabilities as per tender terms and conditions and full fil all such requirements.

(g) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary documents related to each manufacturing unit shall have to be submitted as a separate set with the same Bid. A bidder shall be allowed to submit only one offer for one bided item.

-

(h) Bidder should have valid Product Permission to manufacture the item /drug quoted as per specification given in the Bid from the **State licensing authority / Central licensing authority**. Product permission of brands shall be accepted in the Bid submitted.

(i) WHO-GMP (WHO - Good manufacturing practices Certificate) Certificate issued by the **State licensing authority / Central licensing authority**. The WHO-GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP.

The Importer should produce WHO- GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc.

The Firm will continue to hold WHO-GMP Certificate for the product during entire rate contract period of the product. If WHO-GMP certificate expires, it is firm's responsibility to inform RMSCL about the same and not to accept any further purchase order till re-issue /renewal of WHO-GMP certificate. During the period of non validity of WHO-GMP certificate of the firm the rate contract will deemed to be suspended. If the firm fails to inform RMSCL about the expiry of WHO-GMP certificate and accept purchase order of RMSCL and later on it comes to the knowledge of RMSCL, in this situation firm shall be liable for a panel action.

(j) Bidder have to submit **Marketing Standing** of the bided item (s) as below:-

1. For Manufactured Item (s):- Bidder must have Market Standing Certificate for last three ***years from the last date of bid submission,*** issued by the State Licensing Authority/Central Licensing Authority under Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable for the quoted item (s)from the last date of bid submission.

Note (a) For item code NRD-716 (Olaparib 100 mg Tablet) and NRD-717 (Olaparib 150 mg Tablet) Market Standing Certificate relaxed from three years to 3 months of tendered item and along with this three years Market standing Certificate of similar dosage form is also required (any tablet) but Product Permission should be as per tender specifications.

2. For imported item (s):-

(i) The importer should have at least 3 years standing as manufacturer/ importer of drugs in general.

(ii) In the case of imported products, the product should have minimum 3 years standing in the market.

For which following documents should be submitted:-

(a) <u>Bills of lading / Bills of entry and Sale invoices for last three years along with CA certificate with UDIN verifying details of bills of lading / bills of entry and sales invoices of bidder. (As per Annexure-XVIII)</u>

OR

(b) Market Standing Certificate issued by the **Central Licensing Authority/ State Licensing Authority** under Drugs & Cosmetic Act 1940 and Rules 1945 for last three years.

OR

(c) Market standing for the product in international market would be considered for establishing eligibility regarding this particular clause of the bidding document. Also if a bidder is manufacturing a product abroad at various locations/countries and participating in the bid quoting a product being manufactured at a particular place, market standing of the product manufactured at other than particular place would be considered." In such case Market Standing for the quoted item (s) in international market issued by competent authority of manufacturing country / country of origin or Bills of lading / Bills of entry and Sale invoices for other than manufacturing country / country of origin for last three years should be submitted. If submitted bills of lading / bills of entry and sale invoices are issued in other than English language than verified translated (in English language), self-attested copies of the same should be submit along with original ones.

(k) Bidder must submit Non-conviction Certificate issued by the State Licensing Authority/Central Licensing Authority for all manufacturing licenses / Import licenses as mentioned in Annexure VII. In case of Importer firm, Non- conviction certificate issued for all sale licenses (as mentioned in Annexure VII) of firm may also be acceptable. Submitted Non-conviction Certificate should be recent and not more than one year old form the last date of bid submission.

(l) **In case of proprietary item (s) of a particular firm / bidder, the bidder should submit its proprietary certificate along with detail of validity period.**

(m) Average Annual turnover (for Drugs & Medicines including Surgical and sutures or medical devices Business) in the last three financial years.

Average Annual turnover (for Drugs & Medicines including Surgical and sutures or medical devices Business) in the last three financial years [2020-21, 2021-22 & 2022-23 or 2021-2022, 2022-2023 and 2023-2024 (Audited Final Accounts)] shall not be less than Rs. 20 Crore and for MSME Units of Rajasthan, the average annual turnover in the last three financial years [2020-

21, 2021-22 & 2022-23 or 2021-2022, 2022-2023 and 2023-2024 (Audited Final Accounts)] shall not be less than Rs. 10 Crore.

For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc. bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore .
The same should be supported by audited annual accounts & certified by a Chartered Accountant, based on audited accounts.

Item code 398 (Black Disinfectant Fluid (Phenyl) As per Schedule O Grade III): Reserved for MSME Rajasthan

No provisional accounts shall be accepted/considered.

Annual Turnover Statement without UDIN number shall not be considered.

Explanatory Note:-

The merger / amalgamation / transfer of business / transfer of assets of a firm affect the bid condition relating to 'Turnover' / 'Past Performance' / 'Market Standing Certificate' in preceding years. The eligibility of a bidder in this regard shall be ascertained by the Purchase Committee on the basis of the above stated agreement / BOD resolution / CA certificate or any other document(s) / certificates which shall be annexed with the tender documents.

(n) Details of GST registration. The industries situated in GST free zones will produce the copy of appropriate notification. Bidders has to submit GSTIN number and state where GSTIN registered for every quoted item (s) for which supply will be made (Annexure VII at point no.3).

(o) GST returns file of last 3 months from last date of bid submission

(p) Undertaking (**as in Annexure-VII**) for embossment of logo on packing of drugs and medicines as the case may be, as per conditions specified at Clause 14 herein.

(q) The bidder who are manufacturing firm should have its own in-house testing laboratory wherein all the tests required with respect to the quality standards of quoted products are carried out. An undertaking be submitted in Annexure-VII.

(r) Undertaking that the manufacturer has not been debarred/banned, the product never been declared as Not of Standard Quality (NoSQ) during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure- VII.

(s) List of item (s) quoted to be shown in the **Annexure- VII** point number 6 with license number (manufacturing/Import/Sale license) written on it.

(t) A Checklist (**Annexure-V**) for the list of documents enclosed with their page number. The documents should be serially arranged as per **Annexure-V**. Every bidder shall also be required to submit details of product permission of the quoted item (s) and the desired market standing, in **Annexure-VI**.

-

(u) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document and quoted item (s) confirm all parameters of specification and required standards to be submitted in **Declaration & Undertaking (Annexure-VII point no.12)**

(v) Certificate that bidders with beneficial ownership from countries sharing land border with India, for participation in any public procurement in the State, shall only be allowed after prior registration with the authority as per Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021 (Annexure XV)

(w) A copy of PAN issued by Income Tax Department, GoI

Note:-

- **The bidder must highlight the quoted item(s) in submitted documents to support the technical evaluation of the bid.**

***Special Note to bidder*:-**

1. **Bidders are again advised to fill the Annexure -VII very carefully as after bid opening any amendment in Annexure-VII would not be allowed in any case. Bidders should ensure that all relevant documents i.e. Product Permission, WHO-GMP certificate, Market standing certificate, Non Conviction Certificate should be in accordance with the license no. / Product Permission mentioned in the Annexure VII. Bids Submitted without duly filled Annexure-VII would be declared Non-Responsive.**

2. **Bidders who fail to submit documents as under, would summerly declared as non-responsive:-**

   (a) In case Product Permission either not submitted or not as per tender conditions/specifications of the item; If Product Permission is as per specifications of item mentioned in the tender but it's for export purpose, the Product Permission for domestic manufacturing would be accepted only when asked through clarification and provided that such Product Permission for domestic manufacturing has been issued on or before the last date of bid submission.

   (b) If WHO-GMP certificate and/or Non-Conviction certificate and/or Market Standing Certificate have not been submitted in main bid or not as per tender condition/item specifications. It has also been observed that in certain cases, licensing authority takes time in issuance / renewal of aforesaid certificates, in such cases bidders have to invariably enclose expired documents/certificates along with copy of acknowledgment of application for renewal of such documents filed with licensing authority. In such cases bidders would be allowed to submit renewed documents in form of clarification sought by the RMSCL, provided that the re[illegible]cuments

should have been issued on or before the date of submission of clarifications as sought by the RMSCL.

6. PRICE BID –

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. **The bidder should quote rate for the mentioned packing unit only.**

7. **OPENING OF TECHNICAL AND FINANCIAL BID**

(a)The Technical Bid will be scrutinized by Bid evaluation committee.

(b)Technical Evaluation of the Bid will be done on the basis of documents submitted by the bidder.

(c) Price Bid (BOQ) of the Bidder found eligible on satisfying the criteria for technical evaluation, will only be opened.

8. **BID SECURITY**

The Bid Security shall be @ 2% of Estimated Bid value for each quoted item as per Annexure – VIII. In case Bid Security submitted by the bidder is Less than the required bid security as per total no. of quoted item (s), the quoted items by the bidder will be counted in sequence up to the number matching the Bid Security deposited.

Bid Security will not be taken from undertakings, corporation of GoI & GoR. Further, Bid Security will be taken @ 0.5% of Estimated Bid value for each quoted item as per Annexure – VIII from MSME Units of Rajasthan. They will furnish copy duly attested by gazetted officer of the registration of MSME units of Rajasthan issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs.100 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II(B)).

The Bid Security shall be paid through separate prescribed challan (format enclosed in Annexure-I) in any branch of the BANK OF MAHARASHTRA Account no.-60460019022 & IFSC Code no.MAHB0000389 throughout country upto 24.02.2025 or through D.D. / bankers cheque in favour of M.D. RMSCL or may be given in the form of bank guarantee (e-BG) (for amount above Rs 5 lac) also in specified format (Annexure-XIX) of [illegible] bank

or **Insurance Surety Bonds issued by Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds**. For amount of bid security up to Rs. 5 Lac, it should be deposited through DD/Banker cheque/Challan/ NEFT/RTGS/IMPS. The validity of bank guarantee/e-BG should be for 6 months from the date of issuance of BG/e-BG. (As per Annexure-XIX).

D.D. / BC/BG/e-BG, copy of all the receipts, NEFT/RTGS/IMPS/BANK CHALLAN/ should be submitted physically in the office of RMSCL on 24.02.2025 upto 06.00 PM. Bid security Deposit in any other form will not be accepted.

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the performance security. Other actions would also be taken as per RTPP Act 2012 & Rules 2013 and guidelines for blacklisting/debarring of RMSCL.

9. OTHER CONDITIONS

1. The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (hereinafter referred to as Ordering Authority).
2. **The details of the required drugs, medicines, etc., are shown in Annexure-VIII. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination. The commitment quantity for an item submitted by the bidder (in Annexure VII) shall be taken into account. The whole commitment quantity to be supplied during contract period should not be less than estimated bid quantity. As well, the monthly commitment quantity should not be less than 5% of the whole commitment qty. A bidder having manufacturing capacity less than commitment quantity (either monthly or for whole contract period) may be technically disqualified.**
3. Bid has been floated with the generic names of drugs. The Bidders should quote the rates for the generic products. The composition and strength of each product should be as per details given in Annexure-VIII. Any variation, if found, will result in rejection of the Bid. The products should conform to the specified standards IP/BP/USP. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

4. Rates (inclusive of **all expenses / charges but exclusive of GST)** should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.

5.

a) To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders

b) Orders will be placed periodically during rate contract period based on the RMSCL's requirement to the firms approved for rate contract as per above clause no. 3 .

c) After the conclusion of Price Bid opening, the lowest offer of the Bidder, if required will be considered for negotiations, and rate arrived after negotiations will be L-1 rate and L-1 supplier for an item of drugs/medicines for which the Bid has been invited.

d) The Bidder who has been declared as L-1 supplier for certain item or items of drugs/medicines shall execute necessary agreement for the supply of the Bided quantity of such drugs/medicines as specified in the Bid document on depositing the required amount as performance security and on execution of the agreement, such Bidder is eligible for the placement of purchase orders. **Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.**

e) RMSCL will inform the L1 rate to the Bidders who qualified for Price Bid opening, through RMSCL web site or e-mail; willing bidders may inform in writing their consent to match with the L-1 rate for the item of the Drugs/Medicines quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.

f) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, GST etc.) of price (L-1 rate).

g) The supplier upon receipt of the purchase order finds that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform to the RMSCL immediately

without loss of time and the purchase order shall be returned within 7 days from the date of the order, failing which the supplier is stopped from disputing the imposition of liquidated damages, fine for the delayed supply.

h) If the L1 supplier has failed to supply /intimated RMSCL about his inability/delay in supply as per the purchase order, the required Drugs/ Medicines within the stipulated time or as the case may be, RMSCL may also place purchase orders with the L1 Rate Matched Bidder for purchase of the Drugs/Medicines, provided such rate matched Bidders shall execute necessary agreement indicating the production capacity as specified in the Bid document on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or items of Drugs/Medicines quoted by them.

i) Subject to Para **(h)** above, while RMSCL has chosen to place purchase orders with Matched L1 supplier and there are more than one such matched L1 suppliers, then the purchase orders for the requirement of Drugs/Medicines will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.

j) The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.

k) If the purchase order quantity is very less (which do not make even a normal small batch size; order quantity is less than 1 lac Tab/Cap, or less than 10,000 injections/ bottles/ tubes), the supply may be allowed in brand name to ensure uninterrupted sustained supply. However, the label should possess the required logogram, and the price should not appear on the label.

6. The rates quoted and accepted will be binding on the Bidder during validity period of the bid and any increase in the price (except increase in **GST rate** or any other statutory taxes) will not be entertained.

7. No Bidder shall be allowed to claim revision or modification of bid after opening of bid. If any bidder withdraws or modifies its bid after opening of bid the **Bid security of that item taken from the bidder shall be forfeited.** Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids.

Conditions such as "SUBJECT TO AVAILABILITY" "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.

8. The rates should be quoted only for the composition stated in the Bid.
9. Supplies should be made directly by the bidder and not through any other agency.
10. The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If a Company/Firm does not allow for any such inspection, its Bid / contract may be rejected.

10. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
2. Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more items of the drugs Bided for in a Bid without assigning any reason.
3. Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the continuance of Bid and also has the right to reject the Bid or terminate/cancel the purchase orders issued and or not to reorder, based on adverse reports brought out during such inspections.
4. The acceptance of the Bids will be communicated to the successful Bidders in writing/through E-mail by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit performance security and the agreement within 15 days from issuance of Letter of Acceptance.
5. **The approved rates of the successful Bidders would be valid up to 31.03.2027 (w.e.f date of letter of acceptance) and extendable up to 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.**
6. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

11. PERFORMANCE SECURITY

The Successful Bidders shall be required to pay performance Security Deposit @ 5 % of the Contract value. Performance security will not be taken from undertaking, corporation of GoI & GoR. They have to submit a declaration as per Annexure-XVI for proof of exemption.

-

The MSME Units of Rajasthan shall be required to pay Performance security @ 1% of the contract value.

The performance security shall have an upper limit of Rs. 25 Lac to be deposited by a bidder at the time of signing of agreement (For one or many item). However, when the actual purchase orders cross a threshold for requiring additional security, the same will be required to be deposited by the supplier.

The performance guarantee should be paid upfront in respect of each contract on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee or electronic bank guarantee (e-BG). (Performa given in Annexure XIV) or **Insurance Surety Bonds issued by Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds.** In case the amount exceeds Rs. 5 Lac. For amount of up to 5 Lac. it should be deposited in the form of demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure-1 (the validity of bank guarantee should be for a period of Twenty four month from the date of issuance of Bank Guarantee) in favour of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur before releasing the purchase order by the ordering authority. In case Rate Matched Bidders who have agreed to supply at L-1 price, then the performance security Deposit of such bidders will be 5% of value of quantity fixed for them. (Upper limit Rs 25 Lac). Performance Security shall remain valid and refunded 60 days beyond the date of completion of all contractual obligations or after 36 months from the date of issuance of letter of acceptance, whichever is later**.**

12. AGREEMENT

a) The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days period from the date of Letter of acceptance / Letter of intent or within extended period by the Bid Inviting Authority, i.e. the Managing Director, Rajasthan Medical Services Corporation Ltd. The Specimen form of agreement is available in Annexure-IV. Failing to submission of performance security and execution of agreement within stipulated period as above, will result in forfeiture of Bid Security Deposit & other consequential action. A bidder who is found successful in more than one product; he will be intimated through LOA / LOI to execute agreement for all the products / drugs / items. If such bidder will not execute agreement for one or more items, **in such situation Bid security of that item shall be forfeited and the product for which agreement is not executed shall be**

debarred for a period of not less than 3 years as per guidelines for blacklisting/debarring of RMSCL.

b) The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.

c) All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

13. SUPPLY CONDITIONS

(a) Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Drugs and Medicines will be supplied at 34 district drug ware houses and 6 Medical College Warehouses of Rajasthan.

(b) Purchase orders will be placed on the successful Bidder at the discretion of the Ordering Authority.

(c) The supplier shall supply the entire ordered quantity before the end of **60 days** from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSCL, the supply should be completed by 5.00 p.m. on the next working day. For drug items requiring sterility test and imported ones, the supply period will be **75 days** from the date of issue of purchase order.

(d) All supplies will be scheduled for the period from the date of purchase order till the completion of the bid in installments, as may be stipulated in the purchase order.

(e) **Shelf Life**: The labeled shelf life of drugs supplied should be not less than the period mentioned against each item in list of Drugs (Annexure-VIII). The remaining shelf life of the drugs at the time of delivery should not be less than ¾ of the labeled shelf life. Only those bidders shall quote who can manufacture and supply the product with the required shelf life. The product of labeled shelf life lesser than required shelf life will not be accepted. The product should not have such storage condition requiring it to be stored below 2°C.

For all imported items ± one month relaxation in the labelled shelf life is permissible.

Quality Assurance: The supplier shall guarantee that the products as packed for shipment (i) comply with all provisions of specifications and related documents (ii) meet the recognized standards for safety, efficacy and quality; (iii) are fit for the purpose made; (iv) are free from defects in workmanship and in materials and (v) the product has been manufactured as per WHO-GMP.

In case of imported items the remaining shelf life of 60% or more may be accepted with an undertaking that the firm will replace the unused expired stores with fresh goods. However, firms supplying drugs with remaining shelf life of 75% or more need not submit such undertaking.

(f) The protocol of the tests should include the requirements given in I.P for tablets and those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of drug along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of drugs will be returned back to the supplier and he is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied and the placebo material when demanded for the purpose of testing.

(g) The Drugs and medicines supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents.

(h) If supplies are not fully completed in **60 days** from the date of the Purchase Order **(75 days** for drugs of the category of serum, vaccine, enzymes, blood grouping reagents, biological products, powder for injections and imported drugs), the provisions of liquidated damages of Bid conditions will come into force. The Supplier should supply the drugs at the Warehouse specified in the Purchase Order and if the drugs supplied at a designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.

(i) If the supplier fails to execute at least 50% of the quantity mentioned in a purchase order and such part supply is come into existence in three Purchase orders during the currency of contract period, then supplier shall be liable for debarment for the particular product for two years. Two years period will be reckoned from the date of issuance of such debarment order.

(j) If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Bid inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.

(k) The order stands cancelled after the expiration of delivery period, and if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the performance security and shall invite other penal action like blacklisting/Debarring disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. **.** (As per guidelines for blacklisting/ debarring at annexure- IX including amendment)

(l) It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.

(m) If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause, on a specific request made by the Bidder before expiring of supply period, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes. Reasons must be beyond control of supplier.

(n) The supplier shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Bid Inviting Authority in any trade or business or transactions nor shall the supplier give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Customs" or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.

(o) If the supplier or any of its approved items gets debarred/banned/blacklisted in any state after entering into agreement with RMSCL, it shall be the responsibility of the supplier to inform RMSCL without any delay about the same.

i. In case the Firm is black listed/debarred/banned after submission of bid document, it should inform the RMSCL within 15 days of blacklisting/debarring/banning. If the blacklisted/debarred / banned firm does not inform the RMSCL within stipulated time, a penalty amounting to @ two per cent of purchase orders issued between the date of blacklisting /debarring/banning and the date of informing to RMSCL, both dates inclusive, shall be imposed, subject to a minimum penalty of Rs 20,000 and a maximum penalty up to Rs 2,00,000 only.

ii. If it is brought to the notice of RMSCL that the similar drug of the supplier firm has been found spurious / adulterated in any other state (whether the firm / product has been blacklisted/ debarred/ banned or not); then no further purchase orders shall be issued for the product and the rate contract with the firm for the product shall be cancelled.

(p) If a supplier does not supply any quantity against two successive purchase orders then supplier shall be liable for debarment for the particular product for one year. One year period will be reckoned from the date of issuance of such debarment order.

(q) If a supplier fails to execute first order, without proper justification, a show cause notice may be given to him to respond within 7 days. If it does not respond or does not give reasonable justification, the corporation may order to L-2 and L-3, for entire failed supply on L-1 matched rate. If L-2 and L-3 matched rates are available,

then only purchase may be made on 'Risk and cost basis' as being done presently subject to other condition of Bid documents.

(r) The supplier of sevoflurane anesthetic (Item code no. 491) shall install vaporizers on loan basis free of cost, in required numbers, as per the need of the Healthcare facilities/ institutions. The installation report of the vaporizers should be submitted along with the invoice.

(s) If the supplier fails to execute full supply of the quantity mentioned in a purchase order then a penalty of 15 % of Value of unsupplied quantity shall be charged. Cases of zero supply against a purchase order shall also be dealt with in same manner.

-

14. LOGOGRAMS / Markings

Logogram means, wherever the context occurs, the design as specified below:-

DESIGNS FOR LOGORAMS

Logogram for item code except 448W, 489B, 490W, 490R	Logogram for item code 448W, 489B, 490W, 490R
RAJASTHAN MEDICAL SERVICES CORPORATION RMSC	NATIONAL HEALTH MISSION राष्ट्रीय स्वास्थ्य मिशन

INJECTIONS

Injection in ampoule form should be supplied either in Double constricted neck ampoules or snap off type ampoules with the label bearing the words "Rajasthan Govt. Supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed" overprinted and the following logogram which will distinguish from the normal trade packing. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

RAJASTHAN MEDICAL SERVICES CORPORATION RMSC

The vials should be supplied with aluminum seals containing the following logogram:

-

LIQUIDS

Liquid preparations should be in bottles with pilfer-proof caps bearing the following logogram:

Logogram for item code except 448W, 489B, 490W, 490R	Logogram for item code 448W, 489B, 490W, 490R

The top of the cap and the label to be affixed on the containers should bear a distint colour different from the colour of the label of the trade packs and they should be overprinted in red colour with the words **"Rajasthan Govt. Supply- Not for Sale निःशुल्क वितरण हेतु, QC – Passed"** and the logogram. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

OINTMENTS & CREAMS

Ointments & Creams should be supplied in tubes bearing the following logograms and the words **"Rajasthan Govt. supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed"** overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted backgro

-

TABLETS & CAPSULES

Tablets and Capsules should be supplied in Strips or Blisters or as mentioned in the list of items for bid. The strip, etc, should bear the following logograms and the words **"Rajasthan Govt. supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed"** overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

Logogram for item code except 448W, 489B, 490W, 490R	Logogram for item code 448W, 489B, 490W, 490R
RAJASTHAN RMSC MEDICAL SERVICES CORPORATION	NATIONAL HEALTH MISSION राष्ट्रीय स्वास्थ्य मिशन

SPECIMEN LABEL FOR OUTER CARTON

SHALL BE OF DIFFERENT COLOURS FOR DIFFERENT CLASS OF DRUGS

RAJASTHAN GOVT. SUPPLY
NOT FOR SALE

(Name of Drugs etc.)_____

CONSTITUENTS OF……..
Name of the Drug, Manufactured by, Batch no
Mfg.Date, Exp. Date, Quantity/Kit

Net. Weight:……..Kg

Manufactured by/Assembled by

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

The name of the drug shall be mentioned in Hindi and English and should be legible and be printed more prominently. A uniform colour theme and artwork will be necessary. Apart from this "F**or Govt. of Rajasthan – Not for Sale** निःशुल्क वितरण हेतु, **QC – Passed"** along with logo of RMSCL will be printed on each strip/label of the bottle. The storage directions should be clear, legible and preferably with yellow highlighted background.

1. Bids for the supply for Drugs and medicines etc., shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the strips of tablets and capsules and labels of bottles, ampoules and vials etc., as per the design mentioned above.
2. All tablets and capsules have to be supplied in standard packing in aluminum strip or blisters with aluminium foil back with printed logogram and shall also conform to schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
3. Labels of Vials, Ampoules and Bottles containing the items Bided for should also carry the logogram.
4. Failure to supply Drugs etc., with the logogram will be treated as breach of the terms of agreement and liquidated damages will be deducted from bills payable as per conditions in Clause 18.2 Bidders who are not willing to agree to conditions above will be summarily rejected.
5. In case of imported drugs affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

   Note: For all imported items, logo and logogram printing on inner packing is exempted however, henceforth stamp of logo and logogram is mandatory on outer packing. Sticker of logo and logogram not allowed.

-

15. PACKING

1. The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
2. The pediatric drops should always be supplied with dropper. A measuring cap with suitable markings must be provided for other paediatric oral liquid preparations.
3. The labels in the case of injectables should clearly indicate whether the preparations are meant for IV, IM, SC, etc.
4. Injection vials should have flip off seals.
5. All plastic containers should be made of virgin grade plastic.
6. The name of the drug should be printed in clearly legible bold letters (It is advisable that the colour of font be different from other printed matter to make the name highly conspicuous.
7. It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
8. All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act.
9. Packing should be able to prevent damages or deterioration during transit.
10. In the event of items supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier. In such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 18.2, 19 and 21.

I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES GENERAL SPECIFICATIONS

No corrugate package should weigh over 15 kgs (i.e. product + inner carton + corrugated box).

All items should be packed only in first hand strong boxes only.

Every corrugated box should preferably be of single joint and not more than two joints.

Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.

The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 should not crack.

Every box should be sealed with gum tape running along the top and lower opening.

CARRY STRAP:

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

For item code 310 Every box should be strapped with two parallel nylon carry straps / BoPP Taped Packing (they should intersect.)

LABEL:

Every corrugated box should carry a large outer label clearly indicating that the product is for "Rajasthan Govt. Supply-Not for Sale".

The Product label on the cartoon should be large, atleast 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

OTHERS:

NO box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES

1. The total weight of the box should be approx of 7-8 Kgs.

III. SPECIFIATION FOR LARGE VOLUME BOTTLE i.e., ABOVE 100 ml AND BELOW 1 LIT.

1. All these bottles should be packed only in single row with partition between each and also with top and bottom pad of 3 ply.

IV. SPECIFICATION FOR IV FLUIDS

Each corrugated box may carry maximum of only 24 bottles of 500 ml in a single row or 50 bottles of 100 ml in 2 rows with individual sealed polythene cover and centre partition pad, top and bottom pads of 3 ply.

V. SPECIFICATION FOR LIQUID ORALS

100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and centre pad of 3 ply.

50 bottles of 100 ml – 120 ml may be packed in a similar manner in a single corrugated box.

If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

VI. SPECIFICATION FOR OINTMENT/CREAM/GELS PACKED IN TUBES:

No corrugated box should weigh more than 7-8 Kgs.

Every Ointment/Cream/Gel tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

VII. SPECIFICATIONS FOR INJECTION (IN VIALS AND AMPOULES)

Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

In the case of 10 ml Ampoules or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

If the vial is packed in individual cartoon, there is no necessity for grey board box packing. The individual cartoon may be packed as such in the CB with centre pad.

In case of ampoules every grey board box should carry 5 amps alongwith Cutters placed in a polythene bag.

Vials of eye and ear drops should be packed in a individual cartoon with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

Cutters are not required with ampoules in the case of snap off type ampoules.

VIII. SPECIFICATION FOR ORS

Primary Packing:- The pouches/sachets of ORS should be three layered with following composition

Site	Material	Micron	MM	g/m²
Inner	Polyethylene	50	0.040-0.050	36.9-46.1
Middle	Aluminium	09	0.009-0.015	24.3-40.5
Outside	Polyester	12	0.012-0.015	12.9-20.9

Secondary Packages and Tertiary package:-

50 sachets may be packed in grey board boxes and 10 grey board boxes in a C.B.

IX. LYSOL

Not more than four 5 liters cans may be packed in a single Box.

16. QUALITY TESTING

1. Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSCL will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
2. The Drugs shall have the active ingredients within the permissible level throughout the shelf life period of the drug. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
3. In the event of the samples of the Drugs and medicines supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of items of drugs and medicines for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.
4. If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
5. The products should conform to the standards of IP/BP/USP as the case may be. In case the product is not included in the said compendium, the supplier shall produce the award of

the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP)

6. The supply of any item shall be considered complete for the purpose of calculation of liquidated damages only when reference standards/ standard testing procedure or test protocol/placebo materials are made available to the corporation along with the supply of items as per the purchase order. However these materials and documents shall be made available by supplier to Quality Cell of RMSCL Headquarter. Such requirement will however be indicated in the purchase order.

17. <u>PAYMENT PROVISIONS</u>

1. No advance payment towards costs of drugs, medicines etc., will be made to the B**idder**.
2. On receipt of the prescribed consolidated invoice duly stamped and signed by authorized signatory and analytical laboratory report regarding quality, the payment would be made as soon as possible. (Annexure- XII & XIII)
3. The in charge of district drug warehouse (DDW) will acknowledge the drugs received & ensure entry in e- Aushadhi software online. .
4. All bills/ Invoices should be raised in **triplicate** and in the case of excisable Drugs and Medicines; the bills should be drawn as per **GST Rules / other applicable Rules if any** in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW/**MCDW**.
   a. In house test report of drug.
   b. The challan / invoice copy pertaining to DDW/ **MCDW**
5. **Payments for supplies will be considered after receipt of reports of standard quality on samples having been tested by approved laboratories of ordering authority.**
   (i) Payments can be initiated if 50 % supply has been made against a purchase order by a supplier before expiry of supply period/extended supply period.
   (ii) After expiry of supply period/extended supply period payments for actual supplies made against a purchase order will be made although supplies are less than 50 %.
6. If at any time during the period of contract, the price of Bided items is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.
   In case the price of a drug fixed by NPPA (Govt of India) under applicable DPCO is less than the RMSCL contract price, the supplier shall be bound to make the supplies of such items at price fixed by the Govt.

7(a) In case of any enhancement in **GST as per** notification of the Government after the date of submission of Bids and during the Bid period, the quantum additional

GST so levied will be allowed to be charged extra as a separate item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in **GST**, the Bidder should produce a letter from the concerned Excise authorities / **GST authorities (Central and State)** for having paid additional **GST** on the goods supplied to ordering authority and also must claim the same in the invoice separately. **In case of reduction in rates of GST price will be reduced accordingly.**

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt. **(Including NPPA)**, after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

7(b) In case of successful bidder has been enjoying **GST** exemption **or** any criteria of Turnover etc., such bidder will not be allowed to claim **GST** at later point of time, during the tenure of contract, when the **GST** is chargeable on goods manufactured/**Supplied**.

8. (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.

(ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.

(iii) **Extension in delivery period:-** In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-

a) Delay up to one fourth period of the prescribed delivery period; 2.5%
b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
c) Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
d) Delay exceeding three fourth of the prescribed delivery period; 10%

Note 1:- Bidder should apply for extension before expire of original supply period mentioned in purchase order. No request will be considered after the expiry of supply period.

Note 2:- Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

Note 3:- In specific condition, permission for additional delay of 10 days may be granted for supply, in such a case an additional penalty of 5% shall be levied.

Note 4:- If a supplier seeks extension in supply period beyond two times the time indicated in purchase order, the supply period shall be extended with the condition

that if the rate received in new bid(s) invited are lower than the rate contract in operation, then the supplier shall be entitled to the lower rates so received.

9. If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, wars, fire, storm, tempest or other exceptional cause, on a specific request made by the Supplier before expiry of supply period indicated in P.O , the time for effecting delivery may be extended by the Purchaser surely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.

10. If the firm is Blacklisted/Debarred by State Govt. of Rajasthan during rate contract period/ after rate contract period, the firm has to follow below mentioned conditions:-

- Further Purchase orders should not be placed to firm.
- Purchase orders in process shall be cancelled.
- All unconsumed stock from DDWs should be lifted on the cost of firm.
- If payment is made for unconsumed stock it should be recovered from firm.
- All rate contracts should be cancelled.

18. DEDUCTION IN PAYMENTS:

1. If the supply is received in damaged conditions it shall not be accepted.
2. All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause **No.15.10.**

19. QUALITY CONTROL DEDUCTION & OTHER PENALTIES:

1. If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Bid security Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from blacklisting/ debarring the supplier. (As per guidelines for blacklisting/ debarring at annexure IX)
2. (i) If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action under the existing laws and the entire stock in such batch should be taken back by the supplier within a period of 30 days from the issue of letter from ordering authority the information of which may be communicated by e- mail. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF STANDARD DRUGS IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy the NOT OF STANDARD drugs

within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the drugs rejected till such destruction.

The Supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority.

(ii) **If RMSCL decides not to return the NOSQ drugs to supplier and decides to destroy NOSQ drugs at its level, then provision of demurrage charge will not apply. Means, if RMSCL writes to supplier to take back NOSQ drugs, then demurrage provision as per 19(2)(i) will be applied and if does not write to take back and decides to destroy drugs at its own level, then demurrage charge provision as per 19(2)(i) will not be applied.**

3. The supplier will not be entitled to any payment whatsoever for Items of drugs found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of drugs from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for Black Listing / debarring. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
4. For supply of drugs of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including blacklisting/ debarring. (As per guidelines for blacklisting/ debarring at annexure IX)
5. The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied drugs, medicines etc., shall be final and binding.
6. Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per rules.
8. Non performance of any contract provisions shall be examine and may disqualify the firm to participate in the future Bids.
9. **In the event of making ALTERNATIVE PURCHASE, as specified in Clause 13.10, Clause 15.10 and in Clause 16.3 the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the performance security or from any other money due and become due to the supplier and in the event of such amount being**

insufficient, the balance will be recovered personally from the supplier and provided further that such amount to be levied as per penalty from supplier on account of non-supply shall not be less than 15% of the value of non-supplied even when rates in alternative purchase method are lower / equivalent to rates in original tender.

10. In all the above conditions, the decision of the Bid Inviting Authority, viz Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding; in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
11. All litigations related to the supplier for any defaults will be done by Bid Inviting Authority and his decision will be final and binding.
12. In the case of litigation as per court decision/award by arbitrator, if any amount of interest is payable/receivable etc. then RMSCL will charge interest@9% per annum simple interest and it will be payable @ 6% per annum simple interest only.

20. EMPANELMENT OF BIDDERS (OPTIONAL)

Bidders which are found eligible / responsive on technical grounds / criteria would be empanelled for those item for which they have bided in the NIB as per Annexure VIII. A The empanelment would entitle a firm to participate in RMSCL's limited bids. Such situations may normally arise when the open bid for a Drugs & Medicines fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.

The empanelment can be renewed for the next one year term on payment of the empanelment fee as applicable at the time of renewal.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

22. JURISDICTION

In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench only).

23. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

24. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:

(i) At the time of award of contract, the quantity of Drugs, originally specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The bid quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period.

The supplier shall submit the supply commitment quantity'' in Annexure **VII at point no. 3** which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.

(ii) If the procuring entity does not procure any subject matter of procurement or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.

(iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSCL. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.

25. DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS):

The bid quantity shall be fixed in following manner-
L-1(Single Bidder)100%
Between L-1 and Rate Matched Firm-1in the ratio of 60:40
Among L-1, Rate Matched Firm-1 and 2in the ratio of 50:25:25

Purchase preference shall be given to MSME's unit of Rajasthan as per notification of Finance (GF&AR Division) Department; Government of Rajasthan notification S.O.165 dated 19.11.2015).

The supply orders for quantity fixed as above may be issued as and when required. RMSCL has full rights to increase or decrease the bid quantity upto any limit during the contract period.

26. GRIEVANCE REDRESSAL DURING PROCUREMENT PR...

The Designation and address of the First Appellate Authority is MD, NHM, Rajasthan Jaipur.

The Designation and address of the Second Appellate Authority is The Additional Chief Secretary / Principal Secretary / Secretary Department of Medical Health & Family Welfare, Govt. of Rajasthan.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of procurement;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a procurement process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal (Annexure X)

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

27. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a procurement process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

c) Not indulge in any collusion, Bid rigging or any anti-competitive behaviour to impair the transparency, fairness and progress of the procurement process;

d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;

e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

f) Not obstruct any investigation or audit of a procurement process;

g) Disclose conflict of interest, if any; and

h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest. A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in charge/ consultant for the co

-

28. FALL CLAUSE

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes / reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be automatically reduced with effect from the date of reducing or quoting lower price, for all delivery of the subject matter of procurement under that rate contract and the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving them fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

29. APPLICABILITY OF RULES

Besides above conditions the provisions of RTPP Act 2012 & RTPP Rules 2013 and Drugs and Cosmetic Act 1940 and Rules 1945 will be applicable.

Managing Director
Rajasthan Medical Services Corporation Ltd

ANNEXURE-I

CAUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

BANK of MAHARASHTRA — Bank Copy

Branch — DIST. NO.

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 60460019022

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing Fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹ 0.00

Commission ₹ 0.00

Total amount ₹

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

Annexure-1

Bank of MAHARASHTRA — Customer Copy

Branch — DIST. NO.

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 60460019022

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing Fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹ 0.00

Commission ₹ 0.00

Total amount ₹

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

37

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

ANNEXURE-II (A)
(Ref. Caluse no .3 (ii))

Form A

Application by MSME for price preference or Purchase Preference or both in Procurement of Goods

To,
The General Manager
DIC, District…….

1. Name of Applicant with Post
2. Permanent Address
3. Contact Details
   a) Telephone No.:
   b) Mobile no. :
   c) Fax no.:
   d) Email Address:
4. Name of micro & small enterprise:
5. Office Address:
6. Address of Work Place:
7. No. & Date of Entrepreneurs Memorandum-II/Udyog Aadhaar Memorandam (enclose photo copy)
8. Products for which Entrepreneurs Memorandum-II/ Udyog Aadhaar Memorandum availed:
9. Products for which are at present being produced by the enterprise:
10. Products for which price preference or Purchase preference or both has been applied for:
11. Production capacity as per Capacity Assessment Certificate (enclose photocopy of Capacity Assessment Certificate)

Serial No	Product	Production Capacity	
		Quantity	Value
1			
2			
3			
4			

12. List of Plant & Machinery installed

Serial No	Name of Plant & Machinery	Quantity	Value
1			
2			
3			

13. List of Testing Equipments installed

-

Serial No	Name of Plant & Machinery	Quantity	Value
1			
2			
3			
4			

14. Benefits availed as per price preference certificate in last financial year and current financial year

a. Benefits depositing Bid Security and Performance Security:

Last financial year			Current financial year	
Departments	**Bid Security**	**Performance Security**	**Bid Security**	**Performance Security**

b. Details of Supply orders received:

Last financial year				Current financial year		
Departments	**No. & Date of purchase order**	**Amount for which purchase order received**	**Amount of goods supplied**	**No. & Date of purchase order**	**Amount for which purchase order received**	**Amount of goods supplied**

I declare that the above all facts given in the application are correct and my enterprise is producing the items mentioned in column No. 10

Date

Signature
(Name of the applicant along with seal of post)

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

CERTIFICATE

(See clause 3(ii))

File no. _____

Date_____

It is certified that M/s _____ was inspected by _____on dated _____ and the facts mentioned by the enterprise are correct as per the record shown by the applicant. The enterprise is eligible for Price Preference or Purchase Preference or both under this notification. The certificate is valid for one year from the date of its issue .

Office Seal

Signature
(Full Name of the Officer)
General Manager
District Industries Centre
Rubber Seal/Stamp

Enclosure- (1) Application
(2)
(3)

-

ANNEXURE-II (B)
Ref. Clause No.8 & 3(ii)

Form-'B'
Format of Affidavit
(On Non Judicial Stamp Paper of Rs. 10/-)

I……S/o……..Age……..Yrs……. residing at……Proprietor/Partner/Director of M/s……do hereby solemnly affirm and declare that:

(a) My/Our above noted enterprises M/s…… has been issued acknowledgement of Entrepreneurial Memorandum Part-II by the Districts Industries Center……The acknowledgement No. is…….dated……..and has issued for Manufacture of following items.

(i)
(ii)
(iii)
(iv)
(v)

(b) My/Our above noted acknowledgement of Entrepreneurial Memorandum Part-II has not been cancelled or withdrawn by the Industries Department and that the enterprise is regularly manufacturing the above items.

(c) My/Our enterprise is having all the requisite plant and machinery and is fully equipped to manufacture the above noted items.

Place…….

Signature of Proprietor/Director
Authorized Signatory with Rubber
Stamp and date

VERIFICATION

I……S/
o…….Aged……Yrs……residing at……
Proprietor/Partner/Director of M/s……verify and confirm that the contents at (a), (b) & (c) above are true and correct to the best of my knowledge and nothing has been concealed therein. So help me God.

DEPONENT

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

ANNEXURE-III
(Ref. Clause No. 2 (i), 5 (n))

ANNUAL TURN OVER STATEMENT

The Annual Turnover ***(for Drugs & Medicines including Surgical and sutures or medical devices business)*** of M/s._____for the past three years are given below and certified that the statement is true and correct.

S.No.	Years	Turnover in Crore (Rs)
1	2020-21	
2	2021-22	
3	2022-23	
Total		**Rs.** **Crore**
Average turnover per annual		**Rs.** **Crore**

OR

S.No.	Years	Turnover in Crore (Rs)
1	2021-22	
2	2022-23	
3	2023-24	
Total		**Rs.** **Crore**
Average turnover per annual		**Rs.** **Crore**

Date:

Seal:
(Name in Capital)

Signature of Auditor/
Chartered Accountant
(Name in Capital)

UDIN :

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

ANNEXURE-IV

Ref. Clause No.12(a)

AGREEMENT

This Deed of Agreement is made on this _____day of _____2025 by M/s._____ represented by its Proprietor/Managing partner/Managing Director having its Registered Office at _____and its Factory Premises at _____
(hereinafter referred to as "Supplier" which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs_____(Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 31.03.2027) (F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:-) and technical bid **opened on 25.02.2025** the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.
2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.

   (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no. …….and dated……and it shall remain in force up to **31.03.2027** and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.

   (c) The Bid quantity noted against each item in the schedule attached hereto indicates only the probable total requirements of the Purchaser during the Agreement Period indicated in Clause (b) above. This quantity may increase or decrease at the discretion of the Purchaser. The Supplier shall make supplies of the

Drugs and Medicines on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1 (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as PERFORMANCE SECURITY and cancel the Contract.

(b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser

on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

(c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2 The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3 All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, biding or be of any effect whatsoever.

SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4 The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Supplier permit any [illegible] persons whomsoever to interfere in the management or performance [illegible] or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

-

BANKRUPTCY OF THE SUPPLIER

5 In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SUPPLIER

6 All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.

7 And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.

8 All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SUPPLIER (Signature, Name & Address With Stamp)

EXECUTIVE DIRECTOR (P), RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

Witness (Signature, Name & Address)

1.

2.

Witness

1.

2.

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

ANNEXURE – V
Ref. Clause No. 5 (t)

Check List

Section	Details of requirement	Document Type	Yes/No If Yes Page No.
A	**BID SECURITY DEPOSIT, RISL Fess, Bid Processing Fees, Empanelment Fees.**	Challan/DD/ e–deposit generated receipt of Bid Security Deposit, bid fee, RISL fee, empanelment fee and SSI certificate for exemption with Annexure-II	
B	**Mandatory documents**	Manufacturing Licence/loan licence (as per point 2 (b) of eligibility criteria)/ Manufacturing Licence renewal/Retention /validity certificate	
		For co-marketer- Import license of principle manufacturer of patented/proprietary imported items with other relevant documents (as per point 5(f)(iii))	
		Non Conviction Certificate issued by the Drugs Controller((as per point 2 (f) of eligibility criteria)	
		WHO-GMP Certificate (as per point 2 (e) of eligibility criteria)	
		Import License/ renewal/Retention /validity certificate, if imported. ((as per point 2 (c) of eligibility criteria)	
		Sale License renewal/Retention /validity certificate, in the case of imported drugs ((as per point 2 (c) of eligibility criteria)	
		Record of import/ Market Standing Certificate to establish 3 years market standing, if imported. ((as per point 5 (j)(ii) of eligibility criteria)	
		Product Permissions by the State Licensing Authority / Central Licensing Authority for each and every product quoted. ((as per point 2 (d) of eligibility criteria)	
		Market Standing Certificate issued by the State Licensing Authority / Central Licensing Authority ((as per point 2 (g) of eligibility criteria)	
		Annexure-VII Declaration and Undertaking (as per 2 (h) of eligibility criteria)	
		The instruments such as power of attorney resolution of board etc bidder authorization Certificate (As per 5 (e)	
C	**Other Documents**	Annexure-III -Annual Turnover Statement (as per 2 (i), 5(n) of eligibility criteria)	
		GST registration and GST Return (as per 2 (i) of eligibility criteria)	
		Annexure-VI Check List Of Details Regarding Products Quoted	
		Documentary evidence for the constitution of the company / concern	
		Copies of balance sheet & profit loss account for three years	
		Copy of PAN	
		Annexure-XI Undertaking For Empanelment	
		Annexure -XV Land Border Country Registration Requirement	
		Annexure –XVI Performance Security Declaration	

Note:-In case of non-submission of above mentioned mandatory documents with the original bid, the firm will be treated as Non-responsive and further queries / clarifications will not be sought.

-

Annexure – VI
Ref. Clause No. 5 (h)(i)(j)(k)(t)

Check list of details regarding quoted products

S. No.	Quoted Item /Code no.	Product permission enclosed on page no.	Date of product permission / Approval	WHO-GMP certificate Issue date and enclosed on page no.	Non Conviction certificate Issue date and enclosed on page no.	As per MSC product Mfg & Mkt since last 3 years	
						Page No.	Date of Issue
1							
2							
3							
4							
5							

-

Annexure – VII

Ref. Clause No. 2 (h) (k), 5 (q)(r)(s)(t)(v), 24(i)

Declaration & Undertaking

(For F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:-

(On Non-Judicial Stamp Paper of Rs 500/-)

I Name……S/o…….Age……..Prop./Partner/Director/Power of attorney holder/Authorized person of firm M/s……situated at (Complete address of Mfg. unit)……bearing drug license on Form 25, 28, 10 etc bearing Number……. &……..respectively, issued on dated……..valid/Renewed up to……..do here by declare on oath as follows:-

1. That none of the quoted Drug and Medicines manufactured / imported/co-marketed by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
2. That the quoted product is manufactured/imported/ co-marketed by us, and none has been declared as "Not of standard quality" during last two years.
3. That we have following Commitment of quantity in our plant at above address [**Ref. Clause No. 9(2) & 24 (i)**]:-

S. No.	Quoted item Code No. & Name of Drugs	Monthly Capacity in all shifts in nos.	Annual Production Capacity	Supply Commitment quantity during rate contract period(not be less than estimated bid quantity)	Estimated Bid Quantity as per Annexure VIII	Bid security deposited @ 2% of estimated bid value as mentioned in Annexure VIII. (In Rs.)	GSTIN Number & Name of State where GSTIN registered
1.							
2.							

Bidder is bound to supply minimum 5% of bid quantity on monthly basis and entire bid quantity within the contract period as per Purchase order.

4. That concern/company/firm does not stand blacklisted/banned/debarred on any ground by Bid Inviting Authority or Govt. of Rajasthan or its departments on the date of bid submission.
   The concern/company/firm does not stand blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or its any agencies (central Drugs procurement agencies). **But my firm is blacklisted/banned/debarred on a different ground by a procurement agency, the details of which are given below----------(Write 'NIL' if no such matter exists)**
5. That our Firm/Company and its Proprietor/Partner/Directors/ Power of attorney holders have not been convicted for contravention of any provisions of Drugs & Cosmetic Act, 1940 and rules made there under since grant of license.

Signature Not Verified
Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

S. No.	Code No.	Name of the Product	Date of product permission obtained from the Licensing Authority	Whether Endorsement is in Generic or Trade Name	Issuing Licensing Authority	Sale License no. (in case of imported item(s))	Manufacturing /loan/Import License Number for quoted items
1.							
2.							

7. That we have over three years' experience in the manufacture of the quoted product, or the quoted imported product has over 3 years market standing.
8. That we have own in-house testing laboratory wherein all the tests required w.r.t. the quoted products are carried out.
9. a. That we have approved qualified staff, machines & equipments along with capacity to manufacture above category of drugs
   b. For drug items our unit have been issued **WHO-GMP*** by State Licensing Authority / Central Licensing Authority vide letter No…….dated…….valid upto……..
10. That we hereby confirm that we have deposited all the VAT/Sale Tax/ **GST & filling returns as applicable** as on……..With the department. **Central excise / State commercial department** is due on M/s……as on……..
11. That I will supply the Drug and Medicines as per the designs given in Bid and as per the instructions given in clause No. 14.
12. That I/We have carefully read all the conditions of e- Bid in Ref. no F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:- for Rate Contract cum Supply, of Drugs and Medicines (**Rate Contract for the period ending on 31.03.2027**) for Rajasthan Medical Services Corporation Ltd and accept all conditions of Bid, including amendments if any. If case of typographical error found in submitted documents / affidavits, in this case we accept all the Terms and conditions of bid documents.
13. I/We agree that the Bid Inviting Authority forfeiting the Bid security Deposit and or Performance Security and blacklisting /Debarring/Banning me/ us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Schedule M of the said Act or at any time during the Bid process.
14. I/ we hereby declare under Section 7 & 11 of Rajasthan Transparency in Public Procurement Act, 2012. that:
    a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
    b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the **State Government or any local authority** as specified in the Bidding

Document;

c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;

d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;

e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.

f. I/we have complied and shall continue to comply with the Code of Integrity as specified in the Rajasthan Transparency in Public Procurement Act, the Rajasthan Transparency in Public Procurement Rules and this Bidding Document, till completion of all our obligations under the Contract.

15. The quoted rates of any items is not more than the price fixed by the govt. under the current drugs (Price control) order.

16. **I/We undertake that I/We shall strictly adhere to the provisions of clause number 28 –"Fall clause" of Bid document.**

17. ***The submitted Average Annual Turnover certificate is related to (*for Drugs & Medicines including Surgical and sutures or medical devices business*).***

18. Our complete address for communication……
……
……
Pin…….
Pan No.----------
E-mail address: - ……...
Phone No. /Mobile No……

19. Bank detail for e banking :-
Name of account holder ……..
Full name of Bank with Branch ……..
Address of Bank ……Pin……
A/c no. with full digits…….
IFSC code ……

(Name of Deponent & Signature)
Designation

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Verification

I……..S/o……(Designation)……Affirm on oath that the contents/information from para 1 to 19 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid for which I shall be solely responsible and the firm may be Debarred/Banned/ blacklisted / prosecuted for the same.

(Name of Deponent & Signature)

Witness :- (Name, Address & Signature)
1
2

*Certificates on which validity period has not been mentioned, such certificate should not be older than one year from the last date of submission of application/ bid.

-

Annexure – VIII

Ref. Clause No. 5(a), 9 (2, 3)

List of Drugs with Specifications

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
1	2	Bupivacaine Hydochloride in Dextrose Injection USP Each ml contains Bupivacaine Hydrochloride 5.0 mg Dextrose 80.0 mg [2]	4 ml Amp (10 Amp) (Rate Should be quoted for 10 ampules)	24	784796	4755103	95102	
2	6	Halothane BP [6]	250 ml in Amber Colour Bottle (Rate should be quoted for single unit)	36	4730	5387659	107753	
3	7	Isoflurane USP[7]	100 ml Bottle (Rate should be quoted for single unit)	36	35180	18432561	368651	
4	12	Lignocaine Gel IP 2% [12]	30gm tube in mono carton (Rate Should be quoted for Single Unit)	24	4937262	36831975	736640	
5	13	Lignocaine Inj IP 2% [13]	30 ml vial (Rate Should be quoted for Single Unit)	24	1042558	8173655	163473	
6	21	Fentanyl Citrate Injection IP 50 mcg/ml [21]	2 ml Amp (10 Ampoules)(Rate Should be quoted for 10 Amp)	36	446190	4722475	94450	
7	26	Paracetamol Drops [Paediatric Paracetamol Oral Suspension IP] (Each ml contains Paracetamol 150 mg) [26]	15 ml Bottle (with a separate dropper, which should be able to screw & cap the bottle) in a unit carton (Rate Should be quoted for single unit)	24	16025038	100316738	2006335	
8	27	Paracetamol Syrup IP 125 mg/5ml (40% Sugar base with strawberry flavour and carmoisine colour) [27]	60 ml Bottle (with Measuring Cap) (Rate should be quoted Single Unit)	24	36054030	241201461	4824029	
9	40	Dexamethasone Tab IP 0.5 mg [40]	10x10 Tab Strip (Rate Should be quoted for 100 Tablets)	24	57861644	7776599	155532	
10	42	Hydrocortisone Sodium Succinate Injection IP 100 mg base / vial (IM/IV use) [42]	Vial(Rate should be quoted Single Unit)	36	8024542	64358054	1287161	
11	43	Hydroxyzine Tablets IP 25 mg	10x10 Tab	36	70202708	1351865	347437	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		[43]	Strip/Blister (Rate should be quoted 100 Tab)					
12	44	Methyl Prednisolone Sodium Succinate for Injection USP 500 mg [44]	Vial (Rate should be quoted Single Unit)	36	942800	82155592	1643112	
13	47	Prednisolone Tablets IP 5 mg [47]	10x10 Tab Strip/blister (Rate Should be quoted for 100 Tab)	24	55388882	14888536	297771	
14	50	Promethazine Tablets IP 25 mg [50]	10 X 10 Tab Strip (Rate Should be quoted for 100 Tab)	36	6816176	2061219	41224	
15	51	Naloxone Inj IP 0.4mg/ ml [51]	1 ml Amp (10 Amp) (Rate Should be quoted for 10 amp)	24	45792	2533469	50669	
16	52	Pralidoxime Chloride Injection IP 500mg [52]	Vial(Rate should be quoted Single Unit)	24	304312	17278835	345577	
17	53	Carbamazepine Tab IP 200 mg [53]	10x10 Tab Strip/Blister (Rate Should be quoted for 100 Tab.)	36	16698250	20198264	403965	
18	54	Carbamazepine Tab IP 100 mg [54]	10x10 Tab strip/Blister (Rate Should be quoted for 100 tab.)	36	6940780	5830272	116605	
19	56	Phenobarbitone Tablets IP 30 mg [56]	10 x 10 Tab Strip (Rate Should be quoted for 100 Tab)	36	8171986	2462224	49244	
20	57	Phenytoin Injection BP 50mg/ml [57]	2 ml Amp Amber Colour (25 Amp) (Rate should be quoted 25 amp)	36	3393998	13304480	266090	
21	58	Phenytoin Oral suspension IP 25mg/ml [58]	100 ml Glass bottle with measuring cap(Rate should be quoted Single Unit)	24	211626	3733083	74662	
22	61	Sodium Valproate Gastro resistant Tablets IP 200 mg [61]	10x10 Tab Strip Or 10x15 Tab Strip (Rate should be quoted for 100 Tab)	36	37792570	28650570	573011	
23	63	Acyclovir Tablets IP 200 mg [63]	10 x10 Tab Blister (Rate Should be quoted for 100	24	7902572	7035087	140702	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Tab)					
24	64	Acyclovir Tablets IP 800 mg [64]	10x10 Tab Strip (Rate should be quoted for 100 Tab)	36	15146664	57678634	1153573	
25	65	Albendazole Oral suspension IP 400 mg/10ml [65]	10ml Bottle (Rate should be quoted Single Unit)	24	8386648	31114464	622289	
26	67	Amikacin Inj IP 100 mg [67]	2 ml Vial (Rate Should be quoted for Single Unit)	36	8277292	42628054	852561	
27	68	Amikacin Inj IP 500 mg [68]	2 ml Vial(Rate should be quoted Single Unit)	36	24672268	396483347	7929667	
28	73	Amoxycillin Dispersible Tablets IP 125mg [73]	10 x 10 Tab Strip (Rate Should be quoted for 100 Tab)	24	36517844	24945309	498906	
29	75	Ampicillin Injection IP 500 mg [75]	Vial (Rate Should be quoted for Single Unit)	24	2560364	18229792	364596	
30	81	Benzathine Benzylpenicillin Inj IP 12 lac units [81]	Vial (Rate Should be quoted for single vial)	24	141200	2229548	44591	
31	90	Ceftazidime Injection IP 250 mg [90]	Vial (Rate should be quoted Single Unit)	24	523082	6329292	126586	
32	91	Ceftazidime Injection IP 500 mg [91]	Vial (Rate should be quoted Single Unit)	24	545844	10250950	205019	
33	93	Ceftriaxone Inj IP 1g /vial [93]	Vial (Packed in MonoCarton) (Rate Should be quoted for Single Unit)	24	44980702	629729828	12594597	
34	95	Ceftriaxone Inj IP 500mg/vial [95]	Vial (Packed in MonoCarton) (Rate Should be quoted for Single Unit)	24	13197648	115743373	2314867	
35	98	Chloroquine Phosphate Injection IP 40mg/ml [98]	5 ml Amp (25 ampoules) (Rate Should be quoted for 25 Amp)	24	980084	3342840	66857	
36	99	Chloroquine Phosphate Tab. IP 250mg (Eq to 155 mg of Chloroquine base) (Film Coated) [99]	10 x10 Tab Strip / Blister (Rate Should be quoted for 100 Tab)	36	3444960	2488778	47756	
37	101	Ciprofloxacin Injection IP 200mg/100ml [101]	100ml FFS/ BFS Bottle(Rate	24	3126044	2063489	392698	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Should be quoted for 100ml FFS/ BFS Bottle)					
38	104	Clotrimazole Cream IP 2% w/w [104]	15gm tube in Mono Carton (Rate Should be quoted for Single Unit)	24	21426406	111417311	2228346	
39	106	Compound Benzoic Acid Ointment IP Benzoic Acid 6 o/o + Salicylic Acid 3 o/o [106]	15gm tube in Mono Carton (Rate Should be quoted for Single Unit)	24	1607726	9774974	195499	
40	107	Co-trimoxazole oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg [107]	50 ml Bottle (with measuring Cap) (Rate Should be quoted for Single Unit)	24	10440634	78722380	1574448	
41	108	Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg [108]	10x10 Tab Blister (Rate Should be quoted for 100 Tab)	36	50569684	20334076	406682	
42	116	Gentamicin Injection IP 80mg/2ml (IM/ IV use) [116]	2 ml amp(50 Ampoules)(Rate Should be quoted for 50 Amp.)	24	9345474	25015901	500318	
43	117	Griseofulvin Tablet IP 125 mg [117]	10 x 10 Tab Strip (Rate should be quoted for 100 Tab.)	24	3764524	4298306	85966	
44	119	Meropenem Inj IP 500 mg [119]	vial (Rate Should be quoted for Single unit)	24	802230	43577134	871543	
45	120	Metronidazole Injection IP 500 mg/100ml [120]	100ml FFS/ BFS Bottle (Rate Should be quoted for 100ml FFS/ BFS Bottle)	36	12285784	102463439	2049269	
46	122	Metronidazole Tablets IP 200 mg (Film Coated)[122]	10 x 10 Tab Blister (Rate should be quoted for 100 Tab.)	36	62029302	23546322	470926	
47	124	Norfloxacin Tablets IP 400 mg (Film Coated) [124]	10x10 Tab Blister(Rate Should be quoted for 100 Tab)	24	54845102	77397405	1547948	
48	125	Ofloxacin Tablets IP 200 mg [125]	10x10 Tab Blister (Rate Should be quoted for 100 Tab)	24	91492262	70192893	1403858	
49	132	Quinine sulphate Tablets IP 300mg (Film Coated) [132]	10x10 Tab Blister (Rate should be quoted for 100 Tab)	24	2378850	3620153	72403	
50	136	Chlorambucil Tab IP 5 mg [136]	30 Tab Bottles (Rate Should be quoted for 30 Tab	24	25440	249312	4986	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			)					
51	138	Cyclophosphamide Inj IP 200 mg [138]	10 ml glass Vial (Rate Should be quoted for Single Unit)	24	16490	257574	5151	
52	139	Cyclophosphamide Inj IP 500 mg [139]	25ml Glass Vial(Rate Should be quoted for Single unit)	24	45150	1229886	24598	
53	142	Danazol Cap IP 50 mg [142]	10x10 Cap Blister (Rate Should be quoted for 100 Cap)	36	647200	1804911	36098	
54	143	Daunorubicin Inj IP 20 mg [143]	10 ml glass vial (Rate Should be quoted for 10 ml glass vial)	24	10044	1214922	24298	
55	147	Flunarizine Tablets 5 mg [147]	10 X 10 Tab Blister (Rate Should be quoted for 100 Tab)	36	7918448	1453026	29061	
56	148	Fluorouracil Inj IP 250 mg/ 5ml [148]	5 ml Ampoule (Rate should be quoted Single Unit)	24	138600	1338876	26778	
57	149	L-Asparaginase Inj 10000 IU [149]	Vial(Rate Should be quoted for Single vial)	24	4374	2342277	46846	
58	152	Mercaptopurine Tablets IP 50 mg [152]	10 x 10 Tab strip (Rate Should be quoted for 100 Tab)	24	374040	813712	16274	
59	156	Paclitaxel Inj IP 100 mg [156]	16.7 ml Vial (Rate should be quoted Single Unit)	24	44246	8672216	173444	
60	158	Vinblastine Injection IP 10mg [158]	Vial (Rate should be quoted Single Unit)	24	14316	2431573	48631	
61	159	Vincristine Injection IP 1 mg [159]	Vial / Amp (Rate should be quoted Single Unit)	24	46296	1799526	35991	
62	160	Levodopa and Carbidopa Tablets IP Levodopa 100 mg + Carbidopa 10 mg [160]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	36	1787588	3002989	60060	
63	161	Levodopa and Carbidopa Tab IP 250 mg+ 25 mg [161]	10 X 10 Tab Strip(Rate Should be quoted for 100 Tab)	24	1992950	7879525	157591	
64	165	Deferasirox Tab 100 mg [165]	30 Tab (Rate Should be quoted for 30 Tab.)	18	99600	2108847	42177	
65	169	Desferrioxamine Injection IP	Vial	18	59852	9301001	186020	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		500 mg / Vial (For I.M. Inj and I.V., S.C. Infusion) [169]	(Rate Should be quoted for single vial)					
66	174	Heparin Sodium Inj IP 5000 IU/ml (IM/IV use) [174]	5 ml Vial (Rate Should be quoted for single vial)	36	584682	51732663	1034653	
67	176	rh-Erythropoetin Inj IP 10000 IU [176]	Vial/PFS(Rate Should be quoted for Single Unit)	24	24544	7394616	147892	
68	179	rh-ErythropoetinInj IP 4000 IU [179]	Vial/PFS (Rate should be quoted Single Unit)	24	359386	35500149	710003	
69	193	Dopamine Hydrochloride Inj IP 40 mg/ml [193]	5 ml Amp(Amber Colour)25 Ampoules (Rate Should be quoted for 25 amp.)	36	1044032	6796603	135932	
70	194	Enalapril Maleate Tablets IP 5mg [194]	10x10 / 15 Tab Blister / Strip (Rate should be quoted for 100 Tab)	24	5508640	1202527	24051	
71	195	Enalapril Maleate Tablets IP 2.5mg [195]	10x10 Tab Strip Or 10x15 Tab Strip (Rate should be quoted for 100 Tab)	24	3690670	657314	13146	
72	198	Isosorbide mononitrate Tabs IP 20 mg [198]	10x10 Tab Strip(Rate Should be quoted for 100 Tab)	24	28250866	8252088	165042	
73	202	Methyldopa Tab IP 250mg Film Coated [202]	10X10 Tab Blister (Rate should be quoted for 100 tab)	36	2011320	4662998	93260	
74	203	Nifedipine Cap IP 5mg [203]	10x10 Cap Strip(Rate Should be quoted for 100 Cap)	24	3001290	1863807	37276	
75	204	Nifedipine Tablets IP 10 mg (Sustained Release)[204]	10x10 Tab Blister (Rate Should be quoted for 100 Tab)	36	7281320	3164453	63289	
76	209	Streptokinase Injection 15 lac units IP [209]	Vial (Rate Should be quoted for single vial)	24	43472	26674854	533497	
77	211	Verapamil Tablets IP 40 mg (Film Coated) [211]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	30	785602	52792[illegible]58		
78	220	Miconazole Nitrate Cream IP 2%	15 gm tube in	24	13009068	57500072	1150001	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		[220]	unit carton (Rate Should be quoted for 15 gm tube in unit carton)					
79	222	Povidone Iodine solution IP 5 % [222]	500 ml Bottle(Rate Should be quoted for Single Unit)	24	1690460	123065488	2461310	
80	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg) [223]	10 gm Plastic Bottle with Nozzle to sprinkle powder (Rate Should be quoted for single unit)	18	4210286	49512963	990259	
81	224	Silver Sulphadiazine cream IP 1% [224]	50 gm Tube (Rate should be quoted Single Unit)	24	3689674	92979785	1859596	
82	233	DiatrizoateMeglumine and Diat Sod Inj USP 76%w/v (iodine = 370 mg/ml) [233]	20 ml Ampoule (Rate should be quoted Single Unit)	36	77812	13878548	277571	
83	241	Tropicamide Eye Drops IP 1% [241]	5 ml Vial with sterilized dropper, or squeeze vial (Rate Should be quoted for single vial)	24	258956	3190338	63807	
84	244	Compound Benzoin Tincture IP [244]	500 ml Bottle(Rate Should be quoted for single unit)	30	139772	17054979	341100	
85	248	Hydrogen Peroxide Solution IP 6 o/o (20 Vol) [248]	400 ml bottle with inner cap (Rate Should be quoted for single unit)	24	683782	12253373	245067	
86	249	Lysol (Cresol with Soap Solution) IP (Cresol 50 o/o + Soap 50 o/o) [249]	5 Ltrs Can (Rate Should be quoted for Single Unit)	36	172524	163083487	3261670	
87	250	Povidone Iodine Scrub Solution / cleansing solution 7.5 o/o w/v Povidone Iodine (suitable for hand wash) [250]	500 ml Bottle (Rate Should be quoted for Single Unit)	18	399224	42697007	853940	
88	262	Bisacodyl Tablets IP 5 mg [262]	10x10 Tab Strip(Rate Should be quoted for 100 Tab)	24	43390322	9715088	194302	
89	269	Loperamide Tab IP 2 mg [269]	10 x 10 Tab Strip (Rate Should be quoted for 100 Tab)	36	14114936	2255561	45111	
90	270	Metoclopramide Injection IP 10mg/2ml [270]	2 ml Amp (Amber colour) (25 ampoules) (Rate Should be	24	9109320	1359417	27184	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			quoted for 25 amp)					
91	271	Metoclopramide Tablets IP 10 mg [271]	10x10 Tab Blister (Rate should be quoted for 100 Tab)	36	30323414	6113197	122264	
92	273	Ondansetron Inj IP 2mg/ml [273]	2 ml Amp (10 Amp) (Rate Should be quoted for 10 amp)	36	28146500	35943081	718862	
93	281	CarboprostTromethamine Injection IP Each ml contains Carboprost 0.25 mg/ml [281]	1 ml Amp/Vials (25 Amp/Vial) (Rate should be quoted 25 Amp/Vial)	24	264894	12460896	249218	
94	282	Clomifene Tablets IP 25 mg[282]	10 x10 Tab strip (Rate Should be quoted for 100 Tab)	24	588678	540603	10812	
95	283	Clomiphene Tablets IP 50 mg[283]	10 x10 Tab Strip (Rate should be quoted for 100 Tab.)	24	726416	804706	16094	
96	285	Dinoprostone Cream/ Gel 0.5 mg Dinoprostone in Syringe [285]	Syringe (Rate should be quoted for Single unit)	24	460294	69080924	1381618	
97	286	Ethinyloestradiol Tabs IP 50 mcg[286]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	24	1155328	2249369	44987	
98	288	Gliclazide Tablets IP 40 mg [288]	10 x 10 Tab Strip/Blisteror15x 10 Tab Strip/Blister(Rate Should be quoted for 100 Tab)	24	3982398	1870932	37419	
99	291	Glipizide Tab IP 5mg [291]	10X10 Tab Blister (Rate Should be quoted for 100 Tab)	24	4106454	869346	17387	
100	293	Hydroxyprogesterone Injection IP 250mg/ ml [293]	1 ml Amp(25 ampoules) (Rate Should be quoted for 25 amp)	24	706088	6824880	136498	
101	294	Isophane Insulin Inj IP 40 IU /ml [294]	10 ml Vial (Rate should be quoted Single Unit)	24	373772	27162011	543240	
102	297	Pioglitazone Tab IP 15 mg [297]	10X10 Tab Blister (Rate Should be quoted for 100 Tab)	24	8770326	2121511	42430	
103	298	Progesterone Inj IP 200 mg/ 2ml [298]	2 ml Amp (10 Amp) (Rate should be quoted	24	502830	5003159	100063	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			for 10 ampoules)					
104	300	Insulin Injection IP (Soluble Insulin/Neutral Insulin Injection)40 IU/ml(r.DNA origin) [300]	10 ml Vial (Rate should be quoted Single Unit)	24	845448	56568926	1131379	
105	303	Human Anti D Immunoglobulin Injection IP 300mcg (IM use) / Human Anti D Immunoglobulin Injection 300mcg (IM use)[303]	Pre-filled Syringe/Vial (Rate should be quoted Single Unit)	24	213396	429489325	8589787	
106	304	Human Anti D Immunoglobulin IP150 mcg/ Human Anti D Immunoglobulin 150 mcg [304]	PFS / Vial (Rate should be quoted Single Unit)	24	45874	79123475	1582470	
107	306	Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU [306]	1ml Vial with 1.0 ml diluent (Rate Should be quoted for single unit)	36	2247558	417708654	8354173	
108	307	Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose [307]	Single dose vial with diluent and syringe with needle (Rate Should be quoted for Single Unit)	24	3795580	705408543	14108171	
109	308	Snake Venum Anti Serum IP (Lyophilized) Polyvalent Anti Snake Venum, Serum Enzyme Refined. Contain purified equine globulins. 1 ml of serum neutralizes 0.6 mg of cobra venum, 0.45 mg of common kraite (Bungaras) venum, 0.6 mg of Russell's Viper Venom and 0.45 mg of Saw-scaled Viper Venom. [308]	Vial(Rate Should be quoted for single Vial)	36	1165972	624214770	12484295	
110	310	Tetanus Vaccine (adsorbed) IP 5 ml vial [310]	5 ml Vial (Rate Should be quoted for Single Unit)	36	3141066	84211979	1684240	
111	311	Atracurium Injection IP 10 mg/ml [311]	2.5 ml Amp (10 amp)(Rate Should be quoted for 10 amp)	18	490286	8643322	172866	
112	312	GlycopyrrolateInj IP 0.2 mg/ml [312]	1ml Amp (10 ampoules) (Rate should be quoted for 10 amp)	24	870834	4778244	95565	
113	317	Succinylcholine Inj. IP 50 mg/ml (IV use) [317]	10 ml Vial (Rate should be quoted for Single Unit)	24	135304	4849295	96986	
114	319	Atropine Eye Ointment IP 1% [319]	3 gm tube in Mono carton (Rate should be quoted for single cartoon)	24	255454	22684	59	
115	322	Ciprofloxacin Eye Drops IP 0.3	5 ml Squeeze	36	29253118	81908730	1638175	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		o/o w/v [322]	Vial (Rate Should be quoted for Single Unit)					
116	323	Ciprofloxacin Ophthalmic Ointment USP 0.3% [323]	5 gm Tube in Mono Carton (Rate Should be quoted for Single Unit)	24	2633748	18831298	376626	
117	331	Tobramycin Eye Drops 0.3% [331]	5 ml Vial with sterilized dropper, or squeeze vial(Rate Should be quoted for single unit)	24	6536014	37386000	747720	
118	332	Tobramycin Ophthalmic Ointment USP 0.3% [332]	5 gm Tube in Mono Carton (Rate should be quoted Single Unit)	24	1341334	24935399	498708	
119	334	Isoxsuprine Tab IP 20 mg [334]	10x10 Tab Strip (Rate should be quoted for 100 Tab)	36	4494392	26068	521	
120	336	Methylergometrine Tab IP 0.125 mg [336]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	24	6388586	8012582	160252	
121	340	Alprazolam Tab IP 0.5mg [340]	10x10 Tab Blister/Strip or 15x10 Tab Blister/ Strip (Rate should be quoted for 100 Tab)	36	76271620	13835668	276713	
122	341	Amitriptyline Tab IP 25mg Film Coated [341]	10x10 / 30 Tab Strip(Rate Should be quoted for 100 Tab)	36	30719172	6469464	129389	
123	342	Chlordiazepoxide Tablets IP 10mg[342]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	24	12084680	5021193	100424	
124	344	Chlorpromazine Tablets IP 25 mg [344]	10 x10 Tab Strip (Rate should be quoted for 100 Tab)	36	2086034	630598	12612	
125	345	Chlorpromazine Tablets IP 50 mg (Coated Tablets) [345]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	36	2931870	1473866	29477	
126	349	Diazepam Inj IP 10mg/2ml (1M/IV use) [349]	2 ml Amp (25 Ampoules) (Rate should be quoted for 25 amp)	36	1105482	440775	8815	
127	350	Diazepam Tab IP 5 mg [350]	10x10 Tab strip/ blister	24	9357476	1987890	39758	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			(Rate should be quoted for 100 tab)					
128	352	Fluoxetine Cap/ Tab. IP 20 mg [352]	10X10 Cap / tab(Rate Should be quoted for 100 Cap/Tab.)	24	17990578	5742600	114852	
129	353	Haloperidol Inj IP 5 mg/ml [353]	1 ml Amp (10 Amp) (Rate should be quoted for 10 amp)	24	525216	2000038	40001	
130	354	Haloperidol Tablets IP 1.5 mg [354]	10x10 Tab Strip (Rate Should be quoted for 100 Tab)	24	801058	251225	5025	
131	355	Haloperidol Tablets IP 5 mg [355]	10x10 Tab Strip (Rate should be quoted for 100 Tab)	24	3494166	739722	14794	
132	356	Imipramine Tablets IP 25 mg (Coated Tablets) [356]	10x10 Tab Blister (Rate should be quoted for 100 Tab)	24	4429864	1830435	36609	
133	357	Imipramine Tablets IP 75 mg (Coated)[357]	10x10 Tab Blister (Rate Should be quoted for 100 Tab)	24	2473344	2174031	43481	
134	358	Lithium Carbonate Tablets IP 300 mg[358]	10 x10 Tab Strip(Rate Should be quoted for 100 Tab)	24	5226542	7082953	141659	
135	359	Lorazepam Injection IP 2 mg/ml [359]	2 ml Amp (25 ampoules) (Rate should be quoted for 25 amp)	24	268234	2089473	41789	
136	362	Risperidone Tablets 1 mg [362]	10x10 Tab Blister/Strip (Rate should be quoted for 100 Tab)	36	4605340	732243	14645	
137	363	Sertraline Tablets IP 50 mg [363]	10x10 Tab Strip/ Blister (Rate Should be quoted for 100 Tab.)	24	20507310	8561798	171236	
138	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ ml [369]	15 ml Glass Bottle (Rate Should be quoted for single unit)	24	1391888	14364284	287286	
139	371	Salbutamol Inhalation 100 mcg /dose [371]	200 metered dose container (Rate Should be quoted for single unit)	36	7879186	4443860	87722	
140	372	Salbutamol Nebuliser Solution BP 5 mg/ml[372]	10 ml vial(Rate Should be quoted	24	2911712	2119263	42345	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			for Single Unit)					
141	374	Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg) [374]	2 ml Amp (25 Ampoules) (Rate Should be quoted for 25 amp.)	24	11308980	21278967	425579	
142	377	Compound Sodium Lactate inj. IP [377]	500 ml FFS/BFS Bottle (Rate should be quoted for single unit)	36	24088772	390960770	7819215	
143	378	Dextrose Injection IP 25 % w/v [378]	100 ml FFS/BFS bottle (Rate should be quoted for single unit)	24	2570172	28066278	561326	
144	379	Dextrose injection IP 10% [379]	500 ml FFS/BFS Bottle (Rate should be quoted for single unit)	36	2438980	46169891	923398	
145	380	Dextrose injection IP 5% [380]	500 ml FFS/BFS Bottle(Rate should be quoted for single unit)	36	11235786	173705252	3474105	
146	381	Multiple Electrolytes & Dextrose Injection Type I IP (Electrolyte 'P' Injection) [381]	500 ml FFS / BFS Bottle (Rate should be quoted for single unit)	36	2549472	48822389	976448	
147	382	Multiple Electrolytes & Dextrose Injection Type III IP Electroylte "M" Injection (I.V.) [382]	500 ml FFS / BFS Bottle (Rate should be quoted for single unit)	36	1023990	19609409	392188	
148	385	Sodium Chloride and Dextrose Inj. I.P (0.9%+5%) [385]	500 ml FFS/BFS Bottle (Rate should be quoted for single unit)	36	18288886	283660622	5673212	
149	386	Sodium Chloride Injection IP [386]	500 ml FFS/BFS Bottle (Rate Should be quoted for single unit)	36	21576114	306812341	6136247	
150	391	Ferrous Sulphate with Folic Acid Tab. IP(Paediatric)Each film coated Tab. Containing Dried Ferrous Sulphate IP- eqivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg[391]	10 x 10 Tab Strip/Blister(Rate Should be quoted for 100 Tab)	24	78894762	8820439	176409	
151	393	Multivitamin Drops Each ml contains Vit A 3000 IU, Vit D3 300 IU, Vit B1 1mg, Riboflavine Phosphate Sodium 2mg, D-Panthenol 2.5mg, Niacinamide 10mg, Pyridoxine HCL 1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg [393]	15 ml Bottle (with dropper which should be able to screw and cap the bottle) in a unit carton (Rate Should be quoted for Single	18	8571918	62317844	1246357	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Unit)					
152	394	Multivitamin Tablets NFI Formula Sugar coated Vit A 2500 IU Vit B1-2mg Vit-B6-0.5mg Vit-C-50mg Calcium Pantothenate-1mg Vit-D3-200IU Vit-B2-2 mg Niacinamide-25mg Folic Acid-0.2 mg [394]	10X10 Tab Strip/Blister(Rate Should be quoted for 100 Tab)	24	371496740	170814183	3416284	
153	395	Vitamin B Complex Inj NFI [395]	10 ml vial (Rate Should be quoted for Single Unit)	18	1763100	11354364	227087	
154	398	Black Disinfectant Fluid (Phenyl) As per Schedule O Grade III [398]	5 Ltrs Can (Rate Should be quoted for Single Unit)	18	326986	98390087	1967802	
155	399	Concentrated Solution for Haemodialysis B.P Acetate concentrate in 10 Litre Cans. [399]	10 Ltrs Plastic Can (Rate should be quoted for 10 Ltrs Plastic Can) (Rate Should be quoted for single unit)	24	38658	12209743	244195	
156	401	Peritonial Dialysis Solution IP [401]	1000 ml FFS/ BFS Pack(Rate should be quoted for single unit)	24	16508	619380	12388	
157	406	Factor – IX Concentrate (Purified) IP 500-600 I.U. (Human Coagulation Factor IX) [406]	Vial with Solvent(Rate should be quoted for one I.U.)	24	12226	68684690	1373694	
158	407	Anti Inhibitor Coagulation Complex (Human Plasma Protein with a Factor VIII Inhibitor Bypassing Activity of 500 I.U. per Vial with 10 ml solvent) [407]	Vial with 10 ml solvent (Rate should be quoted for Single Unit)	24	4562	134122800	2682456	
159	411	Labetalol HCl Inj IP 20mg/4ml [411]	4 Ml Ampules (Rate Should be quoted for Single Unit)	24	1000212	12212589	244252	
160	413	Nitrofurantoin Tablets IP 100mg [413]	10 x 10 Tab Blister(Rate Should be quoted for 100 Tab)	24	19486932	14841223	296824	
161	415	Drotaverine Tablets IP 40mg [415]	10 X 10 Tablet Blister (Rate Should be quoted for 100 Tab)	24	40693278	15715752	314315	
162	420	Phenobarbitone Inj IP 200mg/ml [420]	1 ml Amp/Vial (Rate should be quoted for Single Unit)	24	331832	3378050	67561	
163	424	Lidocaine HCl Topical Solution USP 4% [424]	10 ml bottle with dropper / Squeeze bottle (Rate should be	36	200496	3014647	60293	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			quoted for single unit)					
164	425	Fluconazole Eye/Ear Drops 0.3% [425]	5 ml. vial with sterilized dropper,or squeeze vial (Rate Should be quoted for Single Unit)	24	541344	5213143	104263	
165	427	Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125mg/ 5 ml [427]	30 ml Bottle with Measuring Cap(Rate Should be quoted for single Unit)	18	15501676	140600201	2812004	
166	428	Ofloxacin oral Suspension IP 50mg/ 5ml [428]	30 ml Bottle (Rate should be quoted for single unit)	24	4338840	24471058	489421	
167	431	Tinidazole Tab IP 500 mg (Film Coated) [431]	10x10 Tab Blister (Rate should be quoted for 100 Tab)	36	9015614	6851867	137037	
168	436	Indomethacin Capsules IP 25 mg [436]	10x10 Cap Strip (Rate should be quoted for 100 Cap)	36	5124772	2238513	44770	
169	437	Diclofenac Prolonged Release Tablete IP 100mg [437]	10x10 Tab Strip (Rate should be quoted for 100 tab)	36	72734662	22896884	457938	
170	438	Dicyclomine Hydrochloride and Activated Dimethicone suspension Each ml contains Dicyclomine Hydrochloride 10mg Activated Dimethicone 40mg [438]	10 ml Bottle (with dropper which should be able to screw and cap the bottle) in a unit carton(Rate Should be quoted for Single Unit)	24	5241774	29668441	593369	
171	440	Dextromethorphan Hydrobromide Syrup IP 13.5mg / 5ml[440]	30 ml Bottle (Rate should be quoted for single unit)	24	44359014	205825825	4116517	
172	441	Calcium and Vitamin D3 Suspension (Each 5 ml contains Calcium Carbonate equivalent to elemental Calcium 250 mg, Vitamin D3 125 IU) [441]	100 ml Bottle (With Measuring Cap) (Rate should be quoted for single unit)	24	16475204	142345763	2846915	
173	443	Clotrimazole mouth paint (Clotrimazole 1% w/v)[443]	15 ml squeeze bottle (Rate should be quoted for single unit)	36	2338980	16864046	337281	
174	446	Gamma Benzene Hexachloride Lotion 1%(Lindane Lotion USP) (Lindane Application BP) [446]	100 Ml Bottle(Rate Should be quoted for Single Unit)	36	4262888	8525436	85088	
175	448	Iron and Folic Acid Suspension. Each 5ml contains Ferrous Fumerateequivalent to elemental	100 ml bottle in a unit carton with a separate dropper.	24	13115116	18243264	364865	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		iron 100mg, Folic Acid 500 mcg [448]	(Dropper should be able to screw & cap the Bottle; Should be long enough to suit the length of Bottle & should have 1 ml marking to dispense 1 ml) (Rate should be quoted for Single Unit)					
176	449	Surgical Spirit IP (100 ml) [449]	100ML opaque White Bottle with Inner Cap (Rate should be quoted for single unit)	24	2179518	36615902	732318	
177	451	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg [451]	10 x 10 / 15x10 Tab Blister / 14 Tab per Blister (Rate Should be quoted 100 Tab)	24	35303678	21747079	434942	
178	458	Losarton Potassium & Amlodipine tablets IP (Losarton Potassium 50 mg, Amlodipine Besilate eq. to Amlopdipine 5mg) [458]	10x10 Tab Strip/Blister(Rate should be quoted for 100 Tab)	36	46813290	21309414	426188	
179	459	Losartan Potassium and Hydrochlorothiazide Tablets IP(Losartan Potassium 50 mg, Hydochlorothiazide 12.5 mg) [459]	10x10 Tab Blister Or 10x15 Tab Blister (Rate should be quoted for 100 Tab)	24	93206806	40964389	819288	
180	460	Amlodipine and Lisinopril Tablets Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq to Lisinopril (anhydrous) 5 mg [460]	10X10 Tab Strip/Blister (Rate Should be quoted 100 Tab)	36	7516314	2805835	56117	
181	461	Amlodipine and Atenolol Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Atenolol 50mg [461]	10x10 Tab BlisterOr15x10 Tab Blister(Rate should be quoted for 100 Tab)	24	145405024	28993757	579875	
182	463	Enalapril Maleate Tablets IP 10 mg [463]	10 X 10 / 15 Tab Strip (Rate should be quoted for 100 Tab)	24	3908500	1746318	34926	
183	464	Hydrochlorthiazide Tablets IP 25 mg [464]	10x10 Tab strip (Rate should be quoted for 100 Tab)	24	3761522	827110	16542	
184	465	Lisinopril Tablets IP 10 mg [465]	10 x 10 Tab strip/Blister (Rate should be	24	2593658	1304373	27087	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			quoted for 100 Tab)					
185	466	Lisinopril Tablets IP 2.5 mg [466]	10 x 10 Tab strip/ blister (Rate should be quoted for 100 Tab)	24	2498656	611432	12229	
186	468	Piperacillin + Tazobactum for Injection IP 4gm+500mg [468]	Vial (Rate Should be quoted for Single Unit)	24	6800582	326767965	6535359	
187	469	Prednisolone Tablets IP 10 mg [469]	10 x 10 Tab Strip/Blister(Rate should be quoted for 100 Tab)	24	73002050	36632454	732649	
188	470	Prednisolone Tab IP 20 mg [470]	10X10 Tab Strip/Blister (Rate Should be quoted for 100 Tab)	24	15033232	15296281	305926	
189	474	Carbamazepine Oral Suspension USP 100 mg/5ml [474]	100 ml Bottle with measuring Cap (Rate Should be quoted for Single Unit)	24	208104	5358678	107174	
190	475	Cefpodoxime Dispersible Tablets 50 mg [475]	10x10 Tab Strip (Rate should be quoted for 100 Tab)	24	10754364	13369870	267397	
191	478	Metoclopramide Hydrochloride Syrup IP 5 mg/ 5ml [478]	30 ml Bottle (with a separate dropper, which should be able to screw & cap the bottle) in a unit carton (Rate should be quoted for Single Unit)	24	2397002	16179764	323595	
192	480	Diphtheria Antitoxin 10000 IU [480]	Vial(Rate should be quoted for single vial)	24	12210	14102550	282051	
193	482	Iohexol USP (Solution For Injection) Non Ionic Contrast Medium in Sterile aquous Solution 300 mg Iodine/ml [482]	20 ml Pack (Rate Should be quoted for Single Unit)	30	184722	34602125	692043	
194	483	Diclofenac Sod + Paracetamol Tablets IP Diclofenac Sod 50 mg + Paracetamol 325 mg [483]	10 x 10 Tab Blister (Rate Should be quoted for 100 Tab)	24	663158200	154383229	3087665	
195	485	Homatropine Eye Drops IP 2 % [485]	5 ml squeeze Vial (Rate should be quoted for single Vial)	24	193818	3649622	73992	
196	486	Travoprost Eye Drops IP 0.004 o/o [486]	3 ml squeeze vial (Rate Should be quoted for Single	24	144854	4867094	97342	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Unit)					
197	488	Iron Sucrose Injection USP/BP 20mg/ml (For IV use) Each ml contains Ferric Hydroxide in complex with Sucrose equiv. to elemental Iron 20 mg [488]	5 ml Ampoule (Amber Colour) (Rate Should be quoted for Single Unit)	24	8038676	76447809	1528956	
198	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg [492]	10 X 10 Tablet Blister (Rate Should be quoted for 100 Tab)	24	507112002	175511463	3510229	
199	493	Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5% [493]	20 gm Tube in unit carton (Rate Should be quoted for single unit)	24	107335780	619327451	12386549	
200	495	Etoricoxib Tab IP 120mg [495]	10X10 Tab Blister (Rate Should be quoted for 100 Tab)	24	40490640	53034588	1060692	
201	500	Acetylcystine Solution BP/USP (Injection) 200 mg/ml [500]	2ml Amp (5 amp)(Rate should be quoted for 5 amp)	24	242944	1904689	38094	
202	503	Acyclovir Intravenous Infusion IP 500mg [503]	Vial (Rate Should be quoted for single unit)	24	133424	2176145	43523	
203	504	Amikacin Injection IP 250 mg [504]	Vial (Rate Should be quoted for single unit)	24	6793556	62772457	1255449	
204	506	Amoxicillin and Potassium Clavulanate Inj IP 1.2gm [506]	Vial (Rate Should be quoted for Single Unit)	18	4967102	136297279	2725946	
205	524	Vancomycin For Intravenous Infusion IP 1 gm [524]	Vial (Rate Should be quoted for Single Unit)	24	403830	22303531	446071	
206	525	Alpha Interferon Injection Interferon Alpha 2 concentrated Solution IP 3 Million Unit[525]	Vial(Rate should be quoted for single unit)	24	426	138365	2767	
207	526	Carboplatin Injection IP 150 mg [526]	15 ml Vial (Rate should be quoted for Single Unit)	24	37194	16746227	334925	
208	527	Carboplatin Injection IP 450 mg [527]	45 ml vial (Rate Should be quoted for Single Unit)	24	87098	112182224	2243644	
209	532	Gemcitabine for Injection IP 1gm [532]	Vial (Rate Should be quoted for Single Unit)	24	70046	20919[illegible]	[illegible]399	
210	533	Ifosfamide Injection IP 1gm [533]	Vial (Rate should be quoted for single	24	43592	10410360	208387	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			unit)					
211	538	Oxaliplatin Injection USP 50 mg [538]	25 ml Vial (Rate should be quoted for Single Unit)	24	47784	8780310	175606	
212	542	Betahistine Tab IP 16 mg [542]	10X10 Tablets(Rate Should be quoted for 100 Tab)	36	12233394	4247436	84949	
213	543	Cinnarizine Tablets IP 25 mg [543]	10X10 Tab Blister (Rate Should be quoted for 100 Tab)	24	37896044	7082762	141655	
214	544	Cinnarizine Tablets IP 75 mg[544]	10x10 Tablet Blister (Rate Should be quoted for 100 Tab)	24	23277764	6974029	139481	
215	545	Tranexamic Acid Tablets IP 500 mg [545]	10x6 Tablet Blister (Rate should be quoted for 60 Tablet)	24	31214268	85761234	1715225	
216	546	Warfarin Sodium. Tab IP 5mg [546]	10x10 Tablet / 30 Tablet (Rate Should be quoted for 100 Tab)	24	1068284	528809	10576	
217	548	Atorvastatin Tablets IP 40 mg [548]	10X10 / 15 Tab(Rate Should be quoted for 100 Tablet)	24	59419964	35140988	702820	
218	550	Fenofibrate Capsules/ Tab IP 200 mg [550]	10x10 Capsule (Rate Should be quoted for 100 Capsule)	24	1811106	1823597	36472	
219	551	Isoprenaline Injection IP 2mg / ml [551]	1 ml Ampoule (5 Ampoules) (Rate should be quoted for 5 amp.)	24	51476	1556604	31132	
220	552	Metoprolol Tablets IP 25 mg [552]	10X10 Tablet / 15 Tablet (Rate Should be quoted for 100 Tab)	36	38686590	8066156	161323	
221	553	Metoprolol Succinate Extended Release Tablets IP 50 mg [553]	10X10 Tablet / 15 Tablet (Rate Should be quoted for 100 Tab)	24	47018532	17378038	347561	
222	555	Prazosin Tablets (Extended Release) 2.5 mg [555]	10x15 Tablet Strip /blister(Rate should be quoted for 150 Tablet)	24	912103	378346	7571	
223	557	Urokinase Injection 5 Lac Unit (Lyophilized) [557]	Vial (Rate should be quoted for Single	24	22272	45601920	912038	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Vial)					
224	558	Betamethasone Dipropionate Cream IP 0.05% [558]	15 gm Tube in unit carton (Rate should be quoted for Single Unit)	24	8975622	47032259	940645	
225	561	Clobetasol Propionate Cream IP 0.05 o/o [561]	20 gm tube (Rate Should be quoted for Single Unit)	24	3202026	20044683	400894	
226	568	Permethrin Lotion 5% [568]	30 ml (Rate should be quoted for Single unit)	24	3379434	22574619	451492	
227	569	Permethrin Cream 5% [569]	30 gm tube in a unit Carton (Rate should be quoted for Single unit)	24	4780860	34278766	685575	
228	570	Tretenoin cream USP 0.025% [570]	20 gm Tube in unit carton(Rate Should be quoted for Single Unit)	24	1007226	6617475	132350	
229	572	Povidone Iodine Solution IP 10% [572]	100 ml Bottle (Rate should be quoted for Single Unit)	24	899022	24111770	482235	
230	573	Silver Sulphadiazine cream IP 1% 500 gm Jar [573]	500 gm Jar (Rate Should be quoted for Single Unit)	24	253492	55071137	1101423	
231	575	Finasteride Tablets IP 5 mg [575]	10x10 Tablet strip/ blister or 10x30 Tab Strip / Blister (Rate should be quoted for 100 Tab)	24	1773056	1608556	32171	
232	579	Flavoxate Tablets IP 200 mg (Coated Tablet) [579]	10x10 Tablet (Rate Should be quoted for 100 Tablet)	24	7957782	14971805	299436	
233	580	Chlorhexidine Mouthwash IP 0.2%[580]	50 ml Bottle (Rate Should be quoted for Single Unit)	24	6569754	34819696	696394	
234	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base)[581]	10 gm Tube (Rate should be quoted for single unit)	24	4685218	25112768	502255	
235	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base) [582]	50 gm Tube in unit carton (Rate should be quoted for Single unit)	24	6743978	68845805	1376916	
236	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1% [583]	15 ml squeeze vial (Rate should be	24	2754700	17492345	349847	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			quoted for Single Unit)					
237	584	Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel [584]	10 gm Tube in unit carton(Rate should be quoted for Single unit)	24	1342320	7865995	157320	
238	585	Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drop Ciprofloxacin and Dexamethasone Otic Suspension USP / Ciprofloxacin 0.3% and Dexamethasone 0.1% Eye Drops/Ear Drop [585]	5 ml vial with sterilized dropper, or squeeze vial (Rate Should be quoted for single unit)	24	9055782	49625685	992514	
239	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP [588]	5 ml Bottle/vial (with separate dropper)(Rate should be quoted for Single Unit)	24	1156554	31874628	637493	
240	589	Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15% [589]	10 ml Bottle / Vial (with a separate dropper, which should be able to screw & cap the bottle) in a unit carton (Rate should be quoted for 10 ml Bottle / Vial)	24	3121448	26906882	538138	
241	590	Domperidone Oral Drops IP 10mg/ ml (10ml) [590]	10 ml Bottle (with a separate dropper, which should be able to screw & cap the bottle) in a unit carton(Rate should be quoted for Single unit)	24	4179606	32768111	655362	
242	591	Drotaverine and Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg [591]	10x10 Tablet (Rate Should be quoted for 100 Tab)	24	95536808	59920681	1198414	
243	595	Ondansetron Orally Disintegrating Tablets IP 4mg [595]	10x10 Tablet Strip (Rate Should be quoted for 100 Tab)	24	75823364	11464498	229290	
244	598	Allopurinol Tablets IP 100 mg[598]	10x10 Tablet (Rate Should be quoted for 100 Tablet)	24	2293390	1245316	24906	
245	599	Hydroxychloroquine Sulphate Tablets IP 200 mg [599]	10x10 Tablet(Rate Should be quoted for 100 Tablet)	24	11688512	196360	734	
246	605	Medroxyprogesterone acetate Tablets IP 10 mg [605]	10 X 10 Tablet (Rate Should be	24	1370136	1165407	23308	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			quoted for 100 Tab)					
247	608	Octreotide Injection 50 mcg/ ml [608]	1 ml Ampoule (Rate should be quoted for Single amp)	24	245290	5241847	104837	
248	610	Chlorzoxazone , Diclofenac sodium & Paracetamol Tablets (Chlorzoxazone 250mg , Diclofenac sodium 50mg Paracetamol 325 mg) [610]	10x10 Tablet (Rate should be quoted for 100 Tab)	24	186610874	95619425	1912389	
249	617	Budesonide Powder for Inhalation IP 200 mcg [617]	30 Capsule (Rate should be quoted for 30 Cap.)	24	4094436	2430727	48615	
250	619	Terbutaline Tablets IP 2.5 mg[619]	10x10 Tablet(Rate Should be quoted for 100 Tablet)	24	3024390	1151692	23034	
251	620	Xylometazoline Nasal Drops IP 0.1 % [620]	5 ml Vial/ Bottle (with a seperate dropper) in a unit carton (Rate should be quoted for single unit)	24	3463998	14340952	286819	
252	624	Mecobalamin Injection 500 mcg/ ml[624]	1 ml Ampoule (Rate Should be quoted for Single Unit)	24	2434448	6061776	121236	
253	627	Pyridoxine Tablets IP 40 mg[627]	10x10 Tablet Strip (Rate Should be quoted for 100 Tablet)	36	2409804	910904	18218	
254	631	Alendronate Sodium Tablets USP / BP 35 mg [631]	4 Tablets (20 X4Tablet) (Rate Should be quoted for 80 Tablet)	24	221420	905247	18105	
255	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion) [632]	100 ml FFS/BFS Bottle(Rate should be quoted for Single unit)	24	57810	1520981	30420	
256	633	Normal Human Intravenous Immunoglobulin IP 5 gm/ 100 ml[633]	100 ml vial (Rate Should be quoted for Single Unit)	24	131982	887611946	17752239	
257	636	Ramipril Tablet IP 2.5 mg[636]	10 x 10 Tab (Rate should be quoted for 100 Tab.)	24	26066590	7241301	144826	
258	639	Oseltamivir Capsule IP 75 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 75 mg] [639]	Strip/Blister of 10 Capsules (Rate should be quoted for Strip/Blister of 10 Capsules)	48	2123810	16152461	323049	
259	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml (Each	75 ml Bottle with measuring	24	287388	6880687	1376014	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		ml contains 12 mg Oseltamivir base after reconstitution) [642]	Cap(Rate should be quoted for Single Unit)					
260	645	Each Combi Blister Pack : Containing 3 tablet of Artesunate (each tablet of Artesunate 25 mg Strength) and 1 tablet of Sulphadoxine Pyremethamine (250 mg +12.5 mg)[645]	One Combi Blister Pack (Rate Should be quoted for Single Unit)	24	296196	3373672	67473	
261	651	Artemether and Leumefantrine Tablet (80 mg and 480 mg) [651]	1x6 Tablet Blister (Rate Should be quoted for 6 Tablet)	24	2628828	9406823	188136	
262	652	Methyl Cobalmine/Mecobalmin Tablet 500mcg [652]	10X10 Tablet Strip/Blister (Rate should be quoted for 100 Tab)	24	60632260	14666953	293339	
263	659	Levocetrizine Tablet IP 5 mg [659]	10 x 10 Tablet(Rate should be quoted for 100 Tab)	24	567201540	74303397	1486068	
264	661	Sodium Valproate Tablet(Gastro Resistant) IP 500mg [661]	10 x 10 Tablet Strip (Rate Should be quoted for 100 Tab)	24	42875904	57625210	1152504	
265	664	Levetiracetam Tablet IP 500 mg [664]	10 x 10 / 10 x15 Tablet Blister (Rate should be quoted for 100 Tab)	24	29980946	43652190	873044	
266	674	Quetiapine Tablet IP 50mg [674]	10 x 10 Tablet Blister (Rate Should be quoted for 100 Tab)	36	7710000	3139512	62790	
267	680	Insulin Glargine 100 IU/ml[680]	3 ml vial with 15 insulin syringes with needles/ Cartridge 3ml with 15 needles and 1 pen per 20 cartridges(Rate Should be quoted for Single Unit)	24	472650	94893941	1897879	
268	684	Framycetin Sulphate Cream 1 o/o 30gm Pack [684]	30gm Pack (Rate Should be quoted for Single Unit)	24	5025994	165908062	3318161	
269	685	FramycetinSulphate 1% Cream [685]	100gm pack (Rate Should be quoted for Single Unit)	24	1321772	13516[illegible]	[illegible]3288	
270	686	Artemether and Leumefantrine Tablet (40 mg and 240 mg) [686]	1x6 Tablet Blister	24	1967214	4222953	84459	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			(Rate Should be quoted for 6 Tab)					
271	688	Dried Factor VIII Fraction IP (IV use) 500 IU/Vial [688]	Vial with diluent(Rate Should be quoted for Single Unit)	24	82490	216449636	4328993	
272	690	Recombinant Coagulation Factor VIIa 1mg [690]	Vial (Rate Should be quoted for Single Unit)	24	10618	438263259	8765265	
273	693	Insulin Glargine 100IU/ml with 30 Insuline syringes with needle [693]	10ml vial (Rate should be quoted for Single Unit)	24	149668	81875879	1637518	
274	695	Inj Diclofenac Sodium aqueous 75mg/ml 1ml Size, IV & IM use[695]	1 ml amp (Rate Should be quoted for Single Unit)	24	18477916	32151574	643031	
275	699	Tab Tizanidine Hydrochloride IP 2 mg (Each Uncoated Tablet contains Tizanidine Hydrochloride IP 2 mg)[699]	10X10(Rate should be quoted for 100 Tab)	24	1782424	514757	10295	
276	700	Tab Dexamethasone IP 4 mg (Each Uncoated Tablet contains Dexamethasone IP 4 mg)[700]	10 X 10 Tab (Rate should be quoted for 100 Tab)	24	6765140	2924553	58491	
277	703	Tab Oxcarbazepine IP 150 mg (Each Film Coated Tablet contains Oxcarbazepine IP 150 mg)[703]	10X10 (Rate should be quoted for 100 Tab)	24	3776902	7994942	159899	
278	705	Tab Topiramate IP 25 mg (Each Film Coated Tablet contains Topiramate IP 25 mg) [705]	10X10 Tablets (Rate should be quoted for 100 Tab)	24	1032882	462739	9255	
279	709	Cefadroxil Dispersible tablet 250mg (each uncoated Dispersible tablet contain Cefadroxil equivalent to anhydrous cefadroxil 250 mg) [709]	10X10 Tablets(Rate should be quoted for 100 Tab)	24	14442074	26365498	527310	
280	710	Tab.Cefadroxil 500 mg[710]	10X10 (Rate should be quoted for 100 Tab)	24	18782340	71560563	1431211	
281	714	Inj Clindamycin phosphate IP 300 mg [714]	Vial/Amp (Rate should be quoted for Single Unit)	24	735078	6564247	131285	
282	715	Inj Imipenem + Cilastatin 500mg/500mg IP Powder for Solution [715]	Vial (Rate should be quoted for Single Unit)	24	301560	46506583	930132	
283	716	Inj. Polymixin Sulphate B USP 5 Lac I.U. [716]	Vial (Rate should be quoted for Single Unit)	24	107712	7117605	142352	
284	718	Inj Colistimethate IP 1M IU Powder for Solution [718]	Vial (Rate should be quoted for Single	24	107058	3237434	64749	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Unit)					
285	720	Inj. Voriconazole 200mg/Vial [720]	Vial(Rate Should be quoted for single Vial)	24	30746	5130892	102618	
286	721	Tab. Terbinafine Hydrochloride 250 mg [721]	10X10 or 15x10/1x7 Tablet (Rate should be quoted for 100 Tab)	24	5108628	8067501	161350	
287	722	Tab. Valganciclovir 450 mg [722]	10X10 Tablets (Rate should be quoted for 100 Tab)	24	87900	4283226	85665	
288	724	Inj. Ganciclovir Sodium 500mg (lyophilized powder for reconstitution) [724]	Vial (Rate Should be quoted for single Vial)	24	5150	2676713	53534	
289	726	Inj Bendamustine 100 mg [726]	Vial (Rate should be quoted for Single Unit)	24	9724	7351344	147027	
290	727	Tab Capecitabine IP 500 mg (Each Film Coated Tablet contains Capecitabine IP 500 mg)[727]	10X10(Rate should be quoted for 100 Tab)	24	1084060	12627597	252552	
291	729	Capsule Temozolomide IP 100 mg (Each hard Gelatin Capsule contains Temozolomide IP 100mg) [729]	Strip of 5 cap / Bottle of 5 cap (Rate Should be quoted for Strip of 5 cap / Bottle of 5 cap)	24	69360	2532472	50649	
292	730	Inj. Bortezomib 2mg [730]	Vial (Rate should be quoted for Single Unit)	24	20344	6334308	126686	
293	733	Cap Thalidomide USP 100 mg (Each Hard Gelatin Capsule contains Thalidomide USP 100 mg) [733]	10X10 Cap Strip/Blister (Rate Should be quoted for 100 Cap)	24	118520	947360	18947	
294	734	Inj. Bevacizumab 400 mg [734]	Vial (Rate should be quoted for Single Unit)	24	31754	193015101	3860302	
295	735	Inj. Bevacizumab 100 mg [735]	Vial(Rate should be quoted for Single Unit)	24	19922	33343451	666869	
296	736	Tab Cyclophosphamide IP 50 mg (Each Sugar Coated Tablet contains Cyclophosphamide IP 53.5 mg equivalent to Anhydrous Cyclophosphamide 50 mg) [736]	10X10 Tablets (Rate Should be quoted for 100 Tablet)	24	279350	528066	10561	
297	739	Capsule Tacrolimus IP 0.5 mg (Each Hard Gealtin Capsule Tacrolimus IP 0.5 mg) [739]	10X10 (Rate should be quoted for 100 Cap)	24	141960	3775117	75502	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
298	741	Tab. Bicalutamide IP 50 mg (Each Film Tablet contains Bicalutamide IP 50 mg) [741]	10X10 (Rate should be quoted for 100 Tab)	24	399060	1336067	26721	
299	742	Tab. 6 Thioguanine IP 40 mg (Each Uncoated Tablet contains 6 Thioguanine IP 40 mg) [742]	10X10 Tablets(Rate Should be quoted for 100 Tablet)	24	18940	4339	87	
300	747	Inj Tranexamic Acid IP 100mg/ml 5ml Size [747]	5 ml vial/ ampoules (Rate should be quoted for Single Unit)	24	2573248	15645348	312907	
301	749	3rd Generation Recombinant F VIII 250 IU with diluent [749]	Vial with diluents (Rate should be quoted for Single unit)	24	16510	26826769	536535	
302	750	3rd Generation Recombinant F VIII 1000 IU with diluent [750]	Vial with diluent (Rate should be quoted for Single unit)	24	13028	78109374	1562187	
303	752	Tab. Sotalol Hydrochloride USP/BP 40mg (Each Film Coated Tablet contains Sotalol Hydrochloride USP/BP 40mg) [752]	10 X 10 Tab(Rate Should be quoted for 100 Tablet)	24	139520	534341	10687	
304	754	Inj. Sodium Nitroprusside 25mg/ml 2ml Size [754]	2 ml (Rate should be quoted for Single Unit)	24	11474	882810	17656	
305	756	Tab Rosuvastatin IP 20 mg (Each Film Coated Tablet contains Rosuvastatin Calcium IP equivalent to Rosuvastatin 20 mg) [756]	10x10 Tab Or 10x15 Tab (Rate should be quoted for 100 Tab)	24	5244440	2706635	54133	
306	757	Tab Rosuvastatin 10 mg [757]	10 X 10 / 15 Tab (Rate should be quoted for 100 Tab)	24	8510860	3145629	62913	
307	759	Powder Clotrimazole 1% w/w 30 gm [759]	30 gm bottle (Rate should be quoted for Single Unit)	24	2115152	19628611	392572	
308	760	Cream Terbinafine 1%w/w (10 gm Tube) [760]	10 gm tube(Rate should be quoted for Single Unit)	24	1060676	5048818	100976	
309	766	Tab. Mesalamine USP 1.2 gm Enteric Coated (Each Enteric Coated Prolonged Release Tablet Conatin Mesalamine USP 1.2 gm)[766]	10X10 (Rate should be quoted for 100 Tab)	24	2522120	17202740	344055	
310	771	Chloramphenicol 1% w/w Eye ointment IP, 3gm Size [771]	3 gm tube (Rate should be quoted Single	24	1020512	8560418	171208	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Unit)					
311	774	Inj Human Chorionic Gonadotropin IP 5000 I.U. [774]	Vial (Rate should be quoted for Single Unit)	24	204742	30705158	614103	
312	775	Leurprolide Acetate depot 3.75 mg [775]	Vial (Rate should be quoted for Single Unit)	24	10330	6883912	137678	
313	776	Leurprolide Acetate depot 11.25 mg [776]	Vial (Rate should be quoted for Single Unit)	24	17292	45512544	910251	
314	778	Tab. Lorazepam IP 2 mg (Each Uncoated Tablet contains Lorazepam IP 2 mg) [778]	10X10 Tablets(Rate Should be quoted for 100 Tab)	24	9257142	3078911	61578	
315	779	Tab. Zolpidem 5 mg [779]	10X10 Tablets (Rate Should be quoted for 100 Tablet)	24	2130040	626433	12529	
316	781	Ringer Acetate Infusion 500 ml [781]	500 ml bottle (Rate should be quoted for Single Unit)	24	627444	10014006	200280	
317	791	Intravenous Fat Emulsion 20% w/v 250ml [791]	250 ml bottle (Rate Should be quoted for Single unit)	24	18990	7776405	155528	
318	792	Tab Pyridostigmine IP 60 mg (Each Tablet contains Pyridostigmine IP 60 mg) [792]	10X10 (Rate should be quoted for 100 Tab)	24	281684	796225	15925	
319	794	Inj. Amino Acid 10% with minimum required ingredients :- aminoacids L-Leucine, L-Isoleucine, L-Lysine, L-Methionine, L-Pheylalanine, L-Threonine, L-Valine,L-Tryptophan, L-Arginine, L-Histidine, L-Serine, L-Proline, L-Alanine, L-tyrosine and L-Cystine in pack of 100 ml [794]	100 ml bottle(Rate Should be quoted for Single Unit)	24	109450	20961864	419237	
320	798	Inj. Human Immunoglobulin 12% IgM, 12% IgA & 76% IgG in Pack of 10 ml (0.5gm) [798]	10ml vial (0.5gm) (Rate Should be quoted for Single vial)	24	16840	98548017	1970960	
321	78A	Azithromycin Tablets 100 mg Dispersible Tablets [78A]	10x3x3 Tab strip(Strip of 3 Tablet) (Rate should be quoted for 90 Tab)	24	38556498	59419912	1188398	
322	80A	Azithromycin Tab IP 500 mg [80A]	10x3x3 Tab Strip/Blister(Strip /Blister of 3 Tablet)or10x5 Tab Strip/	24	22[illegible]0340	17[illegible]16	[illegible]43[illegible]	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Blister(Rate should be quoted for 90 Tablet)					
323	100A	Chloroquine Phosphate Suspension IP 50 mg/5ml [100A]	60 ML Bottle (With Measuring Cap) (Rate Should be quoted for Single Unit)	30	1363094	11599930	231999	
324	114A	Fluconazole Tab. IP 150mg [114A]	10x10x1 Tab Strip (Perforated) / Blister (Perforated) Or 2 tablet strip / blister (Not more than 100 tablets in a box) (Rate should be quoted for 100 Tab)	24	43185402	64208053	1284161	
325	216A	Fusidic Acid Cream IP 2% [216A]	10gm tube in mono carton(Rate Should be quoted for Single Unit)	24	16662012	298083395	5961668	
326	260A	Antacid Tablets.Formula,Each chewable tablet contains Magnesium Trisilicate 250 mg, Dried Aluminium Hydroxide Gel 120 mg, Peppermint Oil [260A]	10X10 Tab Blister (Rate should be quoted for 100 Tab)	24	48612276	8385622	167712	
327	439A	Dicyclomine and Paracetamol Tablets Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets [439A]	10X10 Tab Blister (Rate should be quoted for 100 Tab)	36	132986240	39018151	780363	
328	448 W	Iron and Folic Acid Syrup IP Each ml of Syrup contains Ferrous Sulphate IP Equivalent to elemental ferrous iron 20mg, Folic Acid IP 0.1mg with any flavour [448W]	50ml Bottle (Amber Colour) with Auto dispenser to dispense 1ml each time,Packed in a unit carton(Rate should be quoted for Single unit)	18(Remaining Shelf life at the time of delivery - 3/4th of labeled Shelf life)	31347720	214104928	4282099	Annexure A-1
329	490 W	Iron and Folic Acid Tablets (IFA-Pink) Each sugar coated tablet shall contain: Dried Ferrous Sulphate IP 150 mg equivalent to-	10x15 Tablets Aluminium Blister Pack (Rate Should be quoted for 150 Tab)	24 (Remaining Shelf life at the	425605440	445187	367	Annexure A-1

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
		Elemental Ferrous iron - 45 mg Folic Acid IP- 0.4mg		time of delivery - 5/6th of labeled Shelf life)				
330	508A	Artesunate Injection 60 mg (I.M. I.V.USE) Each Combo Pack contains Artesunate Injection 60 mgVial, Sodium Bicarbonate Injection IP 5 o/o w/v (1ml ampoule),Sodium chloride Injection IP 0.9o/o w/v (5ml ampoule) [508A]	Each Combo Pack in a Unit carton(Rate Should be quoted for Single Unit)	24	2444980	24596499	491930	
331	NRD -11	Anti Oxidants (Beta Carotene 10 mg,Vit E 25mg,Vit C 100 mg,Copper 1.5 mg,Managanese 1.5 mg,Zinc 7.5 mg,Selenium 150 microgram) Cap. [NRD-11]	10x10 (Rate should be quoted 100 Cap)	24	20008386	21961220	439224	
332	NRD -22	Danazol 100mg Cap. IP [NRD-22]	10x10(Rate Should be quoted for 100 Cap)	24	198800	1122186	22444	
333	NRD -25	Indacaterol and Glycopyronium inhalation powder 110/50 mcg Cap. [NRD-25]	10x10 / 30 Capsules (Rate Should be quoted for 100 Cap)	18	3645230	28372050	567441	
334	NRD -47	Azelaic acid 20% Cream [NRD-47]	15 gm (Rate should be quoted Single Unit)	24	119080	2254184	45084	
335	NRD -49	Desonide 0.05% Cream [NRD-49]	15 gm (Rate should be quoted for Single Unit)	24	390310	14570272	291405	
336	NRD -71	Diastase, Pepsin with simethicone 15ml DropEach ml contains Diastase (1:1200) 33.33mg, Pepsin (1:3000) 5mg & Simethicone emulsion 40mg [NRD-71]	15 ml(Rate Should be quoted for Single unit)	18	335824	4097053	81941	
337	NRD -83	Vitamin – E 50mg/ml Drops 15ml [NRD-83]	15 ml (Rate should be quoted Single Unit)	18	18240	1417613	28352	
338	NRD -102	Flurometholone 0.1% Eye Drop [NRD-102]	5 ml (Rate should be quoted Single Unit)	24	98380	826392	16528	
339	NRD -103	Gatifloxacin 0.30% and Prednisolone Acetate 1% Ophthalmic Suspension [NRD-103]	10ml (Rate should be quoted Single Unit)	24	402838	4978652	99573	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
340	NRD-105	Itraconazole 1% Eye Drop [NRD-105]	5 ml(Rate should be quoted Single Unit)	24	26940	264012	5280	
341	NRD-119	Voriconazole 1 % w/v (Lyophilized) 30mg Eye Drop [NRD-119]	vial (Rate should be quoted Single Unit)	24	22390	6125680	122514	
342	NRD-127	Sodium Chloride 6% Eye Ointment USP [NRD-127]	5 gm (Rate should be quoted Single Unit)	24	16300	228200	4564	
343	NRD-145	Sodium Chloride 3% 100ml Inj. IP [NRD-145]	100 ml (Rate should be quoted Single Unit)	24	405950	4319308	86386	
344	NRD-151	Prostaglandin 500MCG/ml Inj. [NRD-151]	vial / Amp(Rate Should be quoted for Single vial / Amp)	24	5424	9579923	191598	
345	NRD-191	Cetuximab 500mg Inj. [NRD-191]	vial / Amp (Rate Should be quoted for single unit)	24	3590	293518400	5870368	
346	NRD-202	Daratumumab 100 mg Inj. [NRD-202]	vial / Amp (Rate Should be quoted for single unit)	24	5300	77173936	1543479	
347	NRD-203	Daratumumab400 mg Inj. [NRD-203]	vial / Amp (Rate Should be quoted for single unit)	24	2020	117418560	2348371	
348	NRD-206	Darbepoietin Alfa 500mcg Inj. [NRD-206]	vial / Amp/ PFS (Rate should be quoted Single Unit)	24	4284	51819264	1036385	
349	NRD-214	Detemir Insuline 100IU/ml Injection 3ml [NRD-214]	Vial / Pre Filled Pen / Pen alongwith 03 Cartridge and 05 needles(Rate should be quoted Single Unit)	24	12060	9497250	189945	
350	NRD-223	Durvalumab 500mg Inj. [NRD-223]	vial / Amp (Rate Should be quoted for Single vial / Amp)	24	1488	174372470	3487449	
351	NRD-224	Enalaprilat Injection 1.25mg/ml in 1ml Ampoule [NRD-224]	vial / Amp (Rate should be quoted Single Unit)	24	6430	50411	1008	
352	NRD-225	Ephedrine 30 mg/ml Inj. BP in 1ml Ampoule [NRD-225]	vial / Amp (Rate should be quoted Single Unit)	24	13040	92323		
353	NRD-228	Eribulin 0.5mg Inj. [NRD-228]	vial / Amp (Rate should be quoted	24	1052	26089600	521792	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Single Unit)					
354	NRD-238	Fludarabine Phosphate Injection 50mg Inj. IP [NRD-238]	vial / Amp (Rate Should be quoted for Single vial / Amp)	24	1344	1016064	20321	
355	NRD-241	Folic Acid Cynocobalamine and Nicotinamide Injection (Each ml contains Folic Acid 15mg/ml Cynocobalamine 500 mcg/ml and Nicotinamide 200 mg/ml) in 10 ml [NRD-241]	10 ml (Rate should be quoted for single unit)	24	178010	6977992	139560	
356	NRD-251	Haloperidol (Long Acting) 50mg/ml Ampoule Inj. IP 1ml vial/ampoule [NRD-251]	vial / Amp(Rate should be quoted Single Unit)	24	33960	3442186	68844	
357	NRD-255	Hydralazine 20mg/ml Inj. IP 1ml vial/ampoule	vial / Amp (Rate should be quoted for single unit)	24	5400	31644	633	
358	NRD-274	Levosulpride 12.5 mg/ml Injection 2ml [NRD-274]	vial / Amp (Rate should be quoted Single Unit)	24	188130	737470	14749	
359	NRD-275	Inj. Lignocaine (preservative free) (Each ml contains Lignocaine IP 21.3 mg sodium chloride IP 6.0 mg 50 ml vial) [NRD-275]	50 ml vial(Rate Should be quoted for Single Vial)	24	116434	3336998	66740	
360	NRD-288	Inj. Methotrexate 250 mg (each ml contain Methotrexate 25 mg in 10ml vial) [NRD-288]	10ml vial (Rate should be quoted Single Unit)	24	6890	763963	15279	
361	NRD-292	Inj. Methylprednisolone Acetate 125 mg I.P. (Each vial contains Methylprednisolone Acetate 125 mg) [NRD-292]	vial / Amp (Rate should be quoted for single unit)	24	55100	26697052	533941	
362	NRD-293	Inj. Metotrexate 15mg/ml (Each ml contains Metotrexate 15mg) [NRD-293]	Ampoule (Rate Should be quoted for one amp.)	24	7690	82052	1641	
363	NRD-297	Mitomycin 40 mg Inj. IP [NRD-297]	vial / Amp(Rate should be quoted Single Unit)	24	1128	1932941	38659	
364	NRD-312	Nimotuzumab 50 mg Inj.	vial / Amp (Rate should be quoted Single Unit)	24	5780	71209600	1424192	
365	NRD-315	Inj. Sodium Chloride 0.9% 500 ml Glass Bottle Inj. IP [NRD-315]	500 ml Glass Bottle (Rate Should be quoted for single unit)	24	910784	29582264	591645	
366	NRD-316	Inj. Sodium Chloride 0.9% 1000 ml Glass Bottle Inj. IP [NRD-316]	1000 ml Glass Bottle (Rate Should be quoted for Single unit)	24	308966	16610012	332200	
367	NRD-322	Ornidazole 500mg Inj. IP [NRD-322]	vial / Amp (Rate should be quoted Single	24	44300	768162	15363	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Unit)					
368	NRD-333	Phenylephrine Hydrochloride 10 mg/ml Inj. BP/IP 1ml vial [NRD-333]	vial / Amp(Rate should be quoted Single Unit)	24	25310	1148062	22961	
369	NRD-348	Recombinant FSH 150 IU Inj. [NRD-348]	vial / Amp (Rate Should be quoted for Single vial / Amp)	24	19332	22821039	456421	
370	NRD-349	Recombinant FSH 300IU Inj. [NRD-349]	vial / Amp / PFS/ Prefilled Pen (Rate should be quoted Single Unit)	24	5940	13239072	264781	
371	NRD-352	Reteplase 18 mg Inj. [NRD-352]	vial / Amp (Rate should be quoted Single Unit)	24	14236	228689382	4573788	
372	NRD-362	Ropivacaine 0.75% 3 Ml Ampule (Heavy) Injection [NRD-362]	20 ml Amoule(Rate Should be quoted for Single amp.)	24	24840	1579824	31596	
373	NRD-369	Inj. Streptomycin Injection 500mg/ vial (Each Vial Contains: Streptomycin 500 mg) [NRD-369]	Vial (Rate Should be quoted for Single vial)	24	46748	1890957	37819	
374	NRD-373	Tenecteplase 20mg Inj. [NRD-373]	vial / Amp (Rate should be quoted Single Unit)	24	2170	45934560	918691	
375	NRD-381	Tobaramycin 80mg Inj. IP [NRD-381]	vial / Amp (Rate should be quoted Single Unit)	24	7990	126721	2534	
376	NRD-387	Trabectedin 1 mg Inj. [NRD-387]	vial / Amp(Rate should be quoted Single Unit)	24	180	3003840	60077	
377	NRD-389	Trastuzumab 440 mg Inj. [NRD-389]	vial / Amp (Rate Should be quoted for single unit)	24	26810	185658178	3713164	
378	NRD-390	Trastuzumab150Mg Inj. [NRD-390]	vial / Amp (Rate should be quoted Single Unit)	24	19210	45719800	914396	
379	NRD-395	Triptorelin 3.75 mg Inj. [NRD-395]	vial / Amp(Rate should be quoted Single Unit)	24	20480	70189056	1403781	
380	NRD-400	Vinorelbine 10mg Inj. IP [NRD-400]	vial / Amp (Rate should be quoted Single Unit)	24	2368	2442592	48852	
381	NRD-414	Minoxidil Topical Solution 5% in 60ml [NRD-414]	60ml (Rate Should be quoted for Single unit)	24	132060	5289003	105780	
382	NRD-457	Nevirapine 200mg. Each tablet contain Nevirapine 200mg [NRD-457]	10x10 Tab/ 60 Tab(Rate should be quoted for 100 tablet)	24	51[illegible]	[illegible]	[illegible]	
383	NRD	Glycopyrronium Inhalation	2 ml	24	318210	7932975	158660	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
	-458	Solution 25mcg 2 ml [NRD-458]	(Rate should be quoted Single Unit)					
384	NRD -467	Racecadotril 10 mg [NRD-467]	Sachet (Rate should be quoted Single Unit)	24	246840	883687	17674	
385	NRD -475	Suspension Cefaclor 125 mg (Each 5 ml contain Cefaclor 125 Mg I.P.) [NRD-475]	30 ml (Rate should be quoted Single Unit)	24	19260	698945	13979	
386	NRD -476	Codiene Phosphate and Tripolidine Syrup (Each 5ml contains Codiene Phosphate 10mg and Tripolidine 1.25mg) [NRD-476]	60 ml(Rate Should be quoted for single unit)	24	1970542	40061119	801222	
387	NRD -477	Amlodipine oral solution 1 MG/ ML Syrup B.P. [NRD-477]	100 ml (Rate Should be quoted for Single unit)	24	570	8237	165	
388	NRD -482	Cefixime Oral Suspension/Dry Syrup 50MG Each 5 ml contain Cefixime Oral Suspension/Dry Syrup 50MG [NRD-482]	30 ml (Rate Should be quoted for Single unit)	24	5298152	58226690	1164534	
389	NRD -483	Cefixime Oral Suspension / Dry Syrup 100mg Each 5 ml contain Cefixime Oral Suspension/Dry Syrup100mg [NRD-483]	30 ml (Rate Should be quoted for single unit)	24	5344260	84706521	1694130	
390	NRD -494	Drotavarine HCL 20mg / 5ml Syrup/suspension [NRD-494]	30 ml(Rate Should be quoted for Single unit)	24	202382	1908462	38169	
391	NRD -497	Enzyme Syrup (Each 5ml contains Diastase 50mg & Pepsin 10mg) 100ml [NRD-497]	100 ml (Rate should be quoted Single Unit)	18	2510322	36023121	720462	
392	NRD -501	L-Carnitine 500mg/5ml in 30 ml Syrup USP [NRD-501]	30 ml (Rate Should be quoted for Single unit)	24	17042	439002	8780	
393	NRD -503	Levofloxacin Oral Solution/ Syrup 125mg /5ml [NRD-503]	60 ml (Rate Should be quoted for Single unit)	24	114962	2124498	42490	
394	NRD -509	Nitrofurantoin oral suspension 25mg/5ml in 100 Syrup B.P. [NRD-509]	100 ml (Rate Should be quoted for Single unit)	24	11802	238636	4773	
395	NRD -522	Triclofos oral suspension500 mg/ 5ml in 30ml Syrup I.P. [NRD-522]	30 ml(Rate should be quoted for Single Unit)	24	28314	784864	15697	
396	NRD -528	Hydroxyurea 500mg Tab./Cap. I.P. [NRD-528]	10x10 (Rate should be quoted 100 Tab/Cap)	24	1323756	2918970	58380	
397	NRD -530	Everolimus 5mg Tab./Cap. [NRD-530]	10x10 / 4 Tablet (Rate should be quoted 100	24	15680	609780	12196	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Tab/Cap)					
398	NRD-531	Everolimus 10mg Tab./Cap. [NRD-531]	10x10 / 4 Tablet(Rate should be quoted 100 Tab/Cap)	24	14080	814127	16283	
399	NRD-534	Tab. 6-Mercaptopurine 20 mg I.P.[NRD-534]	10x10 Tablet (Rate Should be quoted for 100 Tablet)	24	51100	150234	3005	
400	NRD-538	Aceclofenac+Paracetamol+ Serratiopeptidase (100+325+15 mg) Tab. [NRD-538]	10x10 (Rate Should be quoted for 100 tab)	24	56850030	37077570	741551	
401	NRD-547	Amantadine 100mg Tablet / Capsule [NRD-547]	10x10 / 1x15 (Rate should be quoted 100 Tab/Cap)	24	686400	1837356	36747	
402	NRD-548	Amisulpride 50 mg Tab. I.P. [NRD-548]	10x10 (Rate Should be quoted for 100 Tab)	24	570000	638343	12767	
403	NRD-551	Aripiprazole 10 mg Tab. I.P. [NRD-551]	10x10 (Rate Should be quoted for 100 Tab)	24	1006000	557626	11153	
404	NRD-565	Buprinorphine 2 mg Tab [NRD-565]	10x10 (Rate should be quoted for 100 Tab)	24	51200	258048	5161	
405	NRD-577	Cholchicine 0.5mg Tab. I.P. [NRD-577]	10x10(Rate should be quoted 100 Tab)	24	43400	96348	1927	
406	NRD-580	Clarithromycin 250 MG Tab. I.P. [NRD-580]	10x10 or 10x4 (Not more than 100 tablets in a box) (Rate should be quoted for 100 Tab)	24	383000	2037560	40751	
407	NRD-581	Clarithromycin 500mg Tab. I.P. [NRD-581]	10x10 or 10x4 (Not more than 100 tablets in a box) (Rate should be quoted for 100 Tab)	24	1207520	12563796	251276	
408	NRD-590	Co trimoxazole Tablet IP 480mg (Trimethoprim 80mg and Sulphamethoxazole 400mg) [NRD-590]	10x10 Tab (Rate Should be quoted for 100 Tablet)	24	20012026	14478682	289574	
409	NRD-593	Cyproterone Acetate 2 mg and Ethynil Estradiol. 035mg Tab BP [NRD-593]	1x21 Tab(Rate should be quoted for 21 Tab)	24	96000	192120	42	
410	NRD-600	Dapoxetine 30 mg Tab. I.P. [NRD-600]	10x10 (Rate should be quoted for 100 Tab)	24	164000	193520		

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
411	NRD-608	Diltiazem CR/Prolonged Released Tablet / Capsule 90 mg (Each capsule/ tablet contains Diltiazem 90 mg) [NRD-608]	10x10 Tablet / Capsule (Rate Should be quoted for 100 Tablet/cap)	24	840000	940800	18816	
412	NRD-611	Disulfiram Tablet 500mg [NRD-611]	10x10 (Rate should be quoted for 100 Tab)	24	58100	52290	1046	
413	NRD-617	Eltrombopag 25MG Tablet / Capsule [NRD-617]	10x10 / 7 Tablet / capsule(Rate Should be quoted for 100 Tablet / Capsule)	24	57100	1416537	28331	
414	NRD-618	Eltrombopag 50MG Tablet / Capsule [NRD-618]	10x10 / 7 Tablet / capsule (Rate Should be quoted for 100 Tablet / Capsule)	24	52700	1964909	39298	
415	NRD-630	Etoricoxib+thiocolchicoside(60+8 mg) Tab. [NRD-630]	10x10 / 30 Tablet (Rate Should be quoted for 100 Tab)	24	10551400	37863699	757274	
416	NRD-634	Fexofenadine 120 MG Tab I.P. [NRD-634]	10x10 (Rate should be quoted for 100 Tab)	24	5751880	3478749	69575	
417	NRD-638	Flunarizine 10mg Tab. [NRD-638]	10x10 (Rate Should be quoted for 100 Tablet)	24	1642000	551712	11034	
418	NRD-639	Fluvoxamine 100 mg Tab. I.P. [NRD-639]	10x10(Rate should be quoted for 100 Tab)	24	300000	674640	13493	
419	NRD-648	Ivabradine 5mg Tab. [NRD-648]	10x10 (Rate Should be quoted for 100 Tab)	24	1382800	2322274	46445	
420	NRD-653	Lacosamide 50 mg Tab. B.P. [NRD-653]	10x10 (Rate should be quoted for 100 Tab)	24	484220	1510766	30215	
421	NRD-677	Tab. Methimazole 5 mg (Each tablet contains Methimazole 5 mg) [NRD-677]	10x10 Tablet (Rate Should be quoted for 100 Tablet)	24	89400	649634	12993	
422	NRD-678	Methimazole 10mg Tab. USP [NRD-678]	10x10 (Rate should be quoted 100 Tab)	24	122400	881476	17630	
423	NRD-689	Mirtazapine 7.5mg Tab. I.P. [NRD-689]	10x10(Rate should be quoted for 100 Tab)	24	680800	308811	6176	
424	NRD-690	Mirtazapine 15mg Tab. I.P. [NRD-690]	10x10 (Rate Should be quoted for 100 Tab)	24	557200	37443		
425	NRD-692	Montelukast 4 mg Tab. I.P. [NRD-692]	10x10 / 1x15 (Rate should be	24	149400	179520	2390	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			quoted for 100 Tab)					
426	NRD-697	Moxifloxacin 400 Mg Tab[NRD-697]	10x10 (Rate should be quoted for 100 Tab)	24	2676420	11870369	237407	
427	NRD-704	Nicorandil 5mg Tab. I.P. [NRD-704]	10x10 Tab. (Rate Should be quoted for 100 Tablet)	24	3466200	1242286	24846	
428	NRD-713	Nitazoxanide 500mg Tab. [NRD-713]	10x10(Rate should be quoted for 100 Tab)	24	67200	670656	13413	
429	NRD-716	Olaparib 100 mg Tablet [NRD-716]	10x10 / 8x7 (Rate should be quoted 100 Tab)	24	20200	74831595	1496632	
430	NRD-717	Olaparib 150 mg Tablet [NRD-717]	10x10 / 8x7 (Rate should be quoted 100 Tab)	24	51400	192316266	3846325	
431	NRD-720	Osimertinib 80 mg Tablet [NRD-720]	10x10 / 30 Tablet(Rate Should be quoted for 100 tab)	24	28840	2987775	59756	
432	NRD-721	Oxcarbazepine 300MG Tab. I.P. [NRD-721]	10x10 Tab. (Rate Should be quoted for 100 Tablet)	24	1661800	3889941	77799	
433	NRD-723	Oxazepam 15mg Tab. I.P. [NRD-723]	10x10 (Rate should be quoted for 100 Tab)	24	85600	101008	2020	
434	NRD-744	Prasugrel 10MG TAB [NRD-744]	10x10 (Rate should be quoted 100 Tab)	24	1364800	3038864	60777	
435	NRD-751	Propranolol 10mg Tablet / Capsule [NRD-751]	10x10 / 1x15 (Rate Should be quoted for 100 Tablet/ cap.)	24	8663134	1843508	36870	
436	NRD-757	Regorafenib 40 mg Tab. [NRD-757]	10x10 / 28 Tablet(Rate should be quoted for 100 Tab)	18	4200	1069236	21385	
437	NRD-763	Tab. Rifampicin 600 mg (Each capsule/ tablet contains Rifampicin IP 600 mg) [NRD-763]	10x10 Tablet / Capsule (Rate should be quoted 100 Tab/ cap)	24	69800	644484	12890	
438	NRD-765	Rifaximin 550mg Tab. I.P. [NRD-765]	10x10 (Rate Should be quoted for 100 Tab)	24	1680200	16654142	333083	
439	NRD-769	Rizatriptan 10mg Tab. I.P. [NRD-769]	10x10 / 1x4 (Rate should be quoted 100 Tab)	24	93600	13575	271	
440	NRD-770	Ropinirole 0.25mg Tab. I.P. [NRD-770]	10x10 (Rate Should be quoted for 100	24	396400	279207	5584	

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
			Tab)					
441	NRD-772	Ruxolitinib 5 mg Tablet / Capsule [NRD-772]	10x10(Rate Should be quoted for 100 Tab/cap)	24	16360	26633600	532672	
442	NRD-774	Ruxolitinib 15 mg Tablet / Capsule [NRD-774]	10x10 Tablet / Capsule (Rate Should be quoted for 100 Tablet/ cap.)	24	24960	82638920	1652778	
443	NRD-775	Ruxolitinib 20 mg Tablet / Capsule. [NRD-775]	10x10 Tablet / Capsule (Rate Should be quoted for 100 Tablet/ cap.)	24	25360	84809178	1696184	
444	NRD-776	Selegiline 5mg Tab. I.P. [NRD-776]	10x10 (Rate should be quoted 100 Tab)	24	71700	225138	4503	
445	NRD-782	Sitagliptine 50mg +Metformin 500mg Tab [NRD-782]	10x10/ 10x15 Tab(Rate Should be quoted for 100 Tab)	18	2345600	2573123	51462	
446	NRD-785	Solifenacin succinate 10 mg Tab. I.P. [NRD-785]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	988400	2435418	48708	
447	NRD-788	Sunitinib 12.5 mg Cap.[NRD-788]	10x10 / 1x7 / 28 Capsule (Rate Should be quoted for 100 Capsule)	24	14160	163548	3271	
448	NRD-807	Trypsin Chymotripsin Tablet (Each enteric coated tablet contains 1 Lakhs unit of enzymetic activity) [NRD-807]	10x10 Tablet / 10x20 Tablet (Rate Should be quoted for 100 Tablet)	18	7422820	5071257	101425	
449	NRD-808	Ulipristal 5mg Tab. [NRD-808]	10x10 (Rate should be quoted for 100 Tab)	24	129400	4932728	98655	
450	NRD-818	Zinc 50MG Tab. [NRD-818]	10x10(Rate should be quoted 100 Tab)	24	2590920	829094	16582	
451	NRD-820	Cap. Zonisamide 50 mg (Each Capsule contains Zonisamide 50 mg)	10x10 (Rate should be quoted 100 Cap)	24	124600	853510	17070	
452	NRD-821	Zonisamide 100 mg Tab. [NRD-821]	10x10 (Rate Should be quoted for 100 Tab)	24	104000	1223040	24461	
453	NRD-823	Human Albumin 20% in 50 ml Vial Inj. [NRD-823]	vial / Amp (Rate should be quoted Single Unit)	24	175380	3750780	75016	
454	NRD-889	Glycopegylated Extended Half Life Nonacog Beta pegol F IX 500 IU [NRD-889]	Vial (Rate should be quoted Single Unit)	24	5424	10818144	216363	

-

S.No	Drug Code No	Name of Drug with specification	Packing unit	Minimum labelled Shelf Life (In Months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimated Bid Value (In Rs.)	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.
455	NRD-890	Glycopegylated Extended Half Life Nonacog Beta pegol F IX 1000 IU [NRD-890]	Vial(Rate should be quoted Single Unit)	24	5084	455882280	9117646	
456	NRD-891	Glycopegylated Extended Half Life factor VIII 500 IU [NRD-891]	Vial (Rate should be quoted Single Unit)	24	16824	123479748	2469595	
457	NRD-901	Dapagliflozin 5mg Tablet [NRD-901]	10x10 Tablet (Rate Should be quoted for 100 Tablet)	24	1614994	1175720	23514	
458	NRD-902	Chlorthalidone 12.5 mg Tab [NRD-902]	10x10 Tablet (Rate should be quoted 100 Tab)	24	1073926	303055	6061	
459	NRD-903	Chlorthalidone 25mg Tablet [NRD-903]	10x10 Tablet (Rate should be quoted 100 Tab)	24	692528	542851	10857	
460	NE 68	Hepatitis B Immunoglobulin HBIG 100 IU [NE68]	Vial/PFS (Rate Should be quoted for Single Unit)	24	20174	37747571	754951	
461	NE 75	Morphine Sulphate 30 mg SR Tablet [NE75]	10x10 Tablet(Rate should be quoted for 100 Tab.)	24	9020	45360	907	
462	NE 76	Hepatitis B Vaccine for HRGs	Multi-dose vials 10 ml (10 adult doses of 1 ml). container should be IP type 1 amber coloured tamper proof vial…. or USP type 1 clear / transparent glass vial. (Rate should be quoted for single vial) (All other specifications remains same as Annexure A-2)	As per Annexure A-2	53210	6654000	133080	Annexure A-2

<u>Note :</u> Item code 398 (Black Disinfectant Fluid (Phenyl) As per Schedule O Grade III): Reserved for MSME Rajasthan

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Note:-

The above quantity mentioned for this supply cum rate contract is indicative and may vary as per the actual requirement of hospitals.

The bidder should quote rate for the above mentioned packing unit only.

General Requirement:-

1. The manufacturer should ensure Stability of the formulations and its ingredients in the packing supplied.
2. The blister packing of tablets/Capsules should have Aluminium foil back.
3. Strip packing should be of Aluminium / Alu- Alu foils.
4. Aluminium foil strips refer to thickness not less than 40 microns.
5. The rigid PVC used in blister packing should be of not less than 250 microns.
6. Small tablets packed in blister should be packed to facilitate easy removal of a tablet without breaking/ crushing.
7. Containers for 400 ml (or 400 gm) or more, should have an inner lid also.
8. Syrup and Suspension should be palatable enough.
9. The measuring cap / dropper supplied with oral liquid formulation should have suitable marking.
10. The minimum size (length x breadth) of a blister strip shall be 6.5cm X 3cm.
11. Generic name of a drug should be printed in clearly legible bold letters. The font size of the name of drug on any tablet strip/ blister shall not be less than '9' in bold capital letters of Times New Roman or Arial font, e.g., LOSARTAN TABLETS IP even on small strips/ blisters. The font size shall be correspondingly bigger on bigger strips / blisters. Besides this, other contents on the label should also be legible.
12. The stereo printing of batch no. , Mfg date, Exp date on the reverse side of strip/blister should run atleast two times.
13. **Quote rate in BOQ for the packing exactly given in annexure VIII. For example**
    - **If the packing unit is given for 10x10 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.**
    - **If the packing unit is given for 10x10x1 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.**
    - **If the packing unit is given for 10x14 tablets / capsule, the rate should be quoted for 10x14 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.**
    - **If the packing unit is given for 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 ampoule.**
    - **If the packing unit is given for 2 ml ampoule (10 ampoules), the rate should be quoted for 10 ampoules and not for 1 ampoule.**

Annexure A-1

Annexure-II

Ferrous Sulphate and Folic Acid Syrup& Tablets (For NCB/ICB)

Technical specification for IFA SyrupAnemia Mukt Bharat

A. Specific requirements

Item:

Iron and Folic Acid syrup shall conform to the requirements given in IP 2022 for Iron & Folic Acid Syrup and the general requirements of Oral Liquids given in IP.

The drug shall be currently licensed in India and shall meet all requirements of the licensing authorities of India.

Description:

Iron and Folic Acid Syrup is a mixture of Ferrous sulphate and Folic acid, with a suitable flavouring agent with other excipients as required. It is filled in a sealed container.
Advisory: Manufacturer shall try to make the formulation as much palatable as possible.

Each 1 ml of the syrup shall contain ferrous sulphate equivalent to:

- Elemental Ferrous Iron (derived from Ferrous Sulphate IP): 20 mg and
- Folic Acid IP 0.1 mg

The quality of each constituent should conform to the requirements of IP permissible limits.

Protocol and Testing:

Complete Test Protocol and samples are taken and sent to the laboratory (identified by the purchaser) by the Inspecting Officer duly sealed and signed by him or his authorized representative.

Protocols of tests should include the requirements given in IP 2022 under Iron & Folic Acid Syrup and the general requirements for Oral Liquids.

The drug should be dispatched to the consignee only on clearance from the Testing Laboratory. The formulation shall be released on the basis of Protocol scrutiny by the authorized representative of the Purchaser and testing of the drugs by authorized laboratory.

Each batch should be accompanied with a certificate of analysis from the manufacturer that the formulation meets the specified requirements.

Random sampling will be taken from the supplies of the State (post-delivery) and will be periodically tested quarterly by DoHFW / MoHFW in identified labs separately for monitoring quality assurance.

Storage:

Iron and Folic Acid Syrup should be stored in a cool and dry place, away from sunlight.

Shelf-life:

18 months, at least 3/4th of the shelf life of IFA Syrup must remain at the time of receiving the shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

Labelling:

The label on each bottle shall be of map litho paper with minimum 300 gsm. The label shall conform to the requirements of IP & Rules 96 &97 of Drugs Rules and shall appear in English language. The label should in both English and Hindi/local language of the State.

All labelling of IFA Syrup-AnemiaMukt Bharat should be in weather-proof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP & Rules 96 & 97 of Drugs Rules, as amended from time to time should be followed. All labels shall state the amount of ferrous sulphate and equivalent amount of Elemental Ferrous iron & Folic Acid, name of anti-oxidant (if any) and antimicrobial agent, the name of the manufacturer, manufacturing license number, address of manufacturer, batch number, manufacturing date, expiry date and NHM logo

If an artificial sweetening agent is used, it should be highlighted on the label. Besides, the flavouring agent used should be of Indian Pharmacopoeia grade and in the absence, other pharmacopoeia grade can be used.

A warning should be put on the label that 'Medication should be kept out of reach of children'.

The bottle should have 6 fragmented markings at equal intervals as the entire content (50 ml) has to be consumed in 6 months and the consumption compliance can be verified. The marking can be either embossed on the bottle or printed on the labelling paper stuck on the bottle.

Labelling sticker should have a box space for writing the name of the child on the bottle.

Labelling for secondary packaging:

IFA SYRUP It should indicate the name of the product "IFA Syrup-AnemiaMukt Bharat", number of bottles, the amount of ferrous sulphate and equivalent amount of elemental Ferrous Iron & Folic Acid, the name of manufacturer, batch number, date of manufacture, date of expiry, storage conditions and NHM logo. The label should in both English and Hindi/local language of the State.

Labelling for tertiary packaging (insulated packaging):

The external surface of insulated packages should be either white or in the natural colour of corrugated carton.

IFA SYRUP-AnemiaMukt Bharat -The label should include the name of the product "IFA SYRUP-AnemiaMukt Bharat", the number of secondary packages, the name of the manufacturer, batch number, date of manufacture and date of expiry, storage conditions and NHM logo

Numbering of tertiary packaging:

All boxes should be numbered consecutively. Shipping documents should be included in the box.

Additional Labelling:

All the containers (i.e. bottles, cartons,etc) and other outer containers shall be labeled with the statement:
"GOVT. SUPPLY-NOT FOR SALE" in English and Local language.

B. Quality assurance

Compliance:

The Supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purposes made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per cGMP included in Schedule M of Drugs Rules.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.

The Supplier shall provide a copy of the Certificate of [illegible] for each lot intended for shipment.

The Supplier shall provide the validation data of the analytical procedure demonstrating batch to batch consistency.

The Supplier shall provide to the Purchaser a copy of the approval of each source material, constituent material and component for each lot intended for shipment.

The supplier shall provide documentary evidence that the anti-microbial agent and artificial sweetener if used, is within the permissible limits.

The test data for raw materials, in-process, finished product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Inspection:

The Purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's factory and/or warehouse at a mutually agreeable time prior to / after the shipment of the product.

Testing:

The Purchaser may cause independent laboratory testing of the samples picked randomly from pre and post-delivery shipment to be performed as deemed necessary to assure that the product conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product

C. Packing

Primary Package:

Iron and Folic Acid Syrup shall be packed in 50 ml capacity container (polyethylene terephthalate IP), amber coloured bottles (AA8011 / AA 1200); and provided with temper evident ROPP cap (25 / 15mm or 25/17 mm). The Cap should be provided with inert liner. The bottle is to be provided with auto-dispenser to dispense 1ml each time and packed in a mono carton. The plastic cap-cum-orifice that releases syrup must be firmly attached to the bottle so that it is impossible for the child to accidently swallow the entire content.

The mono carton should also contain a 1 pager instruction leaflet in English, Hindi and local language.

Toll free number must be indicated on every IFA syrup Bottle for contacting in case of product complaints.

Secondary Package:

The bottles should be packed in boxes for easy handling, transport and distribution. The box may contain 10 bottles each. It shall be

fabricated from 3-ply corrugated cardboard having strength $(150)^3$ gsm.

Toll free number must be indicated on every secondary package for contacting in case of product complaints.

Tertiary Package:

The boxes shall be packed in weather resistant triple walled insulated corrugated 7-ply cartons, usually containing 10 secondary packages having sufficient burst strength to hold weight of 100 bottles. The overall dimension of the carton should be such that the product is not damaged during transportation and storage.

Toll free number must be indicated on every tertiary package for contacting in case of product complaints.

D. Qualification of the Manufacturer:

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to cGMP Standards and Schedule M of Drugs Rules.

E. Recalls:

If products must be recalled because of problems with product quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give a full refund if the product has been taken off the market due to safety problems.

In case the quality of the product is found to be not of standard quality or unsatisfactory in quality checks, stringent action would be taken against them and the supplier can be black-listed for future supplies of the product.

F. Colour Coding:

The labels on secondary packing, tertiary packaging and shipper package shall be identified by background. (Standard Red colour)

G. Bar Coding

Bar code shall be used to track down the product. It shall be printed on the label of Millboard/Grey board Boxes and 5 – Ply shipper containing

1) Product identification (GTIN 14) using application identifier
2) Expiry Date in MM/YY format & using application identifier
3) Master batch number using application identifier

Complete details on GS1 standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org

4) Bar-coding to be put on all both Tertiary and Secondary Packing.

H. Markings

All containers and invoices must bear the name of the product, expiry date and appropriate storage conditions. The marking of AnemiaMukt Bharat should also be mentioned.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legible manner which is acceptable to the Purchaser:

- Name IFA SYRUP-AnemiaMukt Bharat
- Generic name of the product
- Manufacturer's name and registered address
- Manufacturer's License number
- Lot or batch number
- Number of bottles contained in box
- Date of manufacture (month and year)
- Expiry date (month and year)
- Instructions for storage and handling
- Place of manufacture (Made in _____)
- Barcode

Exterior Shipping Cartons:

The following information shall be stencilled or labelled on the exterior shipping cartons on all four sides in bold letters at least **Arial font size 14** with waterproof indelible ink in a clearly legiblemanner which is acceptable to the Purchaser:

- Name IFA SYRUP-AnemiaMukt Bharat
- Generic name of the product
- Lot or batch number
- Date of manufacture (month and year)
- Expiry date (month and year)
- Manufacturer's name and registered address

Consignee's address and emergency phone number including mobile number

- Contract number
- Number of bottles/boxes contained in the carton
- Gross weight of each carton (in kg)
- Carton containing no. of _____secondary packages
- Instructions for storage and handling
- Place of manufacture (Made in _____)
- Barcode

I. Documentation

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the product being supplied.

Advance notice of arrival and advance shipping documentation:

Copies of the documentation for the goods to be supplied must be sent at least seven days in advance of arrival of the consignment. In the case of an individual contract for a specific destination that requires a longer period of advance notice, a longer period should apply. The consignee(s) shall be intimated well in advance.
by registered letter/e-mail/ telephone, so that the products are collected immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB) if applicable;
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the Regulatory authority for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarder or the manufacturer to the consignee, the Purchaser, and any other parties specified in the individual contract.

The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight (in kilograms).
- Value of shipment (in Indian Rupees);
- AWB and Flight number(s) if applicable;
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee.
- Invoice

The following information shall be stated on the invoice:

- Consignee's name, address, telephone number (including mobile no.) and e-mail ID.
- Purchase order reference;
- Consignee's requisition reference;
  - Instructions to: "Telephone consignee upon arrival *(repeat telephone number)*

J. Dispatch

Consignments should be scheduled to arrive outside weekends and/or public holidays.

Technical specification for IFA PinkAnemia Mukt Bharat

IFA-Pink (Ferrous Sulphate & Folic Acid Tablets)

A. Specific requirements

Item: Iron and folic acid tablets shall conform to the general requirements of Tablets given in IP 2022 and the requirements given in the Annexure. The drug shall be currently licensed in India and shall meet all requirements of the licensing authorities.

Description:

Iron and Folic Acid Tablets (IFA-Pink) contain Ferrous Sulphate and Folic Acid. They are sugar coated and Pink colored. Approved colors shall be used in the coating.

Each sugar coated tablet shall contain:

Dried Ferrous Sulphate IP 150 mg equivalent to	
Elemental Ferrous iron	45 mg
Folic Acid IP	0.4 mg

The quality of each constituent should conform to the requirements of IP permissible limits.

Protocol and Testing:

Complete Test Protocol and samples are taken and sent to the laboratory (identified by the purchaser) by the Inspecting Officer duly sealed and signed by him or his authorized representative.

Protocols of test should include the requirements given in IP 2022 for Tablets and those included in the **Annexure.**

The drug should be dispatched to the consignee only on clearance from the testing Laboratory. The drug shall be released on the basis of Protocol scrutiny by the authorized representative of the purchaser and testing of the drugs by authorized laboratory.

Each batch should be accompanied with a certificate from the manufacture that the drugs meet the specified requirement.

Random sampling will be taken from the supplies of the State (post-delivery) and will be periodically tested quarterly by MoHFW in identified labs separately for monitoring quality assurance.

Storage:

Iron and Folic Acid Tablets (IFA) should be stored in a cool and dry place, away from sunlight.

Shelf-life:

24 months, at least $5/6^{th}$ of the shelf life of IFA must remain at the time of receiving the shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

Labelling:

The label on each blister pack of IFA Pink-AnemiaMukt Bharat shall conform to the requirements of Rule 96 & 97 of Drug Rules, and shall appear in English language. The label should in both English and Hindi/local language of the State.

All labelling of IFA Pink AnemiaMukt Bharat should be in waterproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP and Rule 96 & 97 of Drug Rules, [illegible] from time to time should be followed. All labels shall state the a[illegible]errous

Sulphate and equivalent amount of Elemental Ferrous Iron & Folic Acid, the name of manufacturer, batch number, manufacturing date, expiry date and NHM logo.

Labelling for secondary packaging:

IFA Pink- AnemiaMukt Bharat - It should indicate the name of the product "IFA Pink-AnemiaMukt Bharat", number of blister packs /tablets, the amount of ferrous sulphate and equivalent amount of Elemental Ferrous Iron and Folic Acid, the name of drug manufacturer, batch number, date of manufacture, date of expiry, storage conditions and NHM logo. The label should in both English and Hindi/local language of the State.

Labelling for tertiary packaging (insulated packaging):

The external surface of insulated packages should be either white or in the natural colour of corrugated carton.

IFA Pink-AnemiaMukt Bharat - The label should include the name of the product "IFA Pink-AnemiaMukt Bharat" Anemia Mukt Bharat", the number of secondary packages (boxes)/blister pack/tablets, the name of the manufacturer, batch number, date of manufacture, date of expiry, NHM logo and storage conditions.

Numbering of tertiary packaging:

All box should be numbered consecutively, shipping documents should be included in the box.

Additional Labelling:

All the containers (i.e. blister packs, cartons, etc) and other outer containers shall be labeled with the statement:
"**GOVT. SUPPLY-NOT FOR SALE**" in English and Local language along with NHM logo.

B. Quality assurance

Compliance:

The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fir for the purpose made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per **cGMP** included in Schedule M of Drugs Rules.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.
The supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.

The supplier shall provide the validation data of the analytical procedure used for testing assaying the components and shall provide the protocols of the tests applied.

The test data for raw materials, in-process, finished, the product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Inspection:

The purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's Factory and/or warehouse at a mutually agreeable time prior to /after the shipment of the Product.

Testing:

The purchaser may cause independent Laboratory testing of the sample picked randomly from pre and post-delivery shipment to be performed as deemed necessary to assure that the product conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product.

C. Packaging

Primary package:

15 Tablets should be packed in an Aluminium blister pack with IFA Pink-AnemiaMukt Bharat name displayed prominently.

Detailed packing specification of the Blister Pack (PVC Blister + Aluminum Foil) is as follows:

Front Side (PVC Blister):

a) Blister Material: PVC Films (No coating) – Heating Mechanism used to from blister in PVC Film
b) Layering Used: Single Layer of PVC Film
c) Thickness of PVC Layer: 250 Micron
d) GSM of PVC Film Used: 340 ± 8% gm/ sq. meter

Black Side (Aluminium Plain Foil):

a) Thickness of Foil: 25 micron
b) Sealant Used: Heat System
c) Any other material used along with plain Foil: Only PVC Film of 250 Micron
d) Layer: Single Layer of Plain Aluminium Foil.

Secondary package:

The blister packs should be packed in boxes for easy handling, transport and distribution with "IFA Pink-AnemiaMukt Bharat" name displayed prominently. The box may contain 10 blister packs. It shall be fabricated from Millboard/grey board/ cardboard with a minimum bursting strength of 400 gsm.

Toll free number must be indicated on every blister pack for contacting in case of product complaints.

Tertiary package:

The boxes shall be packed in weather resistant triple walled insulated corrugated 5-ply cartons, each ply having strength 150 gsm with "IFA Pink-AnemiaMukt Bharat" name displayed prominently. It should be fabricated from virgin quality 'A' grade material. The overall dimension of the carton should be such that the product is not damaged during transportation and storage.

Toll free number must be indicated on every tertiary package for contacting in case of product complaints.

D. Qualification of the Manufacturer

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacture of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to cGMP Standards and Scheduled M of Drugs Rules.

E. Recalls

If products must be recalled because of problems with products quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give refund if the product has been taken off the market due to safety problems.

In case the quality of the product is found to be not of standard quality or unsatisfactory in quality checks, stringent action would be taken against them and supplier can be black-listed future supplies of the product.

F. Colour Coding

The labels on secondary packing, tertiary packaging and shipper package shall be identified by background. (Standard pink colour)

G. Bar Coding

Bar code shall be used to track down the product. It shall be printed on the label of Millboard/Grey Board Boxes and 5-Ply shipper containing

1. Product identification (GTIN 14) using application identifier
2. Expiry date in MMYYYY format & using application identifier
3. Master batch number using application identifier
4. *Complete details on GS1 standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org*
5. Bar coding to be put on all both tertiary and secondary packing.

H. Markings

All containers and invoices must bear the name of the product, manufacturing date, expiry date and appropriate storage conditions. The marking of AnemiaMukt Bharat should also be mentioned.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legibly manner which is acceptable to the Purchasers:

- Name IFA Pink-AnemiaMukt Bharat
- Generic name of product
- Manufacturer's name and registered address
- Manufacturer's License number
- Lot or batch number
- Number of blister packs contained in box
- Date of manufacture (Month and Year)
- Expiry date (Month and Year)
- Instructions for storage and handling
- Place of manufacture
- Barcode

Exterior Shipping Cartons:

The following information shall be stencilled or labelled on the exterior shipping cartons on all four sides in bold letters at least **Ariel font Size 14** with waterproof indelible ink in a clearly legible manner is acceptable to the Purchaser:

- Name IFA Pink-AnemiaMukt Bharat
- Generic name of product
- Lot or batch number
- Date of manufacture (Month and Year)
- Expiry date (Month and Year)
- Manufacture's name and registered address
- Consignee's address and emergency phone number including mobile number
- Contract number
- Number of tables/ blister packs /boxes contained in the carton
- Gross weight of each carton (in kg)
- Carton containing no. of _____secondary packages
- Instructions for storage and handling
- Place of manufacture (Made in _____)
- Barcode

I. Documentation

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the product being supplied.

Advance notice of arrival and advance shipping documentation:
Copies of the documentation for the goods to be supplied must be sent at least seven days in advance of arrival of the consignment. In the case of an individual contract for a specific destination that requires a longer period of advanced notice, a longer period should apply. The consignee (s) shall be intimated well in advance by registered letter/e-mail/telephone, so that the products are collected immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB) if applicable;
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the regulatory authority for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarded or the manufacture to the consignee, the Purchaser, and any other parties specified in the individual contract.
The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight (in kilograms)
- Value of shipment (in Indian Rupees)
- AWB and Flight number(s) if applicable;
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee
- Invoice

The following information shall be stated on the invoice:

- Consignee's name, address, telephone number (included mobile no.) and e-mail ID.
- Purchaser order reference;
- Consignee's requisition reference;
- Instructions to "Telephone consignee upon arrival (repeated telephone number);

J. Dispatch

Consignment should be scheduled to arrive outside weekends and/or public holidays.

Annexure

Ferrous Sulphate and Folic Acid sugar coated tablets contains Dried Ferrous Sulphate and Folic Acid.

The Product shall comply with respect to all test as specified in the latest version of I.P.

Seals Integrity Test:

Check 10 blister packs. Bundle up the blister packs and submerge them under water in a vacuum desiccator or equivalent device. Draw a vacuum of about 18k Pa (15cm of mercury or 0.8 bar) and hold for a minute. Examine for the air leakage indicated by a fine stream of bubbles. Re-establish normal pressure and open blister packs to examine for water penetration.

Microbial Count:

When the test is conducted as per latest version of IP

-Total viable aerobic count- Not more than 10^3 CFU per gram

-Total fungal count - Not more than 10^2 CFU per gram.

-Absence of Escherichia coli.

Technical specification for IFABlue Anemia MuktBhart

IFA-Blue (Ferrous Sulphate & Folic Acid Tablets)

A. Specific requirements

Item: Iron and folic acid tablets shall conform to the general requirements of Tablets given in IP 2022 and the requirements given in the Annexure. The drug shall be currently licensed in India and shall meet all requirements of the licensing authorities.

Description:

Iron and Folic Acid Tablets (IFA-Blue) contain Ferrous Sulphate and Folic Acid. They are sugar coated and blue colored. Approved colors shall be used in the coating.

Each sugar coated tablet shall contain:

Dried Ferrous Sulphate IP 200 mg equivalent to
Elemental Ferrous iron 60 mg
Folic Acid IP 0.5 mg

The quality of each constituent should conform to the requirements of IP permissible limits.

Protocol and Testing:

Complete Test Protocol and samples are taken and sent to the laboratory (identified by the purchaser) by the Inspecting Officer duly sealed and signed by him or his authorized representative.

Protocols of test should include the requirements given in IP 2022 for tablets and those included in the **Annexure.**

The drug should be dispatched to the consignee only on clearance from the testing Laboratory. The drug shall be released on the basis of Protocol scrutiny by the authorized representative of the purchaser and testing of the drugs by authorized laboratory.

Each batch should be accompanied with a certificate from the manufacture that the drugs meet the specified requirement.

Random sampling will be taken from the supplies of the State (post-delivery) and will be periodically tested quarterly by MoHFW in identified labs separately for monitoring quality assurance.

Storage:

Iron and Folic Acid Tablets (IFA) should be stored in a cool and dry place, away from sunlight.

Shelf-life:

24 months, at least 5/6th of the shelf life of IFA must remain at the time of receiving the shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

Labelling:

The label on each blister pack of IFA Blue-AnemiaMukt Bharatshall conform to the requirements of Rule 96 & 97 of Drug Rules, and shall appear in English language. The label should in both English and Hindi/local language of the State.

All labelling of IFA Blue-AnemiaMukt Bharat should be in waterproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP and Rule 96 & 97 [illegible] time to time should be followed. All labels shall state the a[illegible]errous

Sulphate and equivalent amount of Elemental Ferrous Iron & Folic Acid, the name of manufacturer, batch number, manufacturing date, expiry date and NHM logo.

Labelling for secondary packaging:

IFA Blue-AnemiaMukt Bharat: It should indicate the name of the product "IFA-Blue-AnemiaMukt Bharat", number of blister packs/tablets, the amount of ferrous sulphate and equivalent amount of Elemental Ferrous Iron and Folic Acid, the name of drug manufacturer, batch number, date of manufacture, date of expiry, storage conditions and NHM logo. The label should in both English and Hindi/local language of the State.

Labelling for tertiary packaging (insulated packaging):

The external surface of insulated packages should be either white or in the natural colour of corrugated carton.

IFA Blue-AnemiaMukt Bharat: The label should include the name of the product "IFA Blue-AnemiaMukt Bharat", the number of secondary packages (boxes)/blister packs/tablets, the name of the manufacturer, batch number, date of manufacture, date of expiry, NHM logo and storage conditions.

Numbering of tertiary packaging:

All box should be numbered consecutively, shipping documents should be included in the box.

Additional Labelling:

All the containers (i.e. blister packs, cartons, etc) and other outer containers shall be labeled with the statement:
"**GOVT. SUPPLY-NOT FOR SALE**" in English and Local language along with NHM logo.

B. Quality assurance

Compliance:

The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fir for the purpose made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per **cGMP** included in Schedule M of Drugs Rules.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.
The supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.

The supplier shall provide the validation data of the analytical procedure used for testing assaying the components and shall provide the protocols of the tests applied.

The test data for raw materials, in-process, finished, the product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Inspection:

The purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's Factory and/or warehouse at a mutually agreeable time prior to /after the shipment of the Product.

Testing:

The purchaser may cause independent Laboratory testing of the sample picked randomly from pre and post-delivery shipment to be performed as deemed necessary to assure that the product conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product.

C. Packaging

Primary package:

15 Tablets should be packed in an Aluminium blister pack with IFA Blue-AnemiaMukt Bharat name displayed prominently.

Detailed packing specification of the Blister Pack (PVC Blister + Aluminum Foil) is as follows:

Front Side (PVC Blister):

e) Blister Material: PVC Films (No coating) – Heating Mechanism used to from blister in PVC Film

f) Layering Used: Single Layer of PVC Film

g) Thickness of PVC Layer: 250 Micron

h) GSM of PVC Film Used: 340 ± 8% gm/ sq. meter

Black Side (Aluminium Plain Foil):

e) Thickness of Foil: 25 micron

f) Sealant Used: Heat System

g) Any other material used along with plain Foil: Only PVC Film of 250 Micron

h) Layer: Single Layer of Plain Aluminium Foil.

Secondary package:

The blister packs should be packed in boxes for easy handling, transport and distribution with "IFA Blue-AnemiaMukt Bharat" name displayed prominently. The box may contain 10 blister packs. It shall be fabricated from Millboard/grey board/ cardboard with a minimum of bursting strength of 400 gsm.

Toll free number must be indicated on every blister pack for contacting in case of product complaints.

Tertiary package:

The boxes shall be packed in weather resistant triple walled insulated corrugated 5-ply cartons, each ply having strength 150 gsm with "IFA Blue-AnemiaMukt Bharat" name displayed prominently. It should be fabricated from virgin quality 'A' grade material. The overall dimension of the carton should be such that the product is not damaged during transportation and storage.

Toll free number must be indicated on every tertiary package for contacting in case of product complaints.

D. Qualification of the Manufacturer

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to cGMP Standards and Scheduled M of Drugs Rules.

E. Recalls

If products must be recalled because of problems with products quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give refund if the product has been taken off the market due to safety problems.

In case the quality of the product is found to be not of standard quality or unsatisfactory in quality checks, stringent action would be taken against them and supplier can be black-listed future supplies of the product.

F. Colour Coding

The labels on secondary packing, tertiary packaging and shipper package shall be identified by background(Standard Blue colour).

G. Bar Coding

Bar code shall be used to track down the product. It shall be printed on the label of Millboard/Grey Board Boxes and 5-Ply shipper containing

6. Product identification (GTIN 14) using application identifier
7. Expiry date in MMYYYY format & using application identifier
8. Master batch number using application identifier
9. *Complete details on GS1 standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org*
10. Bar coding to be put on all both tertiary and secondary packs

H. Markings

All containers and invoices must bear thename of the product, manufacturing date, expiry dates and appropriate storage conditions. The marking of AnemiaMukt Bharat should also be mentioned.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legibly manner which is acceptable to the Purchasers:

- Name IFA Blue-AnemiaMukt Bharat
- Generic name of product
- Manufacturer's name and registered address
- Manufacturer's License number
- Lot or batch number
- Number of blister packs contained in box
- Date of manufacture (Month and Year)
- Expiry date (Month and Year)
- Instructions for storage and handling
- Place of manufacture
- Barcode

Exterior Shipping Cartons:

The following information shall be stencilled or labelled on the exterior shipping cartons on all four sides in bold letters at least **Ariel font Size 14** with waterproof indelible ink in a clearly legible manner is acceptable to the Purchaser:

- Name IFA Blue-Anemia Mukt Bharat
- Generic name of product
- Lot or batch number
- Date of manufacture (Month and Year)
- Expiry date (Month and Year)
- Manufacture's name and registered address
- Consignee's address and emergency phone number including mobile number
- Contract number
- Number of tables/blister packs/boxes contained in the carton
- Gross weight of each carton (in kg)
- Carton containing no. of _____secondary packages
- Instructions for storage and handling
- Place of manufacture (Made in _____)
- Barcode

I. Documentation

Supplier shall provide to Purchaser a copy of the batch reco[illegible]ng all quality assurance documentation for the product being supplie[illegible]

Advance notice of arrival and advance shipping documentation:
Copies of the documentation for the goods to be supplied must be sent at least seven days in advance of arrival of the consignment. In the case of an individual contract for a specific destination that requires a longer period of advanced notice, a longer period should apply. The consignee (s) shall be intimated well in advance by registered letter/e-mail/telephone, so that the products are collected immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB) if applicable;
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the regulatory authority for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarded or the manufacture to the consignee, the Purchaser, and any other parties specified in the individual contract.
The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight (in kilograms)
- Value of shipment (in Indian Rupees)
- AWB and Flight number(s) if applicable;
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee
- Invoice

The following information shall be stated on the invoice:

- Consignee's name, address, telephone number (included mobile no.) and e-mail ID.
- Purchaser order reference;
- Consignee's requisition reference;
- Instructions to "Telephone consignee upon arrival (repeated telephone number);

J. Dispatch

Consignment should be scheduled to arrive outside weekends and/or public holidays.

Annexure

Ferrous sulphate and Folic Acid sugar coated tablets contains Dried Ferrous sulphate and Folic Acid.

The Product shall comply with respect to all test as specified in the latest version of I.P.

Seals Integrity Test:

Check 10 blister packs. Bundle up the blister packs and submerge them under water in a vacuum desiccator or equivalent device. Draw a vacuum of about 18k Pa (15cm of mercury or 0.8 bar) and hold for a minute. Examine for the air leakage indicated by a fine stream of bubbles. Re-establish normal pressure and open blister packs to examine for water penetration.

Microbial Count:

When the test is conducted as per latest version of IP

-Total viable aerobic count- Not more than 10^3CFU per gram

-Total fungal count - Not more than 10^2CFU per gram.

-Absence of Escherichia coli.

Technical specification for IFA Red Anemia Mukt Bharat

IFA-Red (Ferrous Sulphate & Folic Acid Tablets)

A. Specific requirements

Item: Iron and folic acid tablets shall conform to the general requirements of Tablets given in IP 2022 and the requirements given in the Annexure. The drug shall be currently licensed in India and shall meet all requirements of the licensing authorities.

Description:

Iron and Folic Acid Tablets (IFA-Red) contain Ferrous Sulphate and Folic Acid. They are sugar coated and red colored. Approved colors shall be used in the coating.

Each sugar coated tablet shall contain:

Dried Ferrous Sulphate IP 200 mg equivalent to	
Elemental Ferrous iron	60 mg
Folic Acid IP	0.5 mg

The quality of each constituent should conform to the requirements of IP permissible limits.

Protocol and Testing:

Complete Test Protocol and samples are taken and sent to the laboratory (identified by the purchaser) by the Inspecting Officer duly sealed and signed by him or his authorized representative.

Protocols of test should include the requirements given in IP 2022 for tablets and those included in the **Annexure.**

The drug should be dispatched to the consignee only on clearance from the testing Laboratory. The drug shall be released on the basis of Protocol scrutiny by the authorized representative of the purchaser and testing of the drugs by authorized laboratory.

Each batch should be accompanied with a certificate from the manufacture that the drugs meet the specified requirement.

Random sampling will be taken from the supplies of the State (post-delivery) and will be periodically tested quarterly by MoHFW in identified labs separately for monitoring quality assurance.

Storage:

Iron and Folic Acid Tablets (IFA) should be stored in a cool and dry place, away from sunlight.

Shelf-life:

24 months, at least 5/6th of the shelf life of IFA must remain at the time of receiving the shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

Labelling:

The label on each blister pack of IFA Red-AnemiaMukt Bharat shall conform to the requirements of Rule 96 & 97 of Drug Rules, and shall appear in English language. The label should in both English and Hindi/local language of the State.

All labelling of IFA Red-Anemia Mukt Bharat should be in waterproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in IP and Rule 96 & 97 [illegible] time to time should be followed. All labels shall state the a[illegible] Ferrous

Sulphate and equivalent amount of Elemental Ferrous Iron & Folic Acid, the name of manufacturer, batch number, manufacturing date, expiry date and NHM logo.

Labelling for secondary packaging:

IFA Red-AnemiaMukt Bharat - It should indicate the name of the product "IFA Red-AnemiaMukt Bharat", number of blister packs/ tablets, the amount of ferrous sulphate and equivalent amount of elemental Ferrous Iron and Folic Acid, the name of IFA Red drug manufacturer, batch number, date of manufacture, date of expiry, storage conditions and NHM logo. The label should be in both English and Hindi/local language of the State.

Labelling for tertiary packaging (insulated packaging):

The external surface of insulated packages should be either white or in the natural colour of corrugated carton.

IFA Red-AnemiaMukt Bharat - The label should include the name of the product "IFA Red-AnemiaMukt Bharat", the number of secondary packages (boxes)/ blister packs/tablets, the name of the manufacturer, batch number, date of manufacture, date of expiry, NHM logo and storage conditions.

Numbering of tertiary packaging:

All box should be numbered consecutively, shipping documents should be included in the box.

Additional Labelling:

All the containers (i.e. blister packs, cartons etc) and other outer containers shall be labeled with the statement:
"GOVT. SUPPLY-NOT FOR SALE" in English and Local language along with NHM logo.

B. Quality assurance

Compliance:

The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purpose made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per **cGMP** included in Schedule M of Drugs Rules.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.
The supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.

The supplier shall provide the validation data of the analytical procedure used for testing assaying the components and shall provide the protocols of the tests applied.

The test data for raw materials, in-process, finished, the product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Inspection:

The purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's Factory and/or warehouse at a mutually agreeable time prior to /after the shipment of the Product.

Testing:

The purchaser may cause independent Laboratory testing of the sample picked randomly from pre and post-delivery shipment to be performed as deemed necessary to assure that the product conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product.

C. Packaging

Primary package:

10 Tablets should be packed in an Aluminium blister pack with IFA Red-AnemiaMukt Bharat name displayed prominently.

Detailed packing specification of the Blister Pack (PVC Blister + Aluminum Foil) is as follows:

Front Side (PVC Blister):

i) Blister Material: PVC Films (No coating) – Heating Mechanism used to from blister in PVC Film
j) Layering Used: Single Layer of PVC Film
k) Thickness of PVC Layer: 250 Micron
l) GSM of PVC Film Used: 340 ± 8% gm/ sq. meter

Black Side (Aluminium Plain Foil):

i) Thickness of Foil: 25 micron
j) Sealant Used: Heat System
k) Any other material used along with plain Foil: Only PVC Film of 250 Micron
l) Layer: Single Layer of Plain Aluminium Foil.

Secondary package:

The blister packs should be packed in boxes for easy handling, transport and distribution with "IFA Red-AnemiaMukt Bharat" name displayed prominently. The box may contain 10 blister packs. It shall be fabricated from Millboard/grey board/ cardboard with a minimum of bursting strength of 400 gsm.

Toll free number must be indicated on every blister pack for contacting in case of product complaints.

Tertiary package:

The boxes shall be packed in weather resistant triple walled insulated corrugated 5-ply cartons, each ply having strength 150 gsm with "IFA Red-AnemiaMukt Bharat" name displayed prominently. It should be fabricated from virgin quality 'A' grade material. The overall dimension of the carton should be such that the product is not damaged during transportation and storage.

Toll free number must be indicated on every tertiary package for contacting in case of product complaints.

D. Qualification of the Manufacturer

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to cGMP Standards and Scheduled M of Drugs Rules.

E. Recalls

If products must be recalled because of problems with products quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give refund if the product has been taken off the market due to safety problems.

In case the quality of the product is found to be not of standard quality or unsatisfactory in quality checks, stringent action would be taken against them and supplier can be black-listed future supplies of the product.

F. Colour Coding

The labels on secondary packing, tertiary packaging and shipper package shall be identified by background. (Standard Red colour)

G. Bar Coding

Bar code shall be used to track down the product. It shall be printed on the label of Millboard/Grey Board Boxes and 5-Ply shipper containing

11. Product identification (GTIN 14) using application identifier
12. Expiry date in MMYYYY format & using application identifier
13. Master batch number using application identifier
14. *Complete details on GS1 standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org*
15. Bar coding to be put on all both tertiary and secondary pac

H. Markings

All containers and invoices must bear the name of the product, manufacturing date, expiry date and appropriate storage conditions. The marking of AnemiaMukt Bharat should also be mentioned.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legibly manner which is acceptable to the Purchasers:

- Name IFA Red-AnemiaMukt Bharat
- Generic name of product
- Manufacturer's name and registered address
- Manufacturer's License number
- Lot or batch number
- Number of blister packs contained in box
- Date of manufacture (Month and Year)
- Expiry date (Month and Year)
- Instructions for storage and handling
- Place of manufacture
- Barcode

Exterior Shipping Cartons:

The following information shall be stencilled or labelled on the exterior shipping cartons on all four sides in bold letters at least **Ariel font Size 14** with waterproof indelible ink in a clearly legible manner is acceptable to the Purchaser:

- Name IFA Red-AnemiaMukt Bharat
- Generic name of product
- Lot or batch number
- Date of manufacture (Month and Year)
- Expiry date (Month and Year)
- Manufacture's name and registered address
- Consignee's address and emergency phone number including mobile number
- Contract number
- Number of tables/ blister packs/boxes contained in the carton
- Gross weight of each carton (in kg)
- Carton containing no. of _____secondary packages
- Instructions for storage and handling
- Place of manufacture (Made in _____)
- Barcode

I. Documentation

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the product being supplied.

Advance notice of arrival and advance shipping documentation:
Copies of the documentation for the goods to be supplied must be sent at least seven days in advance of arrival of the consignment. In the case of an individual contract for a specific destination that requires a longer period of advanced notice, a longer period should apply. The consignee (s) shall be intimated well in advance by registered letter/e-mail/telephone, so that the products are collected immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB) if applicable;
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the regulatory authority for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarded or the manufacture to the consignee, the Purchaser, and any other parties specified in the individual contract.
The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight (in kilograms)
- Value of shipment (in Indian Rupees)
- AWB and Flight number(s) if applicable;
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee
- Invoice

The following information shall be stated on the invoice:

- Consignee's name, address, telephone number (including mobile no.) and e-mail ID.
- Purchase order reference;
- Consignee's requisition reference;
- Instructions to "Telephone consignee upon arrival (repeat telephone number);

J. Dispatch

Consignment should be scheduled to arrive outside weekends and/or public holidays.

Annexure

Ferrous Sulphate and Folic Acid sugar coated tablets contains Dried Ferrous Sulphate and Folic Acid.

The Product shall comply with respect to all test as specified in the latest version of I.P.

Seals Integrity Test:

Check 10 blister packs. Bundle up the blister packs and submerge them under water in a vacuum desiccator or equivalent device. Draw a vacuum of about 18k Pa (15cm of mercury or 0.8 bar) and hold for a minute. Examine for the air leakage indicated by a fine stream of bubbles. Re-establish normal pressure and open blister packs to examine for water penetration.

Microbial Count:

When the test is conducted as per latest version of IP

-Total viable aerobic count- Not more than 10^3 CFU per gram

-Total fungal count - Not more than 10^2 CFU per gram.

-Absence of Escherichia coli.

Annexure "A-2"

Government of India Guidelines

Hepatitis B Virus Vaccine Specifications
(For NCB/LCB)

A. Specific requirements:

Item:

Hepatitis B virus vaccine, shall meet the requirements as per Indian Pharmacopoeia (I.P.) and Rule 122B of Drugs and Cosmetics Act

The vaccine shall be currently registered in the country of manufacture and shall meet all requirements of the licensing authority of the country of manufacture. The vaccine also shall be currently registered in the county of use (India) and shall meet all the requirements of the licensing authority of the country of use.

Description:

Hepatitis B virus vaccine may exist in two forms, i.e. as an inactivated (plasma-derived) vaccine and as a recombinant (DNA) vaccine.
Hepatitis B virus vaccine (Inactivated) is a non-infectious inactivated liquid preparation derived from surface antigen of hepatitis virus (HBsAg). The production of vaccine is based on a virus seed lot system.
Hepatitis B virus vaccine (Recombinant) is a non-infectious preparation containing the purified major surface antigen of hepatitis B virus (HBsAg). The antigen is manufactured by recombinant DNA technology by culturing genetically engineered yeast cells lines which carry the gene that codes for the major surface antigen of the hepatitis B virus as approved by the competent authority.
The purified antigen is finally adsorbed on aluminium hydroxide or aluminium phosphate.
The vaccine must be free from all demonstrable viable microbial agents and found suitable for human immunization. It may contain a suitable stabilizing agent with anti microbial properties.
Hepatitis B vaccine contains not less than 20mcg of hepatitis B surface antigen per ml.

Protocol and testing:

Complete Test Protocol along with samples of all batches should be sent to the Head of the vaccine testing laboratory i.e. Central Drugs Laboratory, Kasauli-173204;
For local manufacturers:
Complete Test Protocol and samples are taken and sent to by the Inspecting Officer duly sealed and signed by him or his authorized representative.

The vaccine should be dispatched to the consignee only on clearance from the Central Drugs Laboratory, Kasauli. The vaccine will be released on the basis of protocol scrutiny and testing of the vaccine by Central Drugs Laboratory, Kasauli.

Each batch should be accompanied with a certificate from the manufacturer that the vaccine meets the I.P. requirements.

(6)

Dosage size: By intramuscular injection (Anterolateral part of thigh); when given as part of a primary immunization starting at 6 weeks of age. Three injections are given at monthly intervals. In all institutional deliveries a dose at the time of birth as early as possible and preferably within 24 hours.

Dose package: Single-dose; multi-dose vials contain 10 paediatric doses 0.5ml, or 10 adult doses 1 ml.

Filling volume: Final product should contain 15% overfill.

Storage temperature: In light-resistant containers between +2 and +8°C; **must not be frozen.**

Shelf-life: At least 24 months from date of manufacture when stored between +2 to +8°C ; at least 20 months must remain after shipment. The supplier will provide manufacturer's stability test data substantiating this 24 month shelf life in the proposed vial. At the time of inspection or acceptance for delivery to the country of destination, no more than 6 months shall have expired since the Date of manufacture (or date of beginning of the last satisfactory test for potency) shown on the Certificate of Analysis.

Labelling: The label on each vial shall conform to the requirements of I.P. and shall appear in the language of English.
All labelling shall be indelible ink and shall withstand immersion in water and remain intact.
All labels shall state the name of the vaccine, name of the manufacturer, address of manufacturer, lot number, composition, concentration, dose and mode for administration, expiry date, storage temperature and any other marking that is appropriate.

VVM: The label on each vial should include a Vaccine Vial Monitor (VVM) designed to meet the heat stability curve of the vaccine supplied. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.
The position of the VVM may be on the label or on the neck or on the cap as validated by the supplier
The Vaccine Vial Monitor (VVM) shall be as per WHO Specifications (please refer to Annex I).

Labelling for secondary packaging:
A label must be affixed either to the top and/or front surface of the secondary packages. It should indicate the type of vaccine, the name of the manufacturer, presentation, batch number, date of manufacture, date of expiry, quantity and storage conditions.

Labelling for tertiary packaging (insulated packaging):
The external surface of insulated packages should be either white or in the natural colour of corrugated carton. Dark colours must be avoided.
All labels on tertiary packaging must be attached to all four sides.
Vaccine Rush: A label must be affixed to all four sides of the vaccine package in English/Hindi.
"Do not freeze" sticker in English/Hindi should be attached to all four sides of the vaccine package.

Numbering of tertiary packaging:
All boxes should be numbered consecutively. Shipping documents should be included in the box labelled number 1, and this box should be clearly labelled with the words
"Containing vaccine shipping documents".

Additional Labelling:
All the containers and other outer containers shall be marked with the statement "CGS NOT FOR SALE" in English.
All labels on containers i.e. vials/ampoules, cartons, tubes etc. as well as outer dropper should be marked with the statement "CGS NOT FOR SALE" in bold red letters in English.

Containers:
IP, type 1, amber, coloured, glass tamper proof ampoule/vial or plastic container for parenteral preparation.

Closures:
Vaccine vials shall be fitted with closures that conform to IP requirements for injectable preparations.

Printed materials:
Two (2) information sheets, printed in English and Hindi, shall be included in each secondary package and shall include information as per Annexure III

B. Quality assurance

Compliance:
The Supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet I.P./internationally (WHO as cited above) recognized standard for safety, efficacy and quality; (c) are fit for the purposes made known to the Seller (d) are free from defects in workmanship and in materials and (e), the product has been manufactured cGMP included in Schedule M.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.
The Supplier shall provide a copy of the manufacturing record and procedures to the Purchaser for each lot intended for shipment.
The Supplier shall provide a copy of **Validation record** with regards to process validation demonstrating batch to batch consistency and to confirm that the packaging complies with WHO requirements
The supplier shall provide document that the batch conforms to the WHO requirements of **Shake test.**
The Supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.
The Supplier shall provide to the Purchaser a copy of the approval of each source material, constituent material and component for each lot intended for shipment.
The Supplier shall retain a sample of twenty (20) vials from each lot shipped for two years beyond the printed expiration date.
Chemical, physical and biological test data for in-process and finished product testing must be on record for each lot shipped and must be available to Purchaser's representatives when requested.

Inspection:

The Purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's factory and/or warehouse at a mutually agreeable time prior to the shipment of the product.

Testing:

The Purchaser may cause independent laboratory testing to be performed as deemed necessary to assure that the goods conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on biological products.

C. Packing:

Prior to and at the time of packing, the vaccines must be kept within the storage temperature limits recommended by the manufacturer.

Storage:

Supplier shall state storage volume occupied per infant dose of vaccine (storage volume includes the vaccine vial, packet containing the vaccine vial and any intermediate packaging).

Inner boxes:

_____ (number) individual glass vials or ampoules shall be contained in sturdy white cardboard boxes (of not less than 300 GSM) outfitted with individual segments for protecting and separating each vial.

Temperature monitoring devices:

To be included in all vaccine shipments to document whether temperature limits have been exceeded.
One electronic temperature device is included in each and every vaccine shipping carton
(Please refer to Annex II).
Prior to and at the time of packing, the vaccine must be kept at the storage temperature recommended by the manufacturer.
Vaccine manufacturer is required to validate their packaging twice for a period of 48 hours i) that the warmest temperature inside the insulated packing does not rise above +30°C in the continuous outside ambient temperature of + 43°C and ii) that the coolest storage temperature does not fall below +2°C in the continuous outside temperature of -5°C..

Over packing:

Box shall be over packed so that the vaccine remains refrigerated at between + 2 and +8°C and does not freeze. The containers must be suitable for export shipping in accordance with *WHO guidelines on the international packaging and shipping of vaccines* (WHO/V&B/01.05). The containers must have adequate insulation and or sufficient refrigerant to ensure that the warmest storage temperature of the vaccine does not rise above +30°C in continuous outside ambient temperature of + 43 degrees C nor fall below +2°C in continuous external temperature of -5°C during transit and for a period of at least 48 hours after arrival at the airport of destination[13].
Additional cushioning shall be provided, sufficient to protect the vials from breakage during transit and handling.

Exterior shipping cartons:

Product and printed materials, packaged as specified above, shall be packed in weather-resistant, triple-wall corrugated fibreboard cartons with a bursting test strength of not less than 1900 kPa. The overall dimensions of the exterior shipping cartons should be such that the product does not become damaged during transportation and storage.

Each international shipping carton should weigh less than 50 kg. It is important that individual boxes are not too heavy during transport as they are frequently loaded and offloaded manually at airports and intermediate stores.

[13] When considering "best practices" for transport and storage of vaccines, reference should be made to current recommendations in the appropriate literature.

(10)

b. Markings:

All containers and invoices must bear the name of vaccine, expiry dates of the vaccine and appropriate storage temperature.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legible manner which is acceptable to the Purchaser:

- Generic name and trade name of the vaccine
- Manufacturer's name and registered address
- Manufacturer's national registration number
- Lot or batch number
- Composition and concentration
- Number of vials contained in box
- Date of manufacture (month and year)
- Expiration date (month and year)
- Instructions for storage and handling[14]*
- Place of manufacture (Made in_____)

Exterior shipping cartons:

The following information shall be stencilled or labelled on the exterior shipping cartons on two opposing sides in bold letters at least 'Arial font size 14' high with waterproof indelible ink in a clearly legible manner which is acceptable to the Purchaser:

- Generic name and trade name of the vaccine
- Lot or batch number
- Date of manufacture (month and year)
- Expiration date (month and year)
- Manufacturer's name and registered address
- Manufacturer's national registration number
- Destination country license or registration number
- Consignee's address and emergency phone number including mobile number
- Destination airport
- Contract number
- Number of vials contained in the carton
- Gross weight of each carton (in kg)
- Carton containing ---------- secondary packages
- Instructions for storage and handling[15]*
- Place of manufacture (Made in_____)

[14] * Markings on inner boxes should state clearly that the reconstituted vaccine is good for 6 hours only; additional text to be provided by Purchaser.

[15] * To be provided by Purchaser.

E. Documentation

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the vaccine being supplied.

Advance notice of arrival and advance shipping documentation:
Copies of the documentation for the goods to be shipped must be sent at least seven days in advance of arrival of the shipment. In the case of an individual contract for a specific destination that requires a longer period of advance notice, a longer period should apply. The consignee(s) should be intimated well in advance by registered letter/telegram/telephone, so that vaccines are collected from airport immediately after arrival. Copy of the communication from the supplying firm should be endorsed to the Assistant Commissioner (I) and Deputy Director (UIP), Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi for information.

The documentation must include the following:-
- Pre-advice defined by the Purchaser
- Airway bill (AWB);
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) issued by the national regulatory authority (NRA) of the country of manufacture for each lot of vaccine supplied; and
- Any other document, certificate or instruction specified in the individual order.

The documents should be sent by e-mail and fax by the freight forwarder or the manufacturer to the consignee, the Purchaser, and any other parties specified in the individual contract.

The pre-advice must contain the following information:
- Purchase order reference;
- Consignee requisition reference;
- Number of packages, gross weight (in kilograms) and volume (in cubic meters);
- Type of vaccine, total number of vials and number of doses per vial/ampoule/tube;
- Value of shipment (in Indian Rupees and/or in US $);
- AWB and flight number(s);
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee.

The following information shall be stated on the airway bill:
- Consignee's name, address, telephone number (including mobile no) and e-mail ID.
- Purchase order reference;
- Consignee's requisition reference;
- Type of vaccine and quantity;
- Instructions to: "Telephone consignee upon arrival *(repeat telephone number)*";
- Handling information: **"Medicines – Vaccine – For human use – Highly perishable – Not to be delayed.**

The following instruction should be stated in the AWB: "Throughout shipment, pending reshipment and prior to collection by the consignee, the vaccine must be stored at +2°C to +8°C.

F. Dispatch

Vaccines should travel by a direct route wherever possible, road transport may be used if accompanied by attendant. Where trans-shipment is unavoidable, the journey should be planned through airports that:
a) have cold storage facilities, and
b) are located in countries with a temperate climate.
The maximum transit time from the manufacturer to arrival at the airport of final destination must not exceed 48 hours.

Shipments should be scheduled to arrive outside weekends and/or public holidays in the recipient country and airline bookings should be made well ahead of the date of departure.

-Vaccines must not be transported with radioactive products, fish or meat;
-Correct cold-chain procedures must be observed during transit, warehousing and shipping (i.e., all vaccines must be kept in temperature-controlled environments at all times throughout the shipment process);
-Reactivation of the refrigeration process of shipments must be performed in accordance with the instructions of the supplier of each shipment whenever deemed necessary;

G. References

1) Indian Pharmacopoeia 2007, Indian Pharmacopoeia Commission, Government of India; Ministry of Health & Family Welfare. Ghaziabad.

2) British Pharmacopoeia 2007, Volume III, page 24

3) Guidelines on the international packaging and shipping of vaccines. WHO 2005; Department of Immunization, Vaccines and Biologicals. WHO/IVB/05.23.

4) Procurement of vaccines for public-sector programmes- A reference manual. WHO/IVB/03.16; 2004.

Annexure-I
SPECIFICATION FOR VACCINE VIAL MONITORS (VVM)

Specification reference : E6/ IN5
Applies to test procedures : E6/ Proc/5

Purpose

Vaccine vial monitors serve primarily to warm health workers when the cumulative heat exposure of a vial of vaccine has exceeded a pre-set limit, beyond which the vaccine should not be used. In addition, changes in the appearance of the VVM before this limit is reached will serve to guide health workers to first use more-exposed vials of vaccine.

Format and dimensions:

The VVM is a circle of colour, minimum 7.0mm with a square of colour, Minimum dimension 2.0 x 2.0mm positioned in the centre of the circle (See Figure 1).
The ratio of the area of the square to the area of the circle (including the square) is at least 0.1, whatever dimensions are chosen.



Design:

The circle of the VVM acts as a static, reference colour and the square is a changing, active colour change device. The colour is limited to a change of shade, from light to dark. Any colour is permitted for the VVM design, but changes in hue are not permitted.

Colour:

The colour density change of the indicator is illustrated in the Figure 2 below. At the start point the colour of the square is lighter than the circle. The end point is indicated when the colour of the square matches the circle. The end point is exceeded when the colour of the square is darker than the circle. The following paragraphs describe the colour change in more detail.

Start point		Square lighter than circle
End point		Square matches the circle
End point exceeded		Square darker than the circle

Figure 2. The colour density change of the indicator (The central square is the active surface)

1 Replaces the previous version of 13 August 1999

Definition of the start-point

The colour of the active surface of the VVM at the time of the vaccine vial is

called the 'start point'.
At the start point, the colour density of the square as measured by a colour Densitometer2 must be lighter than the circle by a difference of at least 0.25 OD Densitometer units.

Definition of the end point

The colour of the active surface of the VVM at the limit of use of the vaccine vial is called the "end point".

The end point is reached when the difference in the average colour density obtained from readings at least two different points on the circle and the colour density of the square is 0.00 OD, as measured by the densitometer. The end point is exceeded when the colour of the square is darker than the colour of the circle.

Homogeneity of the reference colour

The colour density of one 2mm diameter portion of the circle must be within 0.01 OD of the colour density at any other two 2mm diameter portions of the circle, when measured with a colour densitometer.

VVM reaction rates:

Reaction rates are specific to four different models of VVM, relating to four Of vaccines according to their heat stability at two specific temperature points
(See table 1)

Table 1: VVM reaction rates by category of heat stability

Category: (Vaccines)	No. of days to end point at +37°C	No. of days to end point at +25°C	Time to end point at +5°C
VVM30 HIGH STABILITY	30	493	> 4 years
VVM14 MEDIUM STABILITY	14	90	> 3 years
VVM7 MODERATE STABILITY.	7	45	> 2 years
VVM2 LEAST STABLE	2	NA*	225 days

*VVM (Arrhenius) reaction rates determined at two temperature points

At +37°C, RH 33% +/-5% and RH 75% +/-5%, at least 90% of VVMs tested Should reach the end point within a range of time whose upper limit is shown in Table 1 or a period set by the vaccine manufacturer, based on published vaccine stability data, and whose lower limit is 25% below the upper limit (See Figure 3).

At +25°C (ambient humidity in submerged plastic/foil pouch) at least 90% of VVMs tested should reach the end point within a range of time whose upper limit is shown in Table 1 for VVM30, VVM14 and VVM7 categories, or a period set by the vaccine manufacturer, based on published vaccine stability data, and whose lower limit is 40% below the upper limit (See Figure 3).

At 5°C(ambient humidity in submerged plastic/foil pouch), all VVM30, VVM14 and VVM7 samples should reach the end point after the lower time limit specified in Table1. Conformance can be determined by extrapolation from high temperature (25°C and 37°C) data. At 5°C(ambient humidity in submerged plastic/foil pouch), at least 90% of VVM2 samples tested should reach the end point within a range of time whose upper limit is 225 days and whose lower limit is 40% below the upper limit (see Figure 3).

A tolerance is allowed in the above tests for up to 5% of VVM samples tested to reach the end point after the upper limit and 5% before the lower limit (See Figure 3).

The colour change shall be monotonic in its response to cumulative heat exposure within the limits of the allowed variation. The observer shall be able to distinguish between unchanged, 50% and the end point of the indicator.



Figure 3. Stability limit criteria by sample group

Global Measurement Accuracy:

The allowable total error for measuring the difference the colour of the circle and Square is ± 0.04OD when using an X-rite 404 GS(X) colour reflectance Densitometer. Major sources of error are instrument error for both the circle and square, repeatability, and variation in end point caused by an allowed temperature variation of ± 0.2° C.

Water Bath Precision and Control:

The VVMs should be tested in water baths controlled to within ± 0.2°C. (Any additional 0.1°C variation in temperature control requires an allowance for additional measurement error.)

Reversion

The indicator shall not revert to a lighter colour at any point in its life when exposed to conditions likely to be found during normal use. After the endpoint is reached, the square shall remain the same colour as the circle or become darker than the circle.

Integrity of VVMs

The integrity of VVMs depends on the presentation of the vaccine:

For liquid vaccines:

The VVM shall be permanently attached to the vaccine vial, even after the vial has been opened and remain readily observable before, after and during use. Prior to opening, the VVM should not be removable: it should resist removal from the vaccine vial as much as a label meeting current requirements.

For freeze dried vaccines:
The VVM shall be attached to the vaccine vial or ampoule, remaining readily observable until the vial or ampoule is opened but not observable after opening. Prior to opening, the VVM should be removable. It should resist removal from the vaccine vial as much as a label meeting current requirements.

Safety.
The performance of the VVM shall not be able to endanger human health. The materials of the VVM shall be non- toxic and non-irritant. The VVM should meet any requirements in force concerning toxicity of labels or packaging in the country of manufacture.

(17)

Annex II: Temperature Monitoring Devices

Table 1: Specifications of the electronic devices for all national and international shipments

Storage temperature Range:	-20°C to +70°C
Operating temperature Range:	-20°C to +55°C
Display visibility Range:	-10°C to +55°C
Temperature measuring accuracy	± 0.5° C or better
Time measuring accuracy	± 10 seconds per day, or better
Initial delay (see point 2 below)	1 hour
Recording period	10 days
Storage before START	minimum of 18 months
Data retention after STOP	minimum of 6 months

A For specific devices with these features, refer to the WHO web site:
http://www.who.int/vaccines-access/vacman/pis/pqs.htmthe

The electronic devices should, at a minimum, meet the specifications outlined in Table 1 (above) and have the functions outlined below.

1) A "start" function to activate the device at the time the carton is being loaded with vaccine.
2) A "stop" function to allow the recipient to stop the recording when the vaccine arrives at its destination.
3) A one hour "initial delay" function so the device can acclimatize to the temperature inside the shipping carton before it starts recording.
4) A "history" function to provide details of violations of the temperature limit in terms of time, range and duration. This function is primarily to provide information for the use of the procurement agency.
5) A liquid crystal display (LCD) screen to provide a visual display of the information and also to show the symbol that indicates whether the device is functional or not. This symbol, and also the alarm indicator, should be static (i.e. should not flash or blink) so as to be visible when the screen is scanned or photocopied for documentation purposes.
6) An alarm set according to WHO's recommended settings (see Tables 2 and 3 below).

Table 2: WHO-recommended alarm settings for national/international shipments of DTP, DT, TT, HepB and combination vaccines

Temperature	Alarm type	Period for triggering the alarm
45°C	single event	1 hour
30°C	cumulative	10 hours
-0.5°C	single event	1 hour

Table 3: WHO recommended alarm settings for all national and international shipments of OPV and freeze-dried BCG, measles, MMR vaccines

Temperature	Alarm type	Period for triggering the alarm
45°C	single event	1 hour
30°C	cumulative	10 hours
10°C	cumulative	20 hours

Vaccine manufacturers are required to validate their packaging twice for a period of 48 hours:

I) at ambient temperatures under +43°C and

II) at ambient temperatures under 5°C.

This validation is critical to ensure that the packaging complies with the above requirements and will not set off an alarm.

Batteries for electronic devices do not perform under extremely cold temperatures, such as when vaccines are being transported with dry ice.

Each electronic device should be attached to a backing card that includes the information outlined below, in the appropriate language.

1. The type of device:
Type 1: for DTP, DT, TT, HepB and combination vaccines
Type 2: for OPV and freeze-dried BCG, measles, MMR vaccines

2. For the person packing/sending the shipment:
a) Instructions on how to activate the device;
b) A reminder that one device must be placed in each shipping carton;
c) Space for the following information to be entered:
- the supplier's name;
- date and time of the packing;
- vaccine purchase order number;
- vaccine type.

3. For the person receiving the shipment:
a) Instructions on how to stop the device;
b) Illustrations to show information on the LCD screen – how it will indicate problems/no problems and the alarm status display;
c) Tables 4 and 5 (below) showing what to do.

(19)

Table 4: Information to be displayed on the backing card of electronic device – Type 1 (for DTP, DT, TT, HepB and combination vaccines)

Alarm temperature	What to do with vaccines
45°C	Contact Consignee.
30°C	Contact Consignee
-0.5°C	Conducts shake tests. USE vaccine if passes. Inform Consignee of test results.

Shake test guidelines can be found on Guidelines on the international packaging and shipping of vaccines. WHO 2005; Department of Immunization, Vaccines and Biologicals. WHO/IVB/05.23.

Table 5: Information to be displayed on the backing card of electronic device – Type 2 (for OPV and freeze-dried BCG, measles, MR, MMR, lyophilized Hib, yellow fever and meningitis vaccines)

Alarm temperature	What to do with OPV	What to do with other vaccines
45°C	Contact Consignee	Contact Consignee
30°C	Contact Consignee	Contact Consignee
10°C	Contact Consignee	Accept

SPECIFICATIONS:

Alarm setting	Type 1: for vaccine: DTP,DT, TT, Hep B and combination vaccines		Type 2: for vaccine: OPV, freeze dried BCG, measles and MMR	
	>=+45°C	1 hour single	>=+45°C	1 hour single
	>=+30°C	10 hours cumulative	>=+30°C	10 hours cumulative
	>=-0.5°C	1 hour single	>=+10°C	20 hours cumulative
Initial start delay	1 hour		1 hour	

MODEL INSERT

Hepatitis-B Vaccine

DESCRIPTION:
Hepatitis B virus vaccine may exist in two forms, i.e. as an inactivated (plasma-derived) vaccine and as a recombinant (DNA) vaccine. Hepatitis B vaccine contains not less than 20mcg of hepatitis B surface antigen per ml.

ADMINISTRATION:
The vaccine should be injected intramuscularly. The preferred site of injection is outer mid-thigh (infants)/outer upper arm (children and adults). (An injection into a child's buttocks may cause injury to the sciatic nerve and is not recommended.)

It must not be injected into the skin as this may give rise to a local reaction. 1 dose is 0.5 ml. A sterile needle and sterile syringe should be used for each injection. Once opened multi-dose vials should be kept between $+2^0$C and $+8^0$ C. Opened vials of vaccine may be used in subsequent immunization sessions until, a new shipment of vaccine arrives providing that the conditions described in WHO/EPI/LHI.5/95.1 are met.

IMMUNIZATION SCHEDULE:
By intramuscular injection (Anterolateral part of thigh); when given as part of a primary immunization starting at 6 weeks of age. Three injections are given at monthly intervals. In all institutional deliveries a dose at the time of birth as early as possible and preferably within 24 hours.

SIDE EFFECTS:
Local soreness and redness, rarely anaphylactic reaction

CONTRAINDICATIONS:
Anaphylactic reaction to a previous dose

STORAGE:
HepB vaccine should be stored and transported between $+2^0$C and $+8^0$C. IT MUST NOT BE FROZEN.

PRESENTATION:
The vaccine comes in vial of 10 doses.

-

Annexure -IX
Ref. Clause No. 13, 16 & 19

RAJASTHAN MEDICAL SERVICES CORPORATION LTD
GUIDELINES FOR BLACK LISTING / DEBARRING OF PRODUCT OR COMPANY

1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:

1.1 The tenderer who submits false, forged or fabricated documents or conceals facts with intent to win over the tender or procure purchase order; EMD of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.

2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:

2.1 **The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, Bid Security Deposit of such Bidder firm shall be forfeited.**

If an LoA for more than one products is issued to a successful bidder and he/she/it fails to execute agreement for few item (s), in such case, Bid security of that item shall be forfeited and the product for which agreement is not executed shall be debarred for a period of not less than 3 years.

2.2 The successful tenderer after entering into an agreement withdraw or fail to honour commitments as per tender conditions, Security Deposit of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years.

3. ON ACCOUNT OF NON-SUPPLY:

3.1 The supplier shall start to supply according to tender condition from the date of purchase order and shall complete the supplies within 60/75 days as mentioned in Purchase Order or as stated in tender condition.

3.2 RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the tender documents. In the event of acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the tender document.

3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.

3.4 If the supplier fails to execute atleast 50% of the quantity mentioned in single purchase order and such failure in supply continues for three p[illegible]rders, then supplier firm will be liable for debarring for a period of 2 years. In such case such supplier will be ineligible to participate in any of the tenders for particular item(s) of drugs / medicines for a period of 2 years.

-

4. ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:

4.1 The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.

4.2 Samples of all sterile surgicals & sutures items falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.

4.3 If such samples **pass** quality test in all respects, RMSC will instruct its Warehouses to issue items of drugs to various hospitals / institutions

4.4 If the sample fails in quality test and report is received certifying that sample is **not of standard quality**, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the tender documents.

Minor defects

4.5 (1) If one batch of a particular item supplied during contract period fails in any of the quality test conducted by the tender inviting authority and/or by the Drugs Control Department, then Penalty of not less than 5.0% of Purchase Order value of that particular item shall be levied."

4.5 (2) If two batches of a particular item supplied during contract period fail in any of the quality tests conducted by the tender inviting authority and/or by the Drugs Control Department, then that particular product of that firm will be blacklisted for a period up to 3 years but not less than 06 months in any case.

(*Tablets/Capsules failing in dissolution test and active contents found 70% and above for thermo labile products and upto 5% less than the prescribed limits for thermo stable products.)

Grossly substandard

4.6 (1) If **any batch of a particular item** supplied under a tender tenure by the supplier is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab which falls in **grossly substandard** category and such failure is further confirmed by another empanelled lab / Govt. Lab, then the product shall be liable for debarring for a period of not Less than one (1) years.

(2) If **two or more batches** supplied under a tender tenure by the supplier is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab, which falls in **grossly substandard** and such failure is further confirmed by Govt. Lab, then the **Product** shall be liable for debarring for a period of not less than two (2) years.

4.7 If the supplier supplied **more than one drug** (subject to a minimum of 6 drugs) during a tender duration and 50% of such drugs are blacklisted, the firm shall be liable to be blacklisted for a period of **2 years** from the date of issue of the order observing the procedure.

Spurious or Adulterated

4.8 In case, any sample (even one batch) is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab which falls in **Spurious or Adulterated** category and if such failure is further confirmed by Govt. Lab during its entire shelf life, the **Company** shall be liable for debarring for a period of **not less than 5 years.**

4.9 If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is challenged then the report of Director, C.D.L., Kolkata shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of debarring of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for debarring the product for not less than 2 years and in case of involvement of three different products the **Supplier / Company** as a whole shall be liable for debarring for a period of not Less than 3years.

5 PROCEDURE IN THE EVENT OF QUALITY FAILURE WILL INVOLVE THE FOLLOWING STEPS:

5.1 On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.

5.2 Warehouse In-charge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.

5.3 Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the by QC Cell.

5.4 The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse In-charge will be directed to contact the District Drugs Control officer for drawing statutory sample of such batch as per Act. The DDW In-charge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.

5.5 In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in sub-Para 5.2 will be followed in respect of stock available with the warehouse. In respect of stock already issued and drug warehouse In-charge will take immediate steps to RETRIEVE the unused stock of such drugs from all such institutions by all possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.

5.6 On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.

5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.

5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC

6.1 Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.

6.2 The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Debarring of the particular product or supplier/ company.

6.3 If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the tenders for the particular item floated by RMSC for the specified period. For such purpose period of debarring will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for participating in any of the tenders for any of the items during blacklisted period.

7. POWER OF REVIEW:

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

8. RIGHT TO APPEAL:

Any supplier / company against whom the above action is taken may prefer an appeal within 30 days of date of debarring order to the Principal Health Secretary, Medical & Health Department, Govt. of Rajasthan who shall decide the appeal.

9. SAVINGS :

The debarring of particular product or supplier / firm will be do without prejudice to other penalty which may be imposed as per the conditions of tender

documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC including respective State Drug Controllers where the supplier / company is located.

10. JURISDICTION:

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

11. EXPLANATIONS:

(i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vis-majeure.

(ii) The Spurious, Adulterated, Grossly sub-standard drug shall have the explanation as per guidelines issued by Govt. of India for taking action on "Not of Standard quality drugs."

On the basis of quantitative analysis (Assay), the NOSQ drug shall be distinguished in the following manner :-

Category of NOSQ drugs	**Active ingredient content (Assay)**	
	Thermo stable	**Thermolabile**
Minor	Upto 5% less than the prescribed lower limit	Above 70% to the prescribed lower limit
Grossly Substandard	Below 5% of the prescribed lower limit to 50%	70% to 40%
Spurious	Below 50%	Below 40%

(iii) Purchase Orders, if any, already issued before taking any debarring action or replacement orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

(iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding tender and in case of any overlapping, the tender condition will prevail.

-

ANNEXURE-X
(Ref. Clause: 26)
FORM NO. 1 [See rule 83 of RTPP]

Memorandum of Appeal under the Rajasthan Transparency in Public Procurement Act, 2012

Appeal No..... of.....
Before the..... (First/Second Appellate Authority)

1. Particulars of appellant:
   (i) Name of the appellant:
   (ii) Official Address, if any:
   (iii) Residential address:

2. Name and address of the respondent (S):
   (i)
   (ii)
   (iii)

3. Number and date of the order appealed against and name and designation of the officer/ authority who passed the order (enclose copy), or a statement of a decision, action or omission of the Procuring Entity in contravention to the provisions of the Act by which the appellant is aggrieved:

4. If the Appellant proposes to be represented by a representative, the name and postal address of the representative:

5. Number of affidavits and documents enclosed with the appeal:

6. Ground of appeal:
.....
.....
..... (Supported by an affidavit)

7.
Prayer:
.....
.....
Place.....
Date.....

Appellant's Signature

-

ANNEXURE-XI
Ref. Clause No. 1(d), 5(c)(j), 20

UNDERTAKING FOR EMPANELMENT

I Name…….S/o…….Age……..Prop./Partner/Director/ Power of attorney holder of firm M/s……..situated at (Complete address of Mfg. unit)…….bearing drug license on Form 25 & 28 or form 10 bearing Number……. &……..respectively, issued on dated……..valid/Renewed up to……..do here by declare on oath as follows:-

1. That I have applied for empanelment for supply of Drugs & Medicines for the items I have quoted in the bid as enlisted in Annexure –VII
2. That I/We have carefully read all the conditions of E- Bid in Ref. no. F.02(420)/RMSCL/PROCUREMENT/DRUG/NIB-14/2024/ Dated:- for supply Cum rate contract and empanelment for supply of Drug and Medicines For Rajasthan Medical Services Corporation Ltd and accept all conditions of Bid, including amendments if any.
3. That I will be considered empanelled for the items which my bid have been declared technically responsive.
4. That I have deposited the required fees for empanelment .

Date

Name & Signature with Seal

-

Annexure-XII
Ref. Clause No.17.2

Supplier Consolidated Invoice

Name of Supplier: ……
Complete Address: ……..
E-mail ID: ……..

DL NO.:	**GST No.:**	**HSN Code**	Invoice No.: Date:

Purchaser: Managing Director **Address:** Rajasthan Medical Services Corporation Ltd, Gandhi-Block, Swasthaya Bhawan, Tilak Marg, C-Scheme, Jaipur Phone No. 0141- 2228066 **RMSCL GSTIN.08AAFCR2824M1Z3**	Purchase Order No.: …….. Date: ……..

Name of Item/Description : …….. **Drug Code (RMSCL) : ……**

S.No	Name of DDW	Odered Qty.	Invoice / Challan no.	Date	Packing Size	Batch No.	Mfg. Date	Exp. Date	Quantity Supplied in No. (Batch wise)	Basic Rate (without GST)	Basic Amount (without GST)
1	2	3	4	5	6	7	8	9	10	11	12

Remarks:	Total Basic Amount	
	Rate of (%) GST(CGST)	
	Rate of (%) GST(SGST)	
	Rate of (%) GST(IGST)	
	Total GST Amount(CGST+SGST+IGST)	
	Grand Total (Basic Amount+ GST Amount)	

Signature Not Verified
…ed Signatory
Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Annexure-XIII
Ref. Clause No. 17.2

Analytical Report Regarding Quality

Name of Supplier:-						
Address:-						
PO No:-		**Date:-**				
Drug Name:-						
Details of in house test report:-						
S. No.	**Name of Lab.**	**Test report No.**	**Date**	**Batch No.**	**Qty. Supplied**	**Result**
1.						
2.						
3.						
4.						
5.						
6.						
7.						
8.						
9.						
10.						
11.						
12.						

Authorised Signatory

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Annexure-XIV
Ref. Clause No. 11

Performance Security form (Bank guarantee)

To,

Managing Director Rajasthan Medical Services Corporation Ltd
WHEREAS…….(Name of Supplier)

Hereinafter called "the Supplier" has undertaken, in pursuance of Contract (Letter of Acceptance) No…….dated…… 2025 to supply……(Description of Goods).

AND WHEREAS it has been stipulated by you in the said Bid that the Supplier shall furnish you a bank Guarantee from a Scheduled Bank for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the supplier a Guarantee:

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of ……..(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the said Bid and/or any other contract or for set off any other dues pending against the supplier, without cavil or argument, any sum or sums within the limit of ……(Amount of Guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This Bank guarantee is payable at Jaipur Branch ……

This guarantee is valid until the……day of…… 2027……...

Signatures and Seal of Guarantors

Date……..……

Address:

……

Note:- The validity of bank guarantee should be for 36 months from the date of issuance of Bank Guarantee.

Signature Not Verified
Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Annexure-XV
(Ref. clause 5(w))

Land Border Country Registration Requirement

(To be executed on a non-judicial stamp paper valued Rs. 50/-)

Name of Bidder _____NIB Number _____

I/We have read the Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021 regarding Provisions for Procurement from a Bidder which shares a land border with India, I/we certify that, bidder M/s_____ (**Name of Bidder)** is

(i) not from such a country

or

(ii) if from such a country has been registered with the Authority i.e. as specified in Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021. **(Evidence of valid registration by the Authority shall be attached)**.

(Bidder to select one option

Name: **[*insert complete name of person signing the bid*]**

In the capacity of **[*insert legal capacity of person signing the bid*]**

Signed: **[*insert signature of person whose name and capacity are shown above*]**

Duly authorized to sign the Bid for and on behalf of **[*insert complete name of the bidder*]**

Date: ***[insert date of signing]***

-

Annexure-XVI
(Ref. clause 11)

Performance Security Declaration
(To be executed on a non-judicial stamp)

Date: _____ **[insert date (as day, month and year)]**
Contract Name and No.: _____**[insert name and number of Contract]**
To: _____ **[insert Designation and complete address of Procuring Entity]**

We, the undersigned, declare that we are a (Strike out which is not applicable. Please enclose an authentic certificate issued by the Administrative Department of respective government under which the bidder entity is constituted.):

(i) Departments/Boards of the State Government or Central Government; or

(ii) Government Companies as defined in clause (45) of section 2 of the Companies Act, 2013; or

(iii) Company owned or controlled, directly or indirectly, by the Central Government, or by any State Government or Governments, or partly by the Central Government and partly by one or more State Governments which is subject to audit by the Auditor appointed by the Comptroller and Auditor-General of India under sub-section (5) or (7) of section 139 of the Companies Act, 2013; or

(iv) Autonomous bodies, Registered Societies, Cooperative Societies which are owned or controlled or managed by the State Government or Central Government.

We understand that we are eligible for submission of a Performance Securing Declaration in lieu of Performance Security under Rule 75 (1) of RTPP Rules, 2013

We understand that, according to your conditions, the Contract must be supported by a Performance Security Declaration as a guarantee to ensure fulfillment of our all performance obligations under the Contract for _____ **[insert name of subject matter of procurement]**

We accept that we will automatically be suspended from being eligible for bidding in any contract with you for the period of time of _____**[Procuring Entity to indicate here the period of time for which the Procuring Entity will declare a Bidder in eligible to be awarded a Contract if the performance Security Declaration is to be executed]** starting on the date that we receive a notification from you, the _____ **[Designation of the Procuring Entity]** that our Performance Security Declaration is executed, if we are in breach of any of our performance obligation under the conditions of the Contract,

We understand this Performance Security Declaration shall expire after 60 days of completion of our all obligations under the Contract including Defect Liability, warranty/ Guarantee, operation, maintenance, etc. in accordance with the conditions of the Contract.

Signed: _____**[insert signature of person whose name and capacity are shown]**
In the capacity of: _____ **[insert legal capacity of person signing the Performance Security Declaration]**
Name: _____**[insert complete name of person signing the Declaration]**
Duly authorized to sign the Contract for and on behalf of: _____ **[insert complete name and address of the Bidder]**
Dated on _____day of _____**[insert date of signing]**
Corporate Seal _____

-

Annexure-XVII
(Ref. clause 5 (e))

BIDDER'S AUTHORIZATION CERTIFICATE

To,
{Procuring entity},
_____,
_____,

I/ We {Name/ Designation} hereby declare/ certify that {Name/ Designation and contact no. with mail id} is hereby authorized to sign relevant documents on behalf of the company/ firm in dealing with NIB reference No. _____ dated _____. He/ She is also authorized to attend meetings & submit technical & commercial information/ clarifications as may be required by you in the course of processing the Bid. For the purpose of validation, his/ her verified signatures are as under.

Thanking you,

Name of the Bidder: -

Signature Verified

Authorised Signatory: -

Seal of the Organization: -

Date:

Place:

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Annexure-XVIII
(Ref. clause No. 5(j(2))

To whom so ever it may concern

It is certified that M/s ..... has imported the following items through the Bills of lading / Bills of entry and Sale invoices for last three calendar /financial years.

S.No.	Item code	Item Specifications	Bill of lading / Bills of entry		Sale invoices	
			Year	Number	Year	Number
1.						
2.						
3.						

This certificate is issued on the basis of documents enclosed with this certificate.

Date:

Signature of
Chartered Accountant
(Name in Capital)
along with Registration

Number
Seal:
(Name in Capital)
UDIN :

Signature Not Verified

Digitally signed by Manoj Kumar
Designation : Executive Director
Date: 2025.01.29 13:10:51 IST
Reason: Approved

-

Annexure-XIX

(Ref. Clause no. 8)

Bank Guarantee Unconditional

(To be executed on a non-judicial stamp paper)

Form of Bid Security

(To be issued by a Scheduled Bank in India or other issuer, acceptable to the Procuring Entity)

[insert Bank's Name, and Address of Issuing Branch or Office)

Beneficiary: [insert name and address of the Purchaser)

Date: [Insert date)

Bid Security No. [insert number]

We have been informed that [**insert name of the Bidder**] (**hereinafter called "the Bidder"**) has submitted to you its bid dated ……. for the execution of ……[insert name of contract] under Notice Inviting Bids No**. ……[insert NIB number]**…… Furthermore, we understand that, according to your conditions, bids must be supported by a bid guarantee.

At the request of the Bidder, we …[**insert name of Bank**] …hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [**insert amount in figures**] [**insert amount in words**] upon receipt by us of your first demand in writing accompanied by a written statement stating that the Bidder is in breach of its obligation(s) under the bid conditions, because the Bidder:

(a) Has withdrawn or modified its Bid after deadline for submission of bids, during the period of bid validity specified by you in the Bid or

(b) Having been notified during the period of bid validity specified in the Bid document, about the acceptance of its Bid by you

(i)Failed or refused to execute the Contract Agreement within the time period specified in the Bid Document, or

(ii) Failed or refused to furnish the performance security, in accordance with the terms and conditions of Bid within the time period specified in the Bid Document, or

(c) Has breached a provision of the Code of Integrity specified in the RTPP Act, RTPP Rules and the terms and conditions of Bid

This guarantee will expire: (a) if the Bidder is the successful Bidder, upon our receipt of copies of the contract signed by the Bidder and the performance security issued to you upon the instruction of the Bidder; and (b) if the Bidder is not the successful Bidder, upon the earlier of our receipt of a copy of your notification to the Bidder of the name of the successful Bidder.

-

Consequently, any demand for payment under this guarantee must be received by us at the office on or before that date.

Signed:_____

[insert signature of person whose name and capacity are shown]

Name:_____

[insert complete name of person signing the Bid Security]

In the capacity of:_____

[insert legal capacity of person signing the Bid Security]

Duly authorized to sign the Bid Security for and on behalf of

[insert name of bank]

Dated on Day of _____

[insert date of signing]

Bank seal_____

[affix seal of the Bank]

Note:- The validity of Bank guarantee should be for 6 months from the date of issuance of bank guarantee.